Novel Proteases That Regulate Interleukin-1 Alpha Activity During Inflammation And Senescence by Wiggins, Kimberley Anne
Novel Proteases That Regulate 
Interleukin-1 Alpha Activity 
During Inflammation And 
Senescence 
Kimberley Anne Wiggins 
Clare College 
University of Cambridge 
 
September 2017 
This dissertation is submitted for the degree of Doctor of Philosophy 
 
 Preface  
 
 
i. Abstract 
Interleukin-1 alpha (IL-1α) is a powerful inflammatory cytokine that modulates both innate and adaptive 
immunity. As such, IL-1α is implicated in the development of multiple inflammatory and autoimmune 
diseases including atherosclerosis, arthritis and cancer. Therefore, understanding the mechanisms that 
regulate IL-1α activity is extremely important.  
For many years, pro-IL-1α was considered to be a fully active alarmin. However, we have previously 
shown that the removal of the pro-domain by calpain, a protease that is activated upon necrosis, 
significantly increases IL-1α bioactivity. The work presented in this thesis demonstrates that multiple 
proteases from diverse biological systems cleave and activate IL-1α. We therefore suggest that IL-1α is 
an important signalling hub that integrates diverse proteolytic danger signals to alert the immune system.   
In particular we have identified the inflammatory caspase, caspase-5, as a novel and potent activator of 
IL-1α. We show that caspase-5 directly cleaves pro-IL-1α during the activation of the non-canonical 
inflammasome by cytosolic LPS, which mimics intracellular bacterial infection. We also demonstrate 
that caspase-5-cleaved IL-1α mediates the senescence-associated secretory phenotype (SASP), which 
drives the deleterious effects of senescent cells in multiple age-related diseases. Therefore, 
therapeutically targeting caspase-5 may be of interest for pathologies mediated by the non-canonical 
inflammasome and/or senescent cells. 
Finally we find that rs17561, a common IL1A polymorphism, reduces active IL-1α release. We find that 
blood from minor allele homozygotes releases significantly less IL-1α than major allele homozygotes 
upon LPS stimulation. Therefore, genotyping patients under consideration for anti-IL-1α therapy could 
predict who would be likely to respond well to the treatment.   
In conclusion, the work presented in this thesis enhances our understanding of how IL-1α activity is 
regulated. The identification of both the caspase-5-mediated pathway of IL-1α activation and the defect 
conferred by the rs17561 SNP could have important clinical implications for the treatment of multiple 
inflammatory diseases.    
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iv. Abbreviations 
(p/m)Ab (Polyclonal/monoclonal) antibody 
APC Antigen presenting cell 
ASC Apoptosis-associated speck-like protein containing a CARD 
ATP Adenosine triphosphate 
BMDM Bone marrow-derived macrophage 
BrDu Bromodeoxyuridine 
BSA Bovine serum albumin 
CARD Caspase recruitment domain 
CD Cluster of differentiation 
cGAS Cyclic GMP-AMP synthase 
CRP C-reactive protein 
Ct Threshold cycle 
C. trachomatis Chlamydia trachomatis 
DAMP Damage-associated molecular pattern 
DC Dendritic cell 
DNA Deoxyribonucleic acid 
dNTPs Deoxyribose nucleoside triphosphate 
E.coli Escherichia coli 
ECM Extracellular matrix 
EGF Epidermal growth factor 
ELISA Enzyme-linked immunosorbent assay 
ER Endoplasmic reticulum 
ESCRT Endosomal sorting complexes required for transport 
FPLC Fast Protein Liquid Chromatography 
GBP Guanylate binding protein 
GM-CSF Granulocyte macrophage colony-stimulating factor 
GSDMD Gasdermin D 
GST Glutathione-S-transferase 
GTP Guanosine triphosphate 
HEK Human embryonic kidney 
HIS-tag Polyhistidine tag 
HIV Human immunodeficiency virus 
hMDM Human monocyte-derived macrophages 
HRP Horseradish peroxidase 
IF Immunofluorescence 
IFN Interferon 
Ig Immunoglobulin 
IHC Immunohistochemistry 
IL Interleukin 
IL-1R Interleukin-1 receptor 
IL-1RAcP Interleukin-1 receptor accessory protein 
IRAK Interleukin-1 receptor-associated kinase 
LDH Lactate dehydrogenase 
LDL Low density lipoprotein 
 Preface  
 
 
(ic)LPS (intracellular) Lipopolysaccharide 
MCP-1 Monocyte chemo-attractant protein -1 
MHC Major histocompatibility complex 
MMP Matrix metalloproteinase 
MyD88 Myeloid differentiation primary response 88 
NET Neutrophil extracellular trap 
NF-κB Nuclear factor kappa B 
NK Natural killer 
NLRP NACHT, LRR and PYD domain-containing protein 
NLS Nuclear localisation signal 
OIS Oncogene-induced senescence 
PAGE Polyacrylamide gel electrophoresis 
PAMP Pathogen-associated molecular pattern 
PBMC Peripheral blood mononuclear cell 
PBS Phosphate buffered saline 
(q)PCR (Quantitative) polymerase chain reaction 
PE Phycoerythrin 
PRR Pattern recognition receptor 
PTM Post translational modification 
PYD Pyrin domain 
(m/si/sh) RNA (messenger / small interfering / short hairpin) ribonucleic acid 
RNS Reactive nitrogen species 
ROS Reactive oxygen species 
SAβGAL Senescence-associated beta galactosidase 
SAHF Senescence-associated heterochromatic foci 
SASP Senescence-associated secretory phenotype 
SDS Sodium dodecyl sulphate 
SEM Standard error of the mean 
(ns) SNP (Non-synonymous) single nucleotide polymorphism 
STING Stimulator of interferon genes 
T3SS Type III secretion system 
TCR T cell receptor 
TGF Transforming growth factor 
TIR Toll-interleukin receptor 
TLR Toll-like receptor 
TNF Tumour necrosis factor 
TRAF TNF receptor associated factor 
VSMC Vascular smooth muscle cell 
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1. INTRODUCTION 
1.1 Immunity and Inflammation 
1.1.1 A brief history of immunology 
Throughout its existence, humankind has continuously experienced epidemics of disease. Even the most 
ancient civilisations, who regarded illness as a punishment from the gods, observed that those who 
survived a disease would not re-catch it. In 430 B.C., during the great plague of Athens, the Greek 
historian Thucydides wrote “Yet it was with those who had recovered from the disease that the sick and 
the dying found most compassion. These knew what it was from experience, and had now no fear for 
themselves; for the same man was never attacked twice – never at least fatally”.  
This phenomenon is now known as immunity, a term derived from the Latin word “immunis” meaning 
‘exempt’. In 925 A.D., the physician Rhazes was the first to explicitly express the theory of acquired 
immunity when he reported that recovering from smallpox infection led to protection against recurrence. 
In the 1700s, it was realised that rubbing pustular fluid from a smallpox patient into a small scratch in 
the skin of a healthy individual would cause the recipient to develop a considerably milder form of the 
disease and gain immunity. This marked the beginning of the vaccination field, which was transformed 
by the work of microbiologist Louis Pasteur who, with Robert Koch and others, showed that each disease 
is the result of infection by a specific microbe.  
In 1884 Elie Metchnikoff proposed his theory of cellular immunity; that the primitive digestive functions 
of unicellular organisms are present in higher multicellular organisms in the form of phagocytic cells 
that are able to digest foreign matter. Six years later, Emil Behring and Shibasaburo Kitasato observed 
that animals immunised with diphtheria and tetanus toxins produced a soluble factor within their blood 
that could neutralise the threat and prevent disease, which became known as the antibody. (Silverstein, 
2001). Over time, immunologists have gradually gained an increasingly detailed knowledge of our 
immune system. However immunology remains a dynamic and developing field, and there is still much 
left to understand.  
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1.1.2 An overview of the immune system 
The immune system has evolved to defend against attack by invading pathogens. There are two arms of 
the immune system: innate and adaptive. The innate immune response is an ancient system present in 
all plants and animals. Innate immune cells, primarily neutrophils and macrophages, recognise 
molecules released by microorganisms known as pathogen-associated molecular patterns (PAMPs) 
through specific cell-surface receptors. For example, transmembrane toll-like receptor 4 (TLR4) has 
evolved to detect the Gram-negative bacterial cell wall component lipopolysaccharide (LPS) (Janssens 
and Beyaert, 2003). Because the innate immune system uses germline-encoded receptors to recognise 
common microbial ligands, it is constantly ready for immediate use and therefore represents the first 
line of defence. PAMP recognition promotes phagocytosis of the microbe and the release of 
proinflammatory mediators that initiate the process of inflammation, which is discussed in more detail 
below.  
Although the innate response is an effective host-protection mechanism, microbes continuously adapt 
and change their surface molecules to evade detection. To respond to this, jawed fish and higher 
vertebrates have evolved an adaptive immune system. As the name suggests, adaptive immune cells 
tailor their response to the invader and, importantly, retain a memory of that response so that future 
infections by the same microbe can be dealt with more efficiently. The caveat of achieving this high 
level of specificity is that the activation of adaptive immunity takes between four and seven days, so the 
initial innate response remains indispensable for host survival. The effector cells of the adaptive immune 
system include CD8+ cytotoxic T cells that secrete noxious granules, CD4+ helper T cells that produce 
cytokines to activate other immune cells, and B cells that secrete antibodies against the target antigen 
(Janeway et al., 2001).  
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1.1.3 Inflammation 
Inflammation is a process that is activated when homeostasis has been compromised, which aims to 
eradicate the source of the insult and remove damaged tissue to restore normality (Medzhitov, 2008). 
Inflammation is traditionally associated with heat, pain, redness and swelling, which are symptoms 
caused by pro-inflammatory cytokines that promote blood vessel dilation and permeabilisation, leading 
to increased blood flow and fluid leakage (Janeway et al., 2001). The inflammatory response (Figure 
1.1) is initiated by molecules that can be either endogenous or exogenous. Signals from invading 
microorganisms include PAMPS and virulence factors, which damage host tissue and indirectly trigger 
inflammation by activating specific proteases or causing abnormal entry of ions into the cell. In addition, 
non-microbial environmental factors such as allergens and toxic compounds can trigger inflammation. 
For example, proteolytic allergens are similar to the enzymes released by helminths and consequently 
induce a similar immune response. Finally, the inflammatory response can be activated in sterile 
conditions by host-derived factors released from stressed or injured tissue, known as damage-associated 
molecular patterns (DAMPs) or alarmins. For instance, necrotic cells release the intracellular factor 
ATP, which binds to P2X7 receptors on macrophages to trigger a potassium ion influx that in turn 
activates the inflammatory cascade. It has been suggested that tissue damage and infection elicit such 
similar inflammatory responses because infection often follows wounding (Nathan, 2002).  
These molecular danger signals activate local endothelial cells, which interact with leukocytes via 
selectins and integrins to allow the selective extravasation of leukocytes, but not erythrocytes, from the 
bloodstream into the tissue. Tissue resident macrophages are also activated, and release cytokines, 
chemokines and extracellular matrix (ECM) –degrading enzymes to facilitate leukocyte movement, and 
promote vascular permeability by secreting prostaglandins, vasoactive amines (e.g. histamine and 
serotonin) and vasoactive peptides (e.g. Substance P.) (Medzhitov, 2008). 
Neutrophils often arrive at the site of inflammation first. They phagocytose dead microbes and release 
granules containing reactive oxygen and nitrogen species (ROS, RNS) and proteases that degrade the 
bacterial membrane. The release of ROS is energetically demanding, and this stage of inflammation is 
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therefore referred to as the ‘respiratory burst’. Neutrophils also release proteases interweaved with 
chromatin fibres to form extracellular traps (NETs) that physically catch and kill microbes (Ashley et 
al., 2012).  
The neutrophils are followed by macrophages, which phagocytose pathogens and dead cells, and T cells 
that mount an adaptive immune response. Resident dendritic cells capture and process antigens, which 
they carry to the lymph node and present to T cells via major histocompatibility complexes (MHCs). If 
the antigen was internalised and digested in vesicles (e.g. from an extracellular bacterium) the peptide 
is presented on a MHCII molecule to CD4+ T cells, whereas if the peptide was digested in the 
proteasome (e.g. from a virus) it is presented on an MHCI molecule to CD8+ T cells. The activated T 
cell then proliferates and re-enters the circulation to travel to the site of inflammation. CD4+ T cells, 
also known as T helper cells, are either pro-inflammatory (Th1) or anti-inflammatory (Th2). Th1 cells 
secrete cytokines including IFNγ, TNFα and IL-2, which promote an ‘M1’ phagocytic macrophage 
phenotype. Th2 cells secrete the cytokines IL-4 and IL-10 that induce B cell differentiation into 
antibody-secreting plasma cells, and promote the ‘M2’ remodelling macrophage phenotype. CD8+ T 
cells, also known as cytotoxic T cells, release granules containing the pore-forming enzyme perforin 
and apoptosis-inducing granzymes (Alberts et al., 2002). If the threat persists, for example when the 
invading organism is too large to be phagocytosed, tissue resident macrophages and dendritic cells form 
a physical barrier surrounding the pathogen known as a granuloma (Adams, 1976). 
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Figure 1.1: The immune response. Schematic illustrating the main stages of inflammation. PAMPs/DAMPs 
activate tissue macrophages and stimulate the production of proinflammatory cytokines, chemokines, 
hormones and vasoactive amines. Neutrophils are recruited first, and release granules containing ROS, RNS 
and proteolytic enzymes. Macrophages engulf the pathogen or dead cells, and T cells mount a tailored adaptive 
immune response. If the pathogen persists, macrophages and dendritic cells form a granuloma, physically 
encapsulating the invading organism. Once the threat has been neutralised, macrophages release compounds 
that block neutrophil recruitment and attract tissue-remodelling monocytes  
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1.1.4 The inflammatory caspases 
The caspases are a family of cysteine-dependent proteases that cleave after an aspartic acid residue. 
They are produced as inactive monomeric zymogens, which are activated by oligomerisation and/or 
cleavage. Caspases can be categorised into two subtypes; the apoptotic caspases initiate signalling 
cascades and execute cleavage of key cellular substrates that culminate in programmed cell death; 
whereas the inflammatory caspases activate cytokines that drive inflammation. As such, the caspases 
are a critical group of enzymes for maintaining cellular homeostasis.  
The proinflammatory caspases, also known as group I caspases, are caspase-1, -4, -5 and -12 in humans 
or caspase-1, -11 and -12 in mice. Their genes are clustered on human chromosome 11 and murine 
chromosome 9, suggesting that they arose from gene duplication events. Caspase-1 was the first 
inflammatory caspase to be identified through its ability to activate the proinflammatory cytokine 
interleukin-1 beta (IL-1β), and was originally known as IL-1β-converting enzyme (ICE) (Thornberry et 
al., 1992, Cerretti et al., 1992) until it was subsequently shown to also activate IL-18 (Ghayur et al., 
1997).  
In 1996, murine caspase-11 was identified as a relative of caspase-1, and was described to enhance 
caspase-1 activity (Wang et al., 1996). When the Casp1-/-  and Casp11-/- mice were engineered, they 
were both reported to be resistant to lethal sepsis (Li et al., 1995). Although it was later uncovered that 
caspase-11 was solely responsible for this resistance to toxic shock, the finding was pivotal for the 
recognition of these caspases as immunomodulatory enzymes. It led to the search for other mammalian 
caspases with similar sequences to caspase-1, which revealed human caspases-4 and -5 (Kamens et al., 
1995, Lin et al., 2000). Although caspase-12 is also homologous to caspase-1, it is not thought to play a 
key role in inflammation. The precise function of caspase-12 is poorly understood, but it is thought to 
mediate endoplasmic reticulum (ER) -stress-induced apoptosis (Nakagawa et al., 2000). 
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1.1.5 The inflammasome: a caspase-1 activation platform 
The inflammasome is an intracellular protein complex that senses danger signals and recruits and 
activates caspase-1 in response. Active caspase-1 triggers proinflammatory cytokine release and 
pyroptosis, an inflammatory form of programmed cell death, thereby simultaneously alerting the 
immune system and destroying the infected or damaged cell. Inflammasomes are distinguished 
according to their sensor molecules. Each sensor detects a specific danger signal (Figure 1.2) and most 
recruit the adaptor protein ASC (apoptosis-associated speck-like protein containing a caspase activation 
and recruitment domain) that aggregates to form a highly stable 1µm structure called the “speck”, which 
recruits the inactive precursor pro-caspase-1. The concentration of pro-caspase-1 at the speck results in 
proximity-induced dimerisation that triggers an activating conformational change. Caspase-1 then 
activates IL-1β and IL-18, and induces pyroptosis (Sharma and Kanneganti, 2016, Lu and Wu, 2015). 
Only one speck is formed per cell, even if multiple inflammasome sensors are engaged (Fernandes-
Alnemri et al., 2007). The speck can also be released into the extracellular space upon pyroptosis where 
it can continue to activate extracellular IL-1β, and be phagocytosed by a neighbouring cell and cause 
activation of the new cell’s inflammasome (Baroja-Mazo et al., 2014, Franklin et al., 2014). 
The majority of protein-protein interactions in the inflammasome occur through pyrin domains (PYD) 
and caspase recruitment domains (CARD) that drive aggregation, also referred to as nucleation. 
Inflammasome sensors containing CARD domains, such as NLRP1, directly recruit pro-caspase-1 
through CARD-CARD interactions. However, most sensor proteins lack a CARD domain and instead 
nucleate the adaptor ASC into filaments through electrostatic and hydrophobic PYD-PYD interactions. 
ASC then recruits caspase-1 through CARD domain associations, and the resulting speck has a multi-
layered ring structure with the active caspase-1 at the core (Figure 1.3).  
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Figure 1.2: Characterised inflammasome pathways. A schematic to illustrate the known inflammasome 
pathways. Despite different activatory stimuli, all inflammasome pathways culminate in caspase-1 activation 
and subsequent cleavage and activation of IL-1β and IL-18. Abbreviations: h (human), m (mouse) NLRP (NACHT, 
LRR and PYD domain protein), PKC (protein kinase C), icLPS (intracellular LPS), T3SS (type 3 secretion system), 
NAIPS (NLR family apoptosis inhibitory proteins) , AIM2 (absent in melanoma 2), dsDNA (double stranded 
DNA), PYD (pyrin domain), NACHT (nucleotide-binding and oligomerisation domain), LRR (leucine-rich repeat), 
FIIND (domain with function to find), CARD (caspase recruitment domain), HIN200 (hematopoietic interferon-
inducible nuclear protein with a 200-amino acid repeat), BBOX (B-box-type zinc finger), PRY (SPRY-associated), 
SPRY (Dictyostelium discoidium dual specificity kinase SplA and ryanodine receptor). [Adapted from (Saavedra 
et al., 2015)] 
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1.1.5.1 The NLRP3 inflammasome 
NLRP3 is a unique inflammasome sensor because, instead of detecting a single ligand, it responds to a 
broad range of stimuli. These signals can be both endogenous and exogenous, ranging from LPS to 
asbestos. It has been suggested that NLRP3 does not sense each of these signals specifically, but rather 
undergoes an activating conformational change in response to secondary products of cellular stress such 
as ROS or potassium efflux (Sharma and Kanneganti, 2016, Man and Kanneganti, 2015). In a resting 
cell, NLRP3 associates with the ER whereas ASC is found in the mitochondria and cytosol (Zhou et al., 
2011). Upon activation dynamic cytoskeletal rearrangements driven by the microtubule affinity 
regulating kinase 4 (MARK4) colocalise NLRP3 and ASC to the microtubule organising centre (MTOC) 
(Li et al., 2017). 
Structurally, NLRP3 is composed of three domains: PYD, NACHT and LRR, which can be post-
translationally modified (PTM) to modulate inflammasome activity. For example, deubiquitination of 
Figure 1.3: The Inflammasome ring structure. A schematic to show the ring-like structure of the inflammasome 
[Adapted from (Virgilio and Alexander, 2013)]. 
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the LRR by the enzyme BRCC3 triggers inflammasome activation (Py et al., 2013), whereas S-
nitrosylation by nitric oxide restricts activity (Mao et al., 2013).  
Canonical activation of the NLRP3 inflammasome is a two-step process of priming followed by 
activation. Priming occurs upon activation of TLRs, nucleotide-binding oligomerisation domain-
containing protein 2 (NOD2), or tumour necrosis factor receptors (TNFRs), which signal via nuclear 
factor kappa B (NF-κB) to upregulate the expression of inflammasome components such as NLRP3 and 
caspase-1. Although the exact mechanism for NLRP3 activation is not fully understood and remains a 
rapidly progressing field, it has been reported that K+ efflux is sufficient to induce NLRP3 
inflammasome activity (Munoz-Planillo et al., 2013). 
 
1.1.6 The non-canonical inflammasome 
The NLRP3 inflammasome can also be activated through an alternative pathway involving the pro-
inflammatory caspases -4, -5 and -11, known as the ‘non-canonical inflammasome’, which will be the 
focus of chapters 5 and 6 of this thesis. The most extensively studied activator of this pathway is 
cytosolic LPS (Figure 1.4), and as such the non-canonical inflammasome is important for combatting 
intracellular infections by Gram negative bacteria, such as Salmonella typhimurium. The lipid A 
component of the LPS molecule interacts with three basic residues in the CARD domain of caspase-11/-
4/-5 to trigger its oligomerisation and auto-activation (Shi et al., 2014). This mechanism of 
proinflammatory caspase activation resembles the activation of Factor C, a serine protease in horseshoe 
crab blood that is also directly activated by LPS contact and triggers the coagulation cascade in response. 
This similarity suggests that caspases-11/-4/-5 are in fact conserved PRRs (Stowe et al., 2015).  
The activated caspase-11/-4/-5 cleaves gasdermin-D (GSDMD) to generate an active 30kDa N-terminal 
fragment (GSDMDN), which both activates the NLRP3 inflammasome, with subsequent IL-1β 
maturation via caspase-1, and induces pyroptosis (Kayagaki et al., 2015, Shi et al., 2015). The GSDMDN 
contains two regions that unwind into amphipathic β-strands that promote membrane insertion, akin to 
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those in the pore forming protein ‘perforin’ secreted by cytotoxic T cells and natural killer (NK) cells 
(Liu and Lieberman, 2017). GSDMDN selectively binds to inner membrane phospholipids, such as 
phosphoinositides and cardiolipin, to form pores of approximately 10-14nm that trigger pyroptosis. 
Because GSDMDN cannot interact with outer membrane lipids, it does not induce pyroptosis in 
neighbouring cells when it is released following cell lysis (Ding et al., 2016, Agliettia et al., 2016). It 
has been reported that GSDMDN can also lyse endosomes, since these are derived from the inner leaflet 
of the plasma membrane, and can disrupt bacterial membranes to directly kill invading microorganisms 
(Liu et al., 2016). However, the most widely accepted hypothesis is that pyroptosis is the principle 
antibacterial mechanism, destroying the pathogen’s niche and exposing them to attack by neutrophils 
(Stowe et al., 2015).  
 
 
 
 
Figure 1.4: The non-canonical inflammasome. The engagement of a PRR (e.g. TLR4) by a pathogenic ligand (e.g. 
LPS) activates the NF-κB signalling pathway to upregulate components of the NLRP3 inflammasome, and the 
IFN signalling pathway to upregulate caspase-11. Bacteria that have been internalised by the phago-lysosome 
act as a source of intracellular LPS (icLPS), which directly binds and activates caspase-11. Caspase-11 cleaves 
gasdmerin D (GSDMD) to release a 30kDa N-terminal fragment that activates the NLRP3 inflammasome and 
triggers pyroptosis. 
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1.1.7 The cost of aberrant inflammation and immunity 
Although inflammation is an essential defence mechanism, it comes at a cost. The unavoidable collateral 
damage incurred by host tissue represents a significant biological compromise. For example, the 
cytotoxic granules and ROS released by infiltrating leukocytes do not discriminate between host and 
microbial cells. Similarly, excessive granuloma formation may result in fibrosis that can culminate in 
organ failure. For certain organs, such as the eye and placenta, this risk of tissue damage outweighs the 
benefits of inflammation. As a result, these regions have evolved to become ‘immune-privileged’, 
meaning that they do not induce an inflammatory response to foreign antigens. (Ashley et al., 2012).  
In addition to collateral damage, a misplaced or dysregulated activation of the inflammatory response 
can cause disease. Mutation of the genes encoding inflammasome components can cause 
autoinflammatory diseases. For instance, activating single nucleotide polymorphisms (SNPs) in the 
NACHT domain-encoding sequence of the NLRP3 gene are associated with cryopyrin-associated 
periodic syndromes (CAPS), such as Muckle-Wells syndrome, where the patient suffers from skin 
rashes, joint and eye inflammation, and fever (Hoffman et al., 2001). In contrast, NLRP3 mutations that 
reduce protein expression levels have been linked to increased risk of Crohn’s disease and colitis. It is 
thought that the NLRP3 inflammasome induces IL-18 release, which facilitates the repair of the mucosal 
barrier in the colon thereby maintaining intestinal homeostasis and protecting against irritable bowel 
syndromes (Pellegrini et al., 2017). Mutations in the CASP1 gene that alter caspase-1 expression, 
structure and function have been shown to increase susceptibility to inflammatory disease. 
Paradoxically, individuals carrying caspase-1 mutations typically display lower IL-1β levels. It has been 
hypothesised that a reduction in the protease function of caspase-1 may in turn favour its binding to the 
kinase RIPK2, which can activate inflammatory NF-κB signalling (Saavedra et al., 2015).  
The inappropriate activation of the inflammatory response is also implicated in allergic and autoimmune 
diseases, such as eczema, asthma and psoriasis, where the body reacts to harmless allergens or host-
derived factors. The ‘hygiene hypothesis’ suggests that allergic disease has become a problem in more 
developed countries due to a decreased exposure of children to infectious agents resulting from an 
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increase in hygiene. This insufficient stimulation of the Th1 response in early childhood leads to a Th2-
dominant immunological phenotype, which is characterised by upregulated IgE production in response 
to allergens (Okada et al., 2010). In addition, genome-wide association studies (GWAS) have suggested 
that autoimmunity can result from polymorphisms in or around immunomodulatory genes, such as the 
human leukocyte antigen (HLA) alleles, which lead to a reduced threshold for immune cell activation. 
Similarly, impaired immune cell regulation can drive autoimmunity. For example, defective immature 
B cell deletion and receptor editing have been described to drive systemic lupus erythematosus (SLE) 
(Rosenblum et al., 2015). 
In addition, although inflammation is initiated locally at the site of infection or injury, inflammatory 
mediators such as IL-1, IL-6 and TNFα can induce a systemic response. Over-production of 
inflammatory cytokines can lead to serious widespread endothelial damage and organ failure, commonly 
known as septic shock. Furthermore, a state of chronic, low-grade inflammation results in increased cell 
turnover and imparts a selection pressure that can result in carcinogenesis (Moss and Blaser, 2005).  
 
1.1.7.1 Atherosclerosis: an example of a chronic inflammatory disease 
Atherosclerosis is an extensively studied cardiovascular disease that results from chronic inflammation. 
It is a disease of the arterial wall that precedes cardiovascular events including myocardial infarction 
and stroke. There are a number of risk-factors associated with atherosclerosis, both genetic and 
environmental, which include elevated cholesterol, high blood pressure, smoking, diabetes, obesity, old 
age and stress (Rafieian-Kopaei et al., 2014). 
The stages of atherosclerosis development (Figure 1.5) have been elucidated using animal models; in 
particular, mice deficient in either apolipoprotein E (ApoE) or the low-density lipoprotein receptor 
(LDLR) fed a high-fat diet. Atherosclerotic lesions preferentially develop at sites of disturbed flow, such 
as vascular bifurcations, where the endothelial cells lining the vessel wall are more permeable and allow 
the entry of low-density lipoprotein (LDL), cholesterol and lipoprotein(a) into the vessel intima 
 Introduction  
15 
 
(Gimbrone, 1999). This accumulation of sub-endothelial lipid is referred to as an early plaque, or a fatty 
streak lesion.  
Over time, the plaques can become more advanced and clinically relevant. LDL is oxidised (oxLDL) 
and activates endothelial cells that recruit leukocytes. Cholesterol crystals activate the NLRP3 
inflammasome in recruited macrophages, which leads to IL-1β activation and release that in turn drives 
proinflammatory cytokine production (Duewell et al., 2010, Rajamaki et al., 2010). The macrophages 
also phagocytose the oxLDL but are unable to process it, become foam cells, and die. Vascular smooth 
muscle cells (VSMC) then migrate into the intima and lay down ECM to generate a fibrous cap, which 
contains the contents of the plaque. However, infiltrating T cells secrete interferon gamma (IFNγ) that 
inhibits VSMC collagen synthesis, and the increasingly necrotic core drives VSMC death. The fibrous 
cap becomes thinner and weaker, and eventually ruptures. The resulting contact between the plaque 
contents and the blood activates the coagulation cascade, leading to thrombosis and blood vessel 
occlusion (Lusis, 2000, Libby et al., 2002). 
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Figure 1.5: Human atherosclerotic plaque development. Adapted from (Libby et al., 2011). (A) The normal 
structure of a human artery. (B) The accumulation of lipid in the intima activates local endothelial cells (ECs) 
which recruit monocytes. The monocytes transmigrate into the vessel wall and differentiate into macrophages, 
which engulf the lipoproteins and become inactive foam cells. (C) Smooth muscle cells (SMCs) migrate from 
the media and secrete extracellular matrix (ECM) molecules to generate the fibrous cap. The foam cells and 
SMCs begin to die and release their necrotic lipid-rich contents into the plaque. (D) The fibrous cap gets thinner 
and weaker, and eventually ruptures. The necrotic core activates the coagulation cascade and platelets 
aggregate over the plaque to form a thrombus, which blocks the lumen of the vessel. 
A. B. 
C. D. 
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1.2 Interleukin-1: A master regulator of inflammation 
1.2.1 The history of the IL-1 family 
In the 1940’s, scientists Eli Menkin and Paul Beeson described the release of a factor from leukocytes 
that promoted rapid onset fever when injected into rabbits. Over the next 40 years this pyrogenic factor 
was isolated and named IL-1. It was found to activate lymphocytes, enhance their responsiveness and 
stimulate the production of the acute phase response protein serum amyloid A, earning IL-1 recognition 
as a ‘master molecule’ in immunity. In 1974, it was realised that there are actually two forms of IL-1 – 
alpha and beta – and the individual genes were successfully cloned in 1984 (Dinarello, 2010). The IL-1 
family is now known to include eleven ligands and ten receptors that either promote or inhibit 
inflammation (Table 1.1) (Boraschi and Tagliabue, 2013).  
 
Table 1.1: Known Members of the IL-1 Family 
Agonists 
(proinflammatory) 
Signalling Receptors Decoy Receptors 
Antagonists / 
Negative Regulators 
IL-1α, IL-1β IL-1R1, IL-1RAcP, 
TILRR 
IL-1R2 IL-1Ra, SIGIRR 
IL-18 IL-18Rα, IL-18Rβ  IL-37, IL-18BP 
IL-33 ST2   
IL-36α, IL-36β, IL-
36γ 
IL-1Rp2  IL-36Ra, IL-38 
 
1.2.2 IL-1 signalling and function 
IL-1α and IL-1β are encoded by adjacent genes on chromosome 2 and are thought to have resulted from 
a gene duplication that occurred over 270 million years ago. The cytokines share a similar three-
dimensional structure, a β-trefoil fold composed of 12 β-strands, despite their low amino acid sequence 
homology (27%) (Gabay et al., 2010). A major difference between the two forms of IL-1 is their 
expression patterns and activation mechanisms, which is reflected by the low sequence homology 
between the IL1A and IL1B promoters. IL-1α is constitutively expressed in many cell types, although 
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its expression can be upregulated following stimulation, and it exists both within the cytosol and on the 
cell surface in a myristoylated form where it can mediate juxtacrine cell-cell signalling (Stevenson et 
al., 1993). Conversely, IL-1β is primarily produced by monocytes and macrophages and is specifically 
upregulated along with other inflammasome components following cell priming (Sims and Smith, 
2010).  
Both IL-1α and IL-1β are translated as 31kDa pro-proteins and require the removal of their pro-domains 
by the proteases calpain and caspase-1, respectively, for full activity (Thornberry et al., 1992, Cerretti 
et al., 1992, Afonina et al., 2011, Zheng et al., 2013). The mechanism of IL-1 secretion remains under 
investigation, since both cytokines lack a conventional signal peptide and are therefore not secreted via 
the ER or the Golgi apparatus (Sims and Smith, 2010). It has been suggested that IL-1α binds to IL-1β 
and is shuttled out of the cell following inflammasome activation (Keller et al., 2008, Fettelschoss et al., 
2011). 
Mature IL-1α and IL-1β signal through the same intracellular pathway (Figure 1.6). They bind to the 
type I receptor (IL-1R1) and trigger the recruitment of the co-receptor IL-1R accessory protein (IL-
1RAcP). The receptors interact with the signalling adaptor protein myeloid differentiation primary 
response gene 88 (MyD88) through their intracellular Toll/interleukin-1 receptor (TIR) domains. 
MyD88 induces the phosphorylation of the IL-1 receptor associated kinase 4 (IRAK4), which then 
phosphorylates IRAK1 and IRAK2. The IRAK proteins then interact with TNF receptor-associated 
factor 6 (TRAF6) to activate NF-κB, p38, ERK and JNK signalling pathways that drive the expression 
of pro-inflammatory genes (Gabay et al., 2010).  
IL-1α and IL-1β exert a plethora of diverse effects on the immune system. They stimulate the production 
of many pro-inflammatory cytokines, including themselves, thereby creating an auto-amplifying 
inflammatory loop. IL-1- signalling also upregulates adhesion molecule expression by endothelial cells 
to aid leukocyte recruitment, and influences adaptive immunity by driving TH17 cell differentiation, 
promoting B cell and T cell expansion and survival, and upregulating MHC expression on dendritic cells 
to enhance their antigen presenting capacity (Sims and Smith, 2010). Furthermore, IL-1 promotes the 
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production of enzymes that stimulate the release of prostaglandins and nitric oxide, which contribute to 
systemic changes including hypotension, fever, neutrophilia and thrombocytosis (Gabay et al., 2010).  
 
 
 
 
 
1.2.3 IL-1 in disease 
The dysregulation of IL-1 signalling is a major causative factor in a wide range of inflammatory 
diseases. The disease DIRA (Deficiency of IL-1RA), caused by a loss-of-function mutation in IL1RN 
that results in unconstrained IL-1 signalling, is characterised by overwhelming inflammation in the 
joints, skin and bone, and results in premature death when left untreated (Dinarello et al., 2012). IL-1 is 
also implicated in many inflammatory diseases because of its ability to drive the differentiation of TH17 
Figure 1.6: The IL-1 signalling pathway. Adapted from (Risbud and Shapiro, 2014). IL-1 forms a complex with IL-
1R1 and IL-1RAcP to activate a MyD88-dependent phosphorylation cascade that activates NF-κB and MAPK 
signalling pathways, which drive the transcription of pro-inflammatory genes including IL-1. Both forms of IL-
1 are translated as pro-proteins that are proteolytically activated. Pro-IL-1α has limited basal activity, and can 
exist in a membrane-bound form that signals to adjacent cells. Negative regulators of IL-1 signalling are also 
shown.  
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cells, a pro-inflammatory subset of CD4+ T cells that are important for the immune response to infection. 
As the name suggests these cells secrete the cytokine IL-17, which induces the production of a broad 
range of additional proinflammatory cytokines and chemokines that recruit neutrophils and 
macrophages to the site of infection. Inappropriate TH17 cell activation has been shown to occur in 
multiple inflammatory disorders including arthritis, psoriasis and asthma (Nakae et al., 2002, Jenson, 
2011, Sims and Smith, 2010, Besnard et al., 2012).  
IL-1 driven inflammation is also known to play a major role in cardiovascular disease. Expression of 
both IL-1 and the IL-1R1 are increased in atherosclerotic plaques, where IL-1 signalling activates 
endothelial cells overlying and macrophages within the lesion (Ait-Oufella et al., 2011). In addition, IL-
1 is thought to drive cardiovascular events in diabetic patients, where pancreatic beta cells produce 
excess IL-1β that in turn contributes to beta cell death. The consequent IL-1 signalling also affects the 
heart by both directly supressing the contractile force of the muscle, thereby weakening the heart, and 
propagating an inflammatory cascade that leads to cardiomyocyte death (Dinarello et al., 2012). 
IL-1 signalling also contributes to inflammatory disease in epithelial tissues where resting cells 
constitutively express high levels of IL-1 to facilitate their barrier function. For example IL-1 is thought 
to enhance the release of T cell chemoattractants by keratinocytes and contribute to the formation of 
psoriatic lesions (Jenson, 2011). Similarly, increased IL-1α and IL-1β levels are found in the inflamed 
intestinal mucosa of inflammatory bowel disease patients (Casini-Raggi et al., 1995).  
Because of these well-established causative roles in inflammatory disease, IL-1 is an attractive 
therapeutic target (Table 1.2). Anakinra is a recombinant form of the IL-1RA that is used clinically to 
treat rheumatoid arthritis, recurrent gout, and CAPS, and is in clinical trials for the treatment of other 
inflammatory disorders including stroke (Dinarello et al., 2012). Canakinumab, a human monoclonal 
antibody against IL-1β that is already used to treat systemic onset juvenile idiopathic arthritis, has been 
shown to significantly reduce the rate of recurrent cardiovascular events in heart attack patients with 
elevated C-reactive protein (CRP) levels in the recent CANTOS study (Canakinumab Anti-
inflammatory Thrombosis Outcomes Study). The study also showed that patients treated with 
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Canakinumab were at lower risk of other inflammatory pathologies including arthritis, gout and cancer 
(Ridker et al., 2017). Both Anakinra and Canukinumab are also currently in trials for treating type I 
diabetes (Dinarello et al., 2012).  
 
Table 1.2: Anti-IL-1 Therapies Adapted from (Dinarello et al., 2012) 
DRUG NAME MECHANISM OF ACTION 
Anakinra Receptor antagonist for IL-1R1 
Rilonacept 
Soluble IL-1 decoy receptor composed of the extracellular IL-
1R1 domain fused with the extracellular domain of IL-1RAcP 
Canakinumab Neutralising anti-IL-1β antibody 
Gevokizumab Neutralising anti-IL-1β antibody 
LY2189102 Neutralising anti-IL-1β antibody 
MABp1 Neutralising anti-IL-1α antibody 
MEDI-8968 Blocking anti-IL-1R1 antibody 
CYT013 Therapeutic vaccine targeting IL-1β 
sIL-1R1 Soluble extracellular domain of IL-1R1 
EBI-005 Chimeric IL-1Ra-IL-1β 
 
 
1.3 Interleukin-1 alpha: stepping into the spotlight 
1.3.1 IL-1α-specific functions 
Most initial IL-1 research largely focussed on IL-1β, with our understanding of IL-1α biology 
developing more recently. IL-1α has a higher affinity for the signalling receptor IL-1R1, and a lower 
affinity for the decoy receptor IL-1R2 than IL-1β. In addition IL-1α, unlike IL-1β, is constitutively 
expressed in the cytosol of many cell-types and therefore serves as an inflammation-inducing DAMP 
when it is released during necrosis. Furthermore, unlike many other DAMP receptors, IL-1R1 is 
expressed on most cell types meaning that IL-1α can also activate non-immune cells. Consistent with 
this function, endothelial and epithelial cells, which form key immune barriers within the body, express 
particularly high constitutive levels of IL-1α (Di Paolo and Shayakhmetov, 2016). 
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Pro-IL-1α can also be expressed on the cell surface. Membrane-bound IL-1α regulates the senescence-
associated secretory phenotype (SASP); the cocktail of inflammatory factors released by senescent cells 
that is the focus of Chapter 6 of this thesis (Orjalo et al., 2009). This is particularly important in the 
context of the tumour microenvironment, where the IL-1α driven SASP induces anti-tumour immune 
cell recruitment, but enhances cancer cell invasiveness (Coppé et al., 2010). Membrane IL-1α has also 
been reported to inhibit hepatocellular carcinoma development by promoting T- and NK- cell activation 
(Lin et al., 2016). 
IL-1α has gained recognition as a ‘dual function cytokine’ because it elicits intracellular effects in 
addition to its extracellular inflammatory signalling. The intracellular activity of IL-1α is reported to be 
mediated by the pro-domain, which contains a nuclear localisation signal (NLS) (Wessendorf et al., 
1993). Pro-IL-1α has been reported in the nucleus of many cell types (Luheshi et al., 2009) where it can 
act as a transcription factor by binding regulatory elements such as the histone acetyltransferase proteins 
p33, Gcn5 and PCAF, and colocalising with spliceosome complexes (Buryskova et al., 2004, Pollock et 
al., 2003). It is reported that intranuclear IL-1α regulates a number of processes including proliferation, 
apoptosis and migration (Luheshi et al., 2009), with oncogenic properties also reported in perivascular 
mesangial cells and acute T-lymphocytic leukaemia cells (Stevenson et al., 1997, Zhang et al., 2017). 
Nuclear IL-1α is also reported to function as a DNA damage sensor, and has been shown to localise to 
areas of DNA damage and shuttle in and out of the nucleus to signal chromatin damage (Cohen et al., 
2015).  
 
1.3.2 The regulation of IL-1α activity 
It is perhaps not surprising, given the powerful inflammatory effects of IL-1α, that its activity is carefully 
regulated. Transcriptionally, IL1A expression is upregulated by signals of cellular insult such as LPS 
and TNFα (Dinarello, 2009). However, cell-specific mechanisms of transcriptional control are also in 
place. In monocytes, a natural antisense transcript known as AS-IL1α is induced following infection, 
which promotes the recruitment of RNA polymerase II to the IL-1α promoter to enhance transcription 
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(Chan et al., 2015). In CD4+ T cells, IL-1α expression is monoallelic and controlled by modulating the 
methylation status of CpG nucleotides in the promoter (Van Rietschoten et al., 2006). In pancreatic islet 
cells, the microRNA miR-30a binds to the 3’ untranslated region (UTR) of the IL1A gene and inhibits 
transcription to prevent overt cytokine activation during inflammation (Jiang et al., 2017). Importantly, 
an increase in IL-1α transcription does not always correspond to an increase in translation, since N-
terminal AU-rich elements (ARE) in IL1A regulate mRNA decay (Fenton, 1992).  
IL-1α is translated as a pro-protein, the activity of which has remained a controversial subject within the 
IL-1α field. For many years, pro-IL-1α was considered fully active (March et al., 1985, Mosley et al., 
1986, Kim et al., 2013), even after it was established as a substrate of the calcium-dependent cysteine 
protease calpain (Kobayashi et al., 1990). However, recent work by ourselves and others has challenged 
this notion and provided compelling evidence that the proteolytic removal of the pro-domain 
significantly increases IL-1α activity by enhancing its affinity for the IL-1R1 (Afonina et al., 2011, 
Zheng et al., 2013). 
IL-1α activity is also regulated spatially. During apoptosis, IL-1α is rapidly shuttled into the nucleus 
where it associates with chromatin to limit its release and maintain the anti-inflammatory nature of 
programmed cell death (Cohen et al., 2010). IL-1α is also controlled in a cell-type dependent manner by 
the decoy receptor IL-1R2. This receptor lacks the intracellular TIR domain critical for IL-1RAcP and 
MyD88 recruitment and therefore cannot propagate the IL-1 signal. IL-1R2 binds to pro- and mature 
IL-1α, and limits interaction with calpain and IL-1R1, respectively. This interaction is abrogated by 
caspase-1 and -5 following cell activation and inflammasome assembly. Interestingly, vascular smooth 
muscle cells (VSMCs) express very low levels of IL-1R2 and consequently they are particularly 
inflammatory following necrosis (Zheng et al., 2013). IL-1 signalling is also negatively regulated by the 
receptor antagonist IL-1RA, which prevents recruitment of the IL-1RAcP into the receptor complex.  
1.3.3 IL-1α in disease 
The distinct expression patterns and functions of IL-1α are reflected by its unique contributions to 
disease. IL-1α has emerged as a key player in atherosclerosis development, where the deletion of IL-1α 
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in the ApoE-/- mouse model provides more protection against disease than IL-1β deletion (Kamari et al., 
2011). A possible mechanism for this involves oleic acid, which accumulates within the plaque as 
atherosclerosis progresses. Oleic acid triggers IL-1α, not IL-1β, secretion from macrophages via the 
mitochondrial uncoupling protein UCP2. The uncoupling of the mitochondrial membrane leads to a 
calcium flux within the macrophages, allowing activation of IL-1α by calpain. Since this mechanism 
bypasses the inflammasome, oleic acid accumulation during plaque development shifts IL-1 release 
from IL-1β towards IL-1α (Freigang et al., 2013). In addition IL-1α is described to play a unique role in 
myocardial infarction where necrotic cardiomyocytes secrete IL-1α, not IL-1β, to drive post-ischemic 
inflammation (Lugrin et al., 2015). Indeed, IL-1α blockade after ischemia-reperfusion injury reduces 
infarct size and preserves left ventricular fractional shortening in mice (Mauro et al., 2017). Similarly, 
IL-1α is released before IL-1β by microglia during cerebral ischaemia, suggesting that this form of IL-
1 is key to initiating sterile inflammation after stroke (Luheshi et al., 2011).  
IL-1α also contributes to the pathology of other inflammatory diseases. For example, chronic 
inflammation that drives neuronal cell death in Alzheimer’s disease is thought to be driven by IL-1α, 
since a SNP within the IL1A gene is associated with disease risk. IL-1α has also been implicated in 
tumour progression and is associated with multiple hallmarks of cancer. In addition to its key role in 
SASP production discussed previously, membrane IL-1α on tumour-infiltrating platelets activates the 
vascular endothelium to promote transendothelial tumour cell migration (XBiotech, 2012). Furthermore, 
IL-1α is a HIF-inducible factor that is upregulated during hypoxia (Rider et al., 2012) and promotes 
angiogenesis (Voronov et al., 2002). The secreted form of IL-1α has also been shown to enhance tumour 
growth and invasiveness, (Rider et al., 2013), and serves as a predictive marker of distant metastases in 
head and neck squamous cell carcinoma patients (León et al., 2015). Increased IL-1α levels have also 
been shown to contribute to a number of autoimmune diseases, including rheumatoid arthritis, psoriasis, 
and systemic sclerosis (Eastgate et al., 1991, Rider et al., 2013, Aden et al., 2010). The importance of 
IL-1α in disease is reflected by the success of mABp1 (Xbiotech), a monoclonal anti-IL-1α antibody 
reported to reduce inflammation in advanced stage cancers, psoriasis and acne, and prevent artery 
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restenosis after angioplasty (Hong et al., 2014, Coleman et al., 2015, Carrasco et al., 2015, El Sayed et 
al., 2016).  
IL-1α is an extremely powerful pleotropic cytokine that is dysregulated in multiple inflammatory 
diseases, and therefore increasing our understanding of how activity is regulated could reveal novel 
therapeutic opportunities. This is the aim of the work presented in this thesis, which investigates novel 
genetic and proteolytic mechanisms regulating IL-1α activity. 
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1.4 PROJECT AIMS 
This PhD thesis has two main objectives: 
1. To investigate the inhibitory role of the IL-1α pro-domain and identify novel proteases that can 
activate IL-1α. 
The biological activity of pro-IL-1α has been a controversial subject in the IL-1α field for many years. 
Recent evidence from ourselves and others has demonstrated that the removal of the pro-domain 
increases IL-1α activity. This project aims to determine how much of the pro-domain is required to limit 
IL-1α activity, identify novel proteases that activate IL-1α, and investigate physiological and 
pathological processes in which these newly-identified enzyme/substrate interactions might occur. 
2. To investigate the effect of the common IL1A SNP, rs17561, on IL-1α activation. A relatively 
common missense polymorphism exists in the IL1A gene, which leads to an amino acid change in the 
IL-1α protein at a location important for cytokine activation. This project aims to determine whether the 
rs17561 SNP affects IL-1α activation.  
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2. Materials and Methods 
2.1 Molecular cloning 
2.1.1 Site-directed mutagenesis 
Human/mouse pro-IL-1α/β or human caspase-5 DNA was amplified by PCR and inserted into pGEX-
4T-3 (GE Healthcare, 28-9545-52) and pcDNA3.1 (Invitrogen, V79020) vectors by Melanie Humphry. 
Individual cleavage site mutants and the rs17561 SNP were introduced by site-directed mutagenesis 
using the primers listed in Table 2.1. The PCR mix included 30ng DNA, 5µl 10x buffer with magnesium 
(Promega, M776A), 1µl dNTPs (10mM each), 1.35µl each primer, 7µl Pfu DNA Polymerase (Promega, 
M774A) and water to a final volume of 50µl. The PCR programme comprised 12 cycles of 30 seconds 
at 95oC, 1 minute at 55oC and 7 minutes at 68oC. The parental DNA strand was digested with 1µl Dpn1 
endonuclease (Promega, R6231) for 1 hour at 37oC. 
2.1.2 Bacterial transformation and plasmid purification 
100µl of competent XL10 Gold Escherichia coli (E.coli) (Stratagene) were transformed with 5µl 
plasmid for 30 minutes on ice, 45 seconds at 42oC and 90 seconds on ice. Bacteria were plated on Luria 
Broth (LB) Agar containing 100µg/ml Ampicillin (Sigma Aldrich, A9518) (LBAmp) overnight at 37oC. 
3ml LBAmp broth was inoculated with a single colony of transformed bacteria and incubated overnight 
at 37oC with shaking. Plasmid DNA was purified using a Miniprep Kit (Qiagen, 27106) as per the 
manufacturer’s instructions and sequenced (Source Bioscience). 
Box 2.1: Bacterial Culture Recipes 
Luria broth (LB) 
10g Tryptone (BD Bacto, 211705) 
5g Yeast Extract (BD Bacto, 212750) 
10g NaCl (Sigma Aldrich, 433209) 
1L ddH2O 
pH7.5 
LB agar 
15g of Agarose (Fischer, BP1356-500) 
1L LB 
100µg/ml Ampicillin was added after 
autoclaving 
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2.1.3 Truncation mutant and His-tag mutagenesis 
Insert DNA was amplified by PCR; mixing 30ng DNA, 5µl 5x GoTaq buffer (Promega, M7911), 1.25µl 
MgCl2 (Promega, A3511), 0.5µl dNTPs (10mM each), 1µl each primer (Table 2.1), 0.5µl GoTaq 
polymerase (Promega, M3002), 0.5µl Pfu polymerase (Promega, M7741) and water up to 25µl. The 
PCR programme comprised an initial denaturing step of 95o for 5 minutes, followed by 25 cycles of 30 
seconds at 95oC, 30 seconds at 55oC and 90 seconds at 72oC. dNTPs and template plasmid DNA were 
removed by an ethidium bromide (EtBr) gel clean-up (1% agarose/ 1xTBE), and plasmid DNA was 
extracted using a QiaQuick Gel Extraction kit (Qiagen, 28704). The insert was ligated into a pre-cut 
pGEMTEasy vector (Promega, A1360) by mixing 30ng insert, 0.5µl vector, 1.5µl 10x ligation buffer 
(Promega, C126), 1µl T4 DNA ligase (Promega, M1801) and water up to 15µl. XL10 Gold E.coli were 
transformed with 10µl ligation mix as described previously and a colony PCR was used to identify 
insert-positive bacteria. The colony PCR mix included 2.5µl 5xGoTaq buffer, 0.75µl MgCl2, 0.25µl 
dNTPs, 0.5µl each primer (Table 2.1), 0.25µl Taq polymerase and 8.25µl water, and was amplified 
using the same programme as before. The PCR mixes were run on an EtBr gel and 3ml overnight cultures 
were inoculated with ligation-positive colonies. Plasmid DNA was purified using a Miniprep Kit and 
sequenced. The insert was removed from the pGEM-T vector by restriction digest. 1.3µg plasmid DNA, 
3µl 10 Buffer C (Promega, R003A), 1.5µl 20x Bovine Serum Albumin (BSA) (Invitrogen, AM2616), 
1µl BamH1 (Promega, R302A), 1µl XhoI (Promega, R616A) and water up to 30µl were mixed and 
incubated for 1 hour at 37oC. The insert was cleaned up by EtBr gel, extracted, and quantified as before. 
The insert was ligated into a pre-cut pGEX-4T-3 vector as described previously. XL10 Gold bacteria 
were transformed and ligation-positive colonies were identified by colony PCR as before, and used to 
generate plasmid stocks.  
Box 2.2: TBE recipe 
5x TBE 
54g Tris Base 
27.5g Boric acid   
20ml 0.5 M EDTA, pH 8.0   
Made up to 1L with ddH2O   
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Table 2.1: Molecular Cloning Primers 
GENE MUTATION PRIMER SEQUENCES (5’-3’) 
Human 
IL-1α 
Δ37 Truncation 
Mutant 
F: ATAGGATCCGTAAGCTATGGCCCACTCCA 
R: ATACTCGAGTAAAGCCTGGTTTTCCAGTAT 
Δ56 Truncation 
Mutant 
F: ATAGGATCCTCTGAAACCTCTAAAACATC 
R: ATACTCGAGTAAAGCCTGGTTTTCCAGTAT 
Δ77 Truncation 
Mutant 
F: ATAGGATCCGGGAAGGTTCTGAAGAAGAG 
R: ATACTCGAGTAAAGCCTGGTTTTCCAGTAT 
Colony PCR 
Primers 
F: CAGGAAACAGCTATGACC 
R: TGTAAAACGACGGCCAGT 
P111A Site 
Mutant 
F: GAAGAAATCATCAAGGCTAGGTCAGCACCTT 
R: AAGGTGCTGACCTAGCCTTGATGATTTCTTC 
P115A Site 
Mutant 
F: AAGCCTAGGTCAGCAGCTTTTAGCTTCCTGA 
R: TCAGGAAGCTAAAAGCTGCTGACCTAGGCTT 
D103A Site 
Mutant 
F: GAGGCCATCGCCAATGCCTCAGAGGAAGAAATC 
R: GATTTCTTCCTCTGAGGCATTGGCGATGGCCTC 
A114S Site 
Mutant 
F: ATCAAGCCTAGGTCATCACCTTTTAGCTTCCTG 
R: CAGGAAGCTAAAAGGTGATGACCTAGGCTTGAT 
Addition of C-
terminal His 
Tag 
F: ATAGGATCCATGGCCAAAGTTCCAGACATG 
R: ATACTCGAGGTGGTGGTGGTGGTGGTGTAAAGCCTGGTTTTC 
CAGTAT 
Human 
IL-1β 
D116A Site 
Mutant 
F: GAGGCTTATGTGCACGCTGCACCTGTACGATCA 
R: TGATCGTACAGGTGCAGCGTGCACATAAGCCTC 
Mouse 
IL-1α 
D106A Site 
Mutant 
F: CAGTCCATAACCCATGCTCTGGAAGAGACCATC 
R: GATGGTCTCTTCCAGAGCATGGGTTATGGACTG 
D26A Site 
Mutant 
F: TACAGTTCTGCCATTGCCCATCTCTCTCTGAAT 
R: ATTCAGAGAGAGATGGGCAATGGCAGAACTGTA 
D37A Site 
Mutant 
F: CAGAAATCCTTCTATGCTGCAAGCTATGGCTCA 
R: TGAGCCATAGCTTGCAGCATAGAAGGATTTCTG 
D49A Site 
Mutant 
F: CATGAGACTTGCACAGCTCAGTTTGTATCTCTG 
R:CAGAGATACAAACTGAGCTGTGCAAGTCTCATG 
Mouse 
IL-1β 
D116A Site 
Mutant 
F: AACCTGCTGGTGTGTGCCGTTCCCATTAGACAA 
R: TTGTCTAATGGGAACGGCACACACCAGCAGGTT 
D88A Site 
Mutant 
F: ACCTTCCAGGATGAGGCCATGAGCACCTTCTTT 
R: AAAGAAGGTGCTCATGGCCTCATCCTGGAAGGT 
D105A Site 
Mutant 
F: GAGCCCATCCTCTGTGCCTCATGGGATGATGAT 
R: ATCATCATCCCATGAGGCACAGAGGATGGGCTC 
Mouse 
CASP 
11 
shRNA 140 
F:TCGAGAAGGTATATTGCTGTTGACAGTGAGCGCAAGCAATGTACTG
AAATTAAATAGTGAAGCCACAGATGTATTTAATTTCAGTACATTGCT
TTTGCCTACTGCCTCGG 
R:AATTCCGAGGCAGTAGGCAAAAGCAATGTACTGAAATTAAATACA
TCTGTGGCTTCACTATTTAATTTCAGTACATTGCTTGCGCTCACTGTC
AACAGCAATATACCTTC 
shRNA 710 
F:TCGAGAAGGTATATTGCTGTTGACAGTGAGCGATCCAGATGTGCTAC
AGTATGATAGTGAAGCCACAGATGTATCATACTGTAGCACATCTGGA
GTGCCTACTGCCTCGG 
R:AATTCCGAGGCAGTAGGCACTCCAGATGTGCTACAGTATGATACAT
CTGTGGCTTCACTATCATACTGTAGCACATCTGGATCGCTCACTGTCA
ACAGCAATATACCTTC 
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shRNA 731 
F:TCGAGAAGGTATATTGCTGTTGACAGTGAGCGCTACCATCTATCAGA
TATTCAATAGTGAAGCCACAGATGTATTGAATATCTGATAGATGGTA
TTGCCTACTGCCTCGG 
R:AATTCCGAGGCAGTAGGCAATACCATCTATCAGATATTCAATACAT
CTGTGGCTTCACTATTGAATATCTGATAGATGGTAGCGCTCACTGTC
AACAGCAATATACCTTC 
shRNA 1124 
F:TCGAGAAGGTATATTGCTGTTGACAGTGAGCGCTCGGGCAACCTTGA
CGAGATATAGTGAAGCCACAGATGTATATCTCGTCAAGGTTGCCCGA
TTGCCTACTGCCTCGG 
R:AATTCCGAGGCAGTAGGCAATCGGGCAACCTTGACGAGATATACA
TCTGTGGCTTCACTATATCTCGTCAAGGTTGCCCGAGCGCTCACTGTC
AACAGCAATATACCTTC 
shRNA 1160 
F:TCGAGAAGGTATATTGCTGTTGACAGTGAGCGATGGCAACTGAGAA
CAAAGCAATAGTGAAGCCACAGATGTATTGCTTTGTTCTCAGTTGCC
AGTGCCTACTGCCTCGG 
R:AATTCCGAGGCAGTAGGCACTGGCAACTGAGAACAAAGCAATACA
TCTGTGGCTTCACTATTGCTTTGTTCTCAGTTGCCATCGCTCACTGTC
AACAGCAATATACCTTC 
shRNA  
sub-
cloning 
miR30_5_XhoI GAAGGCTCGAGAAGGTATATTGCTG 
Mir30_3_XmaI CGGCCCGGGGTGATTTAATTTATACCATTTTAATTCAGCT 
Mutated residues are underlined. Restriction enzyme sites are in italic. 
 
2.1.4 shRNA Vectors 
2.1.4.1 Lentiviral knockdown 
Plasmids were purchased in the form of frozen glycerol stocks (Table 2.2). The glycerol stocks were 
streaked onto LB Agar containing 100µg/ml carbenicillin (LBCarb100) and incubated overnight at 
37oC. 3 colonies per plate were used to inoculate 6ml overnight cultures in 2X LB and incubated 
overnight at 37oC with vigorous shaking. The plasmids were isolated from 5ml overnight culture by 
miniprep.  
 
 
 
Box 2.3: 2X LB Broth 
10g tryptone 
10g yeast extract 
5g NaCl 
10g peptone (BD, 211677) 
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Table 2.2: shRNA plasmid clones 
TARGET 
The RNA Consortium (TRC) 
Code 
Shorthand Code 
Human Caspase 1 
TRCN0000003502 2 
TRCN0000003503 3 
TRCN0000003504 4 
TRCN0000010796 6 
Human Caspase 4 
TRCN0000003511 84 
TRCN0000003513 86 
Human Caspase 5 
TRCN0000003553 89 
TRCN0000003555 90 
 
2.1.4.2 Retroviral knockdown 
The Casp11-targetting shRNA constructs were cloned by Aled Parry. Briefly: 
J2 cells 
The primers in table 2.1 containing the guide sequences were cloned into the MSCV miR30 backbone 
by Aled Parry. Briefly, equimolar amounts of forward and reverse primer were annealed in annealing 
buffer by incubation in a thermal cycler at 95oC for 5 minutes, before gradually reducing the temperature 
(0.5oC/2.5min) to 4oC. MSCV miR30 was digested using XhoI and EcoR1 before ligating with the 
annealed oligonucleotides using T4 DNA ligase (New England Biolabs, M0202).  
Box 2.4: Annealing buffer 
100mM potassium acetate 
30mM HEPES-KOH pH7.4 
2mM Mg-acetate   
 
2.1.4.3 Hydrodynamic Tail Vein Injection 
The selected construct was sub-cloned into pCaNIG miR30 (gifted by Lars Zender) by PCR cloning the 
3’ portion of miR30-shCASP11 using the primers in Table 2.1. The vector and PCR products were 
digested using XhoI and XmaI, and ligated with T4 DNA ligase.  
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2.2 Bacterial protein expression 
100µl BL21 Rosetta E.coli were transformed with 100ng plasmid DNA, plated on LBAmp and 
incubated at 37oC overnight. 50ml cultures were inoculated with a single colony and incubated at 37oC 
overnight with vigorous shaking. 500ml cultures were inoculated with 5ml overnight culture and grown 
to OD600=0.8 at 37oC with vigorous shaking. Protein expression was induced with 1mM Isopropyl-β-D-
1-thiogalactopyranoside (IPTG) (Generon, S-02122) for 4 hours at room temperature. Bacteria were 
centrifuged at 5100rpm for 15 minutes at 4oC and pellets were stored at -80oC.  
 
2.3 Purification of GST-tagged protein 
250ml bacterial pellets were lysed by rolling in 25ml lysis buffer for 30 minutes. Lysed bacteria were 
sonicated at 35% amplitude for 1 minute followed by 1 minute on ice, 3 times. The lysate was 
centrifuged for 1 hour at 4oC at 5100rpm, and the supernatant was filtered (0.45µm). The supernatant 
was loaded onto a GSTrap FF 1ml glutathione column (GE Healthcare, 17513001), washed, and eluted 
using an ÅKTA Pure Fast Protein Liquid Chromatography (FPLC) System (GE Healthcare). The eluted 
protein was dialysed overnight in 10mM Tris pH8 50mM NaCl. Proteins were stored in 10% Glycerol 
at -80oC. 
Box 2.5: GST purification buffer recipes 
Lysis buffer 
In PBS [1 PBS Tablet (Oxoid) per 100ml 
ddH2O]: 
150mM NaCl  
1mM dithiothreitaol (DTT) (Sigma Aldrich, 
D9779) 
1mM EDTA (Sigma Aldrich, E5134) 
10µM phenylmethylsulfonyl fluoride (PMSF) 
(Sigma Aldrich, P1626) 
Protease inhibitor cocktail (Sigma Aldrich, 
P8849) (1:100)  
100U/ml Benzonase (Sigma Aldrich, E1014) 
100U/ml Lysozyme (Novagen, 71110-3) 
Wash buffer 
In PBS: 
1mM DTT 
1mM EDTA 
 
 
Elution buffer 
50mM Tris (Sigma Aldrich, 
T6006) pH8 
100mM NaCl (Fischer, 
S/3160/60) 
1mM DTT 
50mM L-Glutathione reduced 
(Sigma Aldrich, G4251) 
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2.4 Purification of His-tagged protein 
Cell pellets were resuspended in 10 packed-cell volumes of ice cold lysis buffer and incubated at room 
temperature for 5 minutes. Cells were centrifuged at 8000g for 20 minutes at 10oC. The supernatant was 
taken for purification. 
50% HisPur Cobalt Resin (Fisher, 89964) was prepared by washing once with water and then 
resuspending in wash buffer 1. Resin was mixed with cell supernatant at a ratio of 1:6 and rolled for 1 
hour at 4oC. Samples were centrifuged at 700g for 2 minutes and resuspended in wash buffer 1. Samples 
were centrifuged at 700g for 2 minutes and resuspended in wash buffer 2. Samples were centrifuged at 
700g for 2 minutes and resuspended in elution buffer. Samples were centrifuged at 700g for 2 minutes 
and protein-containing supernatents were collected for further experiments.  
Box 2.6: His purification buffer recipes 
Lysis Buffer 
25mM Tris pH7.4 
0.5% NP-40 (AppliChem Panreac, A16940250) 
150mM NaCl 
120µM Calpeptin (Enzo, BML-P1101-0010) 
Protease inhibitor cocktail (Sigma Aldrich 
P8849) (1:100) 
1µl/ml benzonase (Sigma Aldrich, E1014) 
Wash buffers 
50mM Sodium Phosphate pH7.4 
300mM NaCl 
20mM (Wash 1) or 40mM (Wash 2) Imidazole 
Elution buffer 
50mM Sodium Phosphate pH7.4 
300mM NaCl 
250mM Imidazole 
 
 
 
2.5 Protein concentration normalisation 
2.5.1 Bradford assay 
BSA standards (0-2mg/ml) and protein dilutions were prepared in 10mM Tris pH8 50mM NaCl. 10µl 
sample/standard and 200µl dye (Sigma, B6916) were added per well of a 96-well plate. Samples were 
incubated at room temperature for 15 minutes and absorbance at 595nm was read.  
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2.5.2 SDS PAGE and Coomassie staining 
Protein were diluted in 3x lamelli buffer. Concentrations were estimated and normalised to each other 
by SDS PAGE and Coomassie staining. Proteins were resolved on an SDS PAGE gel consisting of a 
stacking gel and 15% separation gel. The gel was then rinsed with water and incubated in IRDye® Blue 
Protein Stain (LiCor, 928-40002) for 30 minutes and destained with water. The Odyssey imager (Li-
Cor) was used to measure the intensity of the infra-red coomassie pro-IL-1α/β bands and concentrations 
were adjusted accordingly and compared to known concentrations of BSA.  
Box 2.7: SDS-PAGE buffer recipes 
1x Laemmli 
0.8ml Tris 1M pH 6.8  
1ml 20% SDS (Sigma Aldrich, 75746) 
1ml glycerol 
0.53ml β-mercaptoethanol (Sigma Aldrich, 
M6250) 
5mg bromophenol blue (Sigma Aldrich, 114391) 
Made to 10ml with ddH2O 
3x Laemmli 
2.4ml Tris 1M pH 6.8   
3ml 20% SDS 
3ml glycerol 
1.6ml β-mercaptoethanol  
5mg bromophenol blue  
Made to 10ml with ddH2O 
Stacking gel 
3.9ml ddH2O 
300µl 1M Tris pH6.8 
50µl 10% sodium dodecyl sulphate (SDS) 
700µl 30% Bis/Acrylamide (Biorad, 161-0158) 
25µl 100mg/ml ammonium persulphate (APS) 
(Thermofisher, 17874)  
10µl TEMED (Biorad, 1610801) 
15% separating gel 
3ml water 
2ml 2M Tris pH8.8 
100µl 10% SDS 
5ml 30% Bis/Acrylamide 
50µl 100mg/ml APS 
25µl TEMED 
Anode Buffer 
30g Tris  
5g SDS  
5L H2O  
pH 8.6 
Cathode buffer 
144g glycine  
30g Tris  
5g SDS  
5L H2O  
pH 8.6   
 
  
Materials and Methods 
36 
 
2.6 Cell culture 
2.6.1 HeLa, HEK-293T, human aortic vascular smooth muscle (VSMC) and mouse fibroblast 
cells 
Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Sigma Aldrich, D5671) with 10% 
foetal calf serum (FCS), 10U/ml penicillin, 10mg/ml streptomycin and 5mg/ml L-glutamine. Cells were 
passaged at 80% confluence using trypsin (Sigma Aldrich, T4049) 
2.6.2 THP-1, U937 and J2 cells 
Cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 Medium (Gibco, 31870-025)  with 
10% FCS, 10U/ml penicillin, 10mg/ml streptomycin and 5mg/ml L-glutamine. Cells were passaged to 
maintain a cell density of 2x105 cells/ml. 
2.6.3 Primary human macrophages 
Peripheral blood mononuclear cells (PBMCs) and serum were generously provided by members of 
Edwin Chilvers’ group (Department of Medicine, University of Cambridge) following blood separation 
by ficoll density gradient centrifugation. Cells were washed with Iscoves Modified Eagle Medium 
(IMEM) (Gibco, 21980) and centrifuged at 220g for 5 minutes. Cells were resuspended to 4x106 cells/ml 
and plated at 4ml/6-well or 500µl/48-well. Cells were incubated at 37oC for 1 hour, and non-adherent 
lymphocytes were washed away by pipetting. Cells were maintained in IMEM with 10% autologous 
serum, 10U/ml penicillin, 10mg/ml streptomycin and 5mg/ml L-glutamine for 6-7 days until 
macrophage-like.  
2.6.4 IMR90 fibroblasts 
IMR90 cells were cultured in phenol red free DMEM (Invitrogen, 31053) supplemented with 10% L-
Glutamine (Invitrogen, 25030-024), pyruvate (Invitrogen, 11360-070), penicillin, streptomycin and 
FCS.  
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2.6.5 Murine bone marrow-derived macrophages 
Bone marrow-derived macrophages (BMDM) from wild-type, Casp11-/- or Casp1-/-Casp11Tg mice 
(C57BL6/J background, 8-12 weeks old) were differentiated in RPMI 1640 with penicillin, 
streptomycin, L-glutamine and 10% FCS and 15% L929 conditioned media.  
 
2.7 Cell transfection 
2.7.1 Overexpression 
HEK-293T or HeLa cells were plated at 300,000 cells/well in a 6-well plate and incubated overnight at 
37oC. Plasmids and Fugene-HD (Promega, E2311) were mixed at a ratio of 1µg:3µl in a 200µl solution 
of Optimem medium (Gibco, 31985062), vortexed briefly, and incubated at room temperature for 20 
minutes. 100µl of plasmid/fugene was added per well, dropwise. Transfected cells were incubated for 2 
days at 37oC before further treatment. 
THP-1 and U937 cells were nucleofected with the Amaxa (Lonza) using the Cell Line Kits V (Lonza, 
VCA-1003) and C (VCA-1004) respectively. 1x106 cells were resuspended in 100µl supplemented 
nucleofector solution. 2µg plasmid DNA was added to the cells, which were transferred to a cuvette and 
nucleofected using the programme U-001 for THP-1s or W-001 for U937s. 500µl warm media was 
added directly to the cuvette, and the cells were then transferred to 1ml pre-warmed media containing 
100ng/ml PMA (Sigma, 16561-29-8) in a 12-well plate and incubated at 37oC overnight before 
treatment. 
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2.7.2 siRNA delivery 
Knockdown in primary macrophages was performed with 10pmol of non-targeting or CASP5-targeted 
siGENOME siRNA pool (Dharmacon), whilst knockdown in IMR90s was performed with 10pmol of 
individual siGENOME siRNAs (Table 2.3), using Lipofectamine RNAiMAX (Invitrogen, 13778030) 
as per the manufacturer’s instructions. 
 
Table 2.3: siRNAs (siGENOME, GE Dharmacon) 
GENE PROBE TYPE CATALOGUE NUMBER 
CASP5 
SMARTPool M-004405-02-0005 
Individual D-004405-19-0002 (si1) 
Individual D-004405-20-0002 (si2) 
CASP4 
Individual D-004404-01-0002 (si1) 
Individual D-004404-02-0002 (si2) 
GSDMD 
Individual D-016207-01-002 (si1) 
Individual D-016207-19-002 (si2) 
cGAS 
Individual D-015607-01-0002 (si1) 
Individual D-015607-02-0002 (si2) 
 
2.8 Lentiviral caspase knockdown 
2.8.1 Producing lentivirus 
HEK293T cells were grown to 50-70% confluency. For each tube, 1.6ml optimem and 42µl TransIT 
2020 (Mirus, MIR5400) were mixed and incubated for 5 minutes at room temperature. 4µg BYE (gifted 
by Jane Goodall), 4µg VSVg (gifted by Jane Goodall) and 6µg shRNA plasmid were added to each 
tube, vortexed and incubated at room temperature for 15 minutes. The mix was transferred to 12ml warm 
RPMI media supplemented with 10% FCS, 10U/ml penicillin, 10mg/ml streptomycin and 5mg/ml L-
glutamine. The plasmid-containing media was applied onto a T75 flask of HEK-293T cells. The media 
was replaced after 24 hours, and the 24 and 48 hour supernatants were pooled. The virus particles were 
pelleted by ultracentrifugation using a superspin 360 rotor at 30,000g for 90 minutes at 4oC. Media was 
tipped into virkon, and the virus was resuspended in the residual medium and stored at -80oC. 
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2.8.2 THP-1 infection 
1x105 THP-1 cells in 100µl media were seeded per well in a 96-well U-bottomed plate. 20µl virus was 
added per well and the plate was centrifuged at 2000rpm for 45 minutes at 37oC. Cells were transferred 
to 4ml warm media in a 6 well plate and incubated at 37oC for 72 hours. Transformed cells were selected 
using 1µg/ml puromycin for 72 hours.  
 
2.9 Retroviral caspase knockdown 
The retroviral infection of J2 cells was carried out by Aled Parry. Briefly, to produce retrovirus, 
amphotrophic phoenix packaging cells were transiently transfected using the calcium phosphate method. 
Cells were plated to achieve approximately 50-60% confluence the day before transfection. A 
DNA/CaCl2 solution for each plate was prepared by mixing 250mM CaCl2 with 15µg DNA vector in a 
total volume of 500µl before adding drop-wise to 500µl of BES buffered saline with continuous and 
vigorous mixing. The solution was added drop-wise to the phoenix packaging cells before overnight 
incubation. The media was changed and virus was allowed to accumulate for 24 hours. 
Conditioned media from the phoenix packaging cells was filtered (0.45µm) and transferred to the target 
cells with 5µg/ml polybrene three times in a single day, 4 hours apart, replacing the phoenix cell media 
each time. Target cells were incubated for 12-18 hours before changing the media. Cells were incubated 
for 24 hours to allow transgene expression, and selected using 6µg/ml puromycin for 3 days.   
Box 2.8: Retroviral infection buffer recipes 
BES buffered saline 
280mM NaCl 
1.5mM Na2HO4.2H2O 
50mM BES (NN-bis(2-hydroxyethyl)-2aminoethanesulphonic acid) pH6.95 
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2.10 Generation of necrotic cell lysates 
500,000 VSMCs were washed twice with 500µl PBS and resuspended in 50µl serum-free DMEM with 
or without 3mM calpeptin (Enzo, BML-PI101-0010) as indicated. Cells were incubated for 20 minutes 
at 37oC. Cells were then resuspended in 50µl of enzyme-specific cleavage buffer (as indicated in Table 
2.4) and freeze/thawed three times in liquid nitrogen. Cells were then centrifuged at maximum rpm to 
pellet debris, and the supernatant was taken for cleavage assays.  
 
2.11 Protease cleavage assays 
All cleavage assays were carried out using recombinant GST-p33 IL-1α / p33 IL-1β / pro-caspase-5 at 
4µg/ml. Enzymes were used at the concentrations / units per reaction stated. Table 2.4 below lists buffer, 
temperature and incubation time for each enzyme unless otherwise stated in Figure legends. Inhibitors 
were prepared as described in Table 2.5 and used at concentrations stated in Figure legends.  
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Table 2.4: Enzyme cleavage assay conditions 
ENZYME 
SOURCE & 
CATALOGUE 
NUMBER 
ASSAY BUFFER 
ASSAY 
TEMPERATURE 
ASSAY 
DURATION 
Calpain 
Merck, Calbiochem, 
Z08713 
100mM NaCl 2mM 
CaCl2 1mM DTT 
Room Temperature 1 hour 
Thrombin Merck, 69671-3 
10X Buffer provided in 
kit 
Room Temperature 2 hours 
Chymase 
Sigma Aldrich, 
C8118 
27mM Tris pH7.7 
150mM NaCl 
Room Temperature 2 hours 
Elastase 
Enzo, BML-SE284-
0100 
50mM Tris pH8.8 Room temperature 2 hours 
Granzyme B Biovision, 7233-10 PBS Room temperature 1 hour 
Staphylococcus 
GluC 
Peprotech, 450-46 10mM Tris pH8 Room temperature 2 hours 
Cathepsin B 
Enzo, BML-SE 
198-0025 
10mM Sodium Phosphate 
pH6 1.3mM EDTA 1mM 
DTT 
40oC 1 hour 
Proteinase 3 
Enzo, BML-SE498-
0025 
100mM MOPS pH 7.5 
500mM NaCl 10% 
DMSO 
Room temperature 1 hour 
Proteinase K 
Roche, 
03115828011 
PBS 
Room temperature / 
on ICE 
30 minutes 
HIV Protease Abcam, ab84117 50mM Tris pH 4.7 Room temperature 1 hour 
FAPα R&D, 3715-SE-010 
50mM Tris pH 7.5, 1M 
NaCl, 1mg/ml BSA 
Room temperature 1 hour 
MMP2 Peprotech, 420-02 
50mM Tris pH7.6 5mM 
CaCl2 1µM ZnCl2 
Room temperature 30 mins 
MMP8 R&D, 908-MP-010 
50mM Tris pH7.6 5mM 
CaCl2 1µM ZnCl2 
Room temperature 30 mins 
MMP9 R&D, 911-MP-010 
50mM Tris pH7.6 5mM 
CaCl2 1µM ZnCl2 
Room temperature 30 mins 
C1s R&D, 2060-SE-010 
50mM Tris pH 8 250mM 
NaCl 
Room temperature 1 hour 
KLK5 R&D, 1108-SE-010 
0.1M Sodium Phosphate 
pH 8 
Room temperature 1.5hours 
Caspase 14 
Enzo, BML-SE417-
5000 
1.1M Sodium Citrate Room temperature 2  hours 
Human 
Caspases 1-10 
Enzo, BML-
AK010-0001 
50mM HEPES pH7.4, 
100mM NaCl, 0.1% 
CHAPS, 1mM EDTA, 
10% glycerol, 10mM 
DTT 
37oC 1 hour 
Murine Caspase 
11 
Enzo, BML-SE155-
5000 
100mM MES pH6.5, 
0.1% CHAPS, 10% PEG 
(MW8KDa), 10mM DTT 
Room Temperature 1 hour 
Murine Caspase 
1 
Novus Biologicals, 
NBP1-99607 
50mM HEPES pH7.2, 
50mM NaCl, 0.1% 
CHAPS, 10mM EDTA, 
5% Glycerol, 10mM DTT 
Room temperature 1 hour 
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Table 2.5: Enzyme Inhibitors  
INHIBITOR SOURCE COMMENTS 
Calpeptin Enzo, BML-P1101-0010 
Used at 120µM unless otherwise 
stated 
PPACK Enzo, BML-PI117 
Used at 100µM unless otherwise 
stated. 
Thrombomodulin R&D, 3947-PA 
Reconstituted at 0.1mg/ml in sterile 
water. Used at 10:1 
thrombomodulin:thrombin.  
Fibrinogen ThermoFisher, RP-43142 
Reconstituted by layering on top of 
37oC PBS at 9mg/ml and gently 
agitating. Sterile filtered through a 
0.2µm filter.  
Z-LEVD-fmk Enzo, ALX-260-142-R100 
Used 600µM in recombinant protein 
assays and 20µM in cell-based assays 
Z-YVAD-fmk Enzo, ALX-260-154-R100 
Used 600µM in recombinant protein 
assays and 20µM in cell-based assays 
Z-VAD-fmk Enzo, ALX-260-138-R100 
Used 600µM in recombinant protein 
assays and 20µM in cell-based assays 
 
 
2.12 Activating complement in human serum 
10ml blood was drawn using a 21G needle into 1ml 3.8% pH7 sodium citrate and centrifuged at 280g 
for 20 minutes at room temperature. The platelet-rich-plasma (PRP) layer was removed and transferred 
into a 15ml falcon tube. 22µl/ml 1M CaCl2 was added and the plasma was incubated at 37oC until 
clotted. The tube was centrifuged at maximum speed for 1 minute and the serum was removed and stored 
at -20oC. The serum was activated with 350µg/ml Zymosan in PBS pH7.5 0.15mM CaCl2 0.5mM MgCl2 
for 2 hours at 37oC with/without 1mM PPACK. 
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2.13 Calpain plasma IL-1α reveal assay 
20µl of plasma was incubated with either 5µl PBS or 4µl calpain + 1µl 60mM CaCl2 for one hour at 
room temperature.  
 
2.14 IL-1 activity assay 
10,000 HeLa cells or mouse fibroblasts in 200µl full media were plated in a 48-well tissue culture plate 
and incubated at 37oC overnight. Media was replaced, and treatments were added as indicated, with 
2µg/ml of human IL-1α (Peprotech, 500-P21A), human IL-1β (Peprotech 200-01B), murine IL-1α 
(Peprotech, 211-11A) or murine IL-1β (Peprotech, 211-11B) antibody to demonstrate IL-1 dependent 
activity. IL-1R2 (R&D, 263-2F/CF) and/or IL-1RAcp (Sino Biologics, 10121-H08H) were pre-
incubated for 20 minutes and added at the doses indicated. For each experiment, a negative control of 
media alone and a positive control of 10ng/ml recombinant human IL-1α (Peprotech, 200-010A) human 
IL-1β (R&D, AF-201-NA), murine IL-1α (R&D, AF-400-NA) or murine IL-1β (Peprotech, 500-P51) 
were included. Data were normalised to the positive control.  
 
2.15 Inflammasome activation 
Cells were primed in full media for 4 hours with 1µg/ml LPS-Ultrapure (Sigma) or 2µg/ml PAM3CSK4 
(Invivogen, tlrl-pms) as indicated. For canonical inflammasome activation cells were treated with 5mM 
ATP (Invivogen, tlrl-atp) in Opti-MEM (Gibco, 31985062) for 16-18 hours. For non-canonical 
inflammasome activation, a 2x LPS fugene mix was prepared. Per 1ml optimem, 10µl 1mg/ml LPS 
ultrapure and 5µl Fugene-HD (Promega, E2311) were added. The mix was vortexed briefly and 
incubated at room temperature for 20 minutes. Cells were treated with an equal volume of optimem and 
LPS/fugene mix for 16-18 hours. Supernatants were taken for future analysis and cells were lysed in 
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either 0.5% NP-40 (Sigma, 7435) or lamelli buffer. Supernatants from murine BMDMs infected with 
Chlamydia trachomatis were generously provided by the Goodall group. 
 
2.16 Senescent cell assays 
2.16.1 IMR90s 
Senescence was induced in ER:HRASG12V IMR90 cells by treatment with 100nM 4-hydroxytamoxifen 
(Sigma Aldrich, H7904) for 7 days. Cells were seeded in a 6-well plate (300,000 cells/ml). siRNA-
mediated knockdown was performed on day 3 for surface IL-1α analysis, or day 5 for cytokine 
measurements. Cells were harvested for flow cytometry and cytokine measurement on days 5 and 7 
respectively. IMR90s were treated from day 0 with 5µM punicalagin (Sigma ,P0023) or 100µM ascorbic 
acid (Sigma, A4403) where indicated. 
2.16.2 Primary murine fibroblasts 
Senescence was induced with 50µg/ml bleomycin sulphate (Sigma, B1141000) for 3 hours, followed by 
7-14 days of incubation at 37oC. 
 
2.17 Hydrodynamic tail vein injection 
This animal work was carried out by the Narita group at the Cancer Research UK Cambridge Institute. 
Mice were handled and kept under pathogen-free conditions in accordance with UK law and institutional 
guidelines at the University of Cambridge. Transposon-mediated gene transfer by hydrodynamic tail 
vein injection was as previously described (Kang et al., 2011). Briefly, female C57BL/6 mice (Charles 
River) were injected via the lateral tail vein with MLP CaNIGmir30 (20µg) and SB13 transposase vector 
(5µg) in PBS at a volume equivalent to 10% of body weight in less than 10 seconds, and livers were 
harvested at the times indicated. 
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2.18 Human SNP study design 
Study participants were recruited by the Cambridge Bioresource (CBR) based on pre-defined criteria. 
Subjects were males aged 18-40 with a BMI between 18.5 and 32 and no known inflammatory 
conditions or infections. Subjects were not included if they had been vaccinated within the last three 
months, taken painkillers (e.g. paracetamol, asprin, ibuprophen) on the day of blood donation, or steroids 
on the week of blood donation. Individuals were also excluded if they were taking medication for 
allergies or high blood pressure. Blood was drawn by nurses at the CBR and passed directly to the 
researcher waiting outside so that participants remained anonymous. The initial pilot study included 20 
participants: 10 homozygous for the major allele and 10 homozygous for the minor allele. Power 
calculations based on the results from the pilot study led to the recruitment of a further 15 individuals 
per group (50 total participants). Both the pilot and subsequent studies were carried out blinded, and 
genotypes were revealed after all data had been collected.  
 
2.19 Whole blood LPS stimulation 
Blood was drawn into either EDTA for full blood counts or lithium heparin for IL-1α assays, which 
were carried out in triplicate. Blood was diluted as indicated in a 6-well plate into IMEM with 10U/ml 
penicillin, 10mg/ml streptomycin and 5mg/ml L-glutamine with or without 1µg/ml LPS (Sigma, 
L2630). The blood was incubated at 37oC for 22 hours and centrifuged at 400g for 5 minutes. Plasma 
from individual triplicates was taken and stored at -80oC for later analysis, and the remaining red blood 
cell pellets were pooled and stored at -80oC. Adherent monocytes were washed with PBS and harvested 
into trizol, pooling triplicate wells, and stored at -80oC for later analysis.  
 
 
 
Materials and Methods 
46 
 
2.20 RNA extraction 
RNA from most samples was extracted using the RNeasy Mini Kit (Qiagen, 74104) according to kit 
instructions. For liver-derived RNA, the tissue was collected into RNAlater, stored overnight at 4oC, 
and transferred to -80oC until purification, and homogenised in RLT using a TissueLyser-LT (Qiagen). 
RNA from the whole blood LPS-stimulation experiments were extracted using trizol. Adherent 
monocytes were directly collected into 200µl trizol and incubated at room temperature for 5 minutes. 
40µl chloroform was added and each sample was shaken vigorously for 15 seconds and incubated at 
room temperature for 2-3minutes. The samples were centrifuged at 12000g for 15 minutes at 4oC. The 
upper aqueous phase was taken for RNA extraction. 100µl 100% isopropanol was added to each sample 
and incubated for 10 minutes at room temperature. Samples were centrifuged at 12000g for 10 minutes 
at 4oC to pellet the RNA. The supernatant was discarded and the RNA pellet was washed with 200µl 
75% ethanol. The samples were vortexed briefly and centrifuged at 7500g for 5 minutes at 4oC. The 
supernatants were discarded and the pellets were air dried and resuspended in 20µl RNAase/DNAase 
free water. RNA was incubated at 55-60oC for 10 minutes. All RNA was quantified using a Nanodrop 
and stored at -80oC. 
 
2.21 cDNA Synthesis 
cDNA was synthesised using the Reverse Transcription System (Promega, A3500) 1.5µg RNA was 
diluted to 9µl with water. 1µl oligodT, 0.5µl random primers and 2µl dNTPs per sample were added, 
and tubes were incubated at 70oC for 10 minutes and then immediately transferred to ice. 4µl MgCl2, 
5µl 10x buffer, 0.5µl RNAsin and 1µl AMV Reverse Transcriptase were added per tube and samples 
were incubated for 10 minutes at 25oC, 50 minutes at 42oC, and 5 minutes at 95oC. Samples were cooled 
to 4oC and stored at -20oC. 
cDNA from study participants of the human recall-by-genotype study was prepared using the 
SuperScriptTM VILOTM cDNA synthesis kit (ThermoFisher, 11754050). 8µl RNA was added to 2µl 
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mastermix, and incubated for 10 minutes at 25oC, 10 minutes at 50oC, and 5 minutes at 85oC. 0.5µl of 
each sample was pooled for the standard curve, and samples were stored at -20oC.  
 
2.22 qPCR 
Each sample contained 2µl 10X Buffer, 1.6µl 25mM MgCl2, 0.1µl AmpliTaq Gold (all from 
Thermofisher, LifeTechnologies), 0.4µl dNTPs (10mM each), 0.5µl Taqman Probe (Table 2.6) 1µl 
cDNA and 14.4µl H2O. The qPCR reaction was carried out using a Rotorgene thermocycler and 
analysed using the 2-ΔΔCT method. For the rs17561 human study, a standard curve was produced by 
pooling 1µl of each RNA sample, and creating a serial dilution.  
 
Table 2.6: Taqman Probes (Life Technologies) 
SPECIES GENE CATALOGUE NUMBER 
HUMAN 
GUSB Hs00939627_m1 
CASP1 Hs00354836_m1 
CASP4 Hs01031951_m1 
CASP5 Hs00362078-m1 
cGAS Hs00403553_m1 
GSDMD Hs00986739_g1 
MOUSE 
GUSB Mm00446957_m1 
CASP1 Mm00438023_m1 
CASP11 Mm00432304_m1 
 
2.23 LDH assay 
Reagents from the Pierce LDH Cytotoxicity Assay Kit (Thermoscientific, 88954) were warmed to room 
temperature prior to use and the assay was carried out as per the kit instructions. 
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2.24 IL-1R2 ELISA 
Reagents from the IL-RII ELISA kit (R&D, DR1B00) were warmed to room temperature prior to use 
and the ELISA was carried out as per the kit instructions. 
 
2.25 Bead ELISAs 
Reagents from kits listed in Table 2.7 were used for the bead ELISAs in a 96-well MultiScreen 1.2µm 
filter plate (Merck Millipore, MSBVN1250). Per well, 1.25µl antibody beads, 5µl biotinylated 
secondary antibody and 20µl buffer (PBS 1% BSA) were added to 25µl sample and incubated for 2 
hours at room temperature in the dark with agitation. Wells were washed twice with 200µl buffer. 50µl 
4µg/ml streptavidin-PE (eBioscience 12-4317-87) was added per well and incubated for 1 hour at room 
temperature in the dark. Wells were washed twice with 200µl buffer, resuspended in a 200µl buffer, and 
analysed by flow cytometry. The average PE fluorescence was measured for 300 beads on the flow 
cytometer (BD Accuri), and concentrations were determined using a standard curve. 
 
Table 2.7: Luminex Bead Kits (Novex Life Technologies) 
SPECIES CYTOKINE CATALOGUE NUMBER 
HUMAN 
IL-1α LHC0811 
IL-1β LHC0011 
IL-6 LHC0061 
IL-8 LHC0081 
MCP-1 LHC1011 
CRP LHP0031 
MOUSE 
IL-1α LMC0811 
IL-1β LMC0011 
IL-6 LMC0061 
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2.26 p18 IL-1α ELISA 
The anti-hIL-1α/Immp18 antibody was generated by immunising rabbits with a KLH conjugated 
peptide, followed by affinity purification and biotinylation (Innovagen). 
A 96-well flat bottom ELISA plate (CoStar, 3591) was coated with 100µl 1µg/ml anti-human IL-1α 
antibody in PBS (R&D, AF-200-NA) overnight. The plate was washed four times, blotted dry on paper 
towel, and blocked for 1 hour. The plate was washed 4 times and 100µl sample/standard (Peprotech, 
200-01A) was added per well and incubated for 2 hours. The plate was washed 4 times and 100µl 
400ng/ml anti-hIL1α/Immp18 antibody (Innovagen) was added per well and incubated for 2 hours. The 
plate was washed 4 times and 100µl of 164ng/ml biotinylated anti-rabbit antibody (Dako, E0432) was 
added per well and incubated for 1 hour. The plate was washed 4 times and 100µl of Streptavidin-HRP 
(R&D, DY998) was added per well and incubated for 1 hour. The plate was washed 4 times and 100µl 
of substrate solution was added per well and incubated in the dark until good standard curve colour 
development was achieved. 50µl 2N H2SO4 was added per well to stop the reaction, and the plate was 
read at 450nm (corrected at 540nm). All incubations were at room temperature with agitation. 
Box 2.9: p18 ELISA buffers 
Wash buffer 
0.05% Tween 20 
PBS 
Block buffer 
1% BSA 
PBS 
Antibody / HRP diluent buffer 
0.1% BSA 
005% Tween 
PBS 
Substrate solution 
0.1M Sodium citrate pH5 
0.006% H2O2 
75µg/ml TMB 
 
2.27 Western blotting 
Western blots on caspase 11 cleavage assay samples were run using pre-cast 1mm NuPAGETM NovexTM 
4-12% Bis-Tris Protein Gels (ThermoFisher, NP0322BOX) in MES Buffer. For all other blots, proteins 
were resolved on a 15% SDS PAGE gel. 15µl Western Blot lysates were loaded and run alongside 15µl 
of protein ladder (Biorad, 161-0374). The gel was run using a chamber filled with anode and cathode 
buffers at 100V until the dye front reached the bottom of the gel. The gel was equilibrated with transfer 
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buffer (2M Glycine, 250mM Tris pH 8.6) for 5 minutes before being blotted onto 0.2µm PVDF 
membrane (Biorad, 162-0177) at 85mA for 2 hours. The gel was stained with coomassie (Biorad, 161-
0787) and vacuum dried whilst the membrane was blocked for 1 hour in PBS 5% milk (Marvel). The 
membrane was incubated with primary antibody diluted in block buffer overnight at 4oC, washed 4 times 
with PBS/Tween 0.05%, incubated in secondary antibody diluted in block buffer for 1 hour at room 
temperature, washed 4 times with PBS/Tween 0.05%, developed with mixed ECL reagent (GE 
Healthcare, RPN2106) and exposed to film (Fujifilm). All antibody combinations are listed in Table 2.8. 
When used, the unstained protein ladder (Biorad,1610343) was run alongside the stained ladder. 
Following transfer, the membrane was cut halfway through the stained ladder. The membrane was then 
stained with 0.1% Coomassie R-250 in 50% MeOH (BioRad, 1610400) for 30 minutes at room 
temperature and destained with 50%MeOH 10%Acetic Acid and allowed to dry. The stained ladder was 
used to realign the membrane. 
Table 2.8: Western Blot Antibodies 
TARGET PRIMARY ANTIBODY 
(DILUTION) 
SECONDARY ANTIBODY 
(DILUTION) 
Human IL-1α 
Rabbit anti-hIL-1α ,Peprotech 
500-P21A (1:250-1:500) 
Donkey Anti-Rabbit HRP, GE 
Healthcare NA934V (1:2000) 
Human IL-1β 
Goat anti-hIL1β, R+D AF-201-
NA (1:500) 
Cow Anti-Goat HRP, Jackson 
805-035-186 (1:2000) 
Human Caspase 5 
Rabbit anti-human caspase-5, 
ProteinTech 17991-1-AD (1:500) 
Donkey Anti-Rabbit HRP, GE 
Healthcare NA934V (1:2000) 
Murine IL-1α 
Goat anti-mIL-1α, R&D AF-400-
NA (1:500) 
Cow Anti-Goat HRP, Jackson 
805-035-186 (1:2000) 
Murine IL-1β 
Rabbit anti-mIL-1β, Peprotech 
500-P51 (1:500) 
Donkey Anti-Rabbit HRP, GE 
Healthcare NA934V (1:2000) 
 
2.28 N-terminal sequencing 
Samples containing the cleavage reaction, the enzyme alone and the substrate alone were resolved on a 
15% SDS-PAGE gel and transferred onto a PVDF membrane as previously described. The membrane 
was rinsed with water and stained with 0.1% Coomassie R-250 in 50% MeOH for 5 minutes at room 
temperature, destained with 50%MeOH 10%Acetic Acid, air-dried, and sent for N-terminal sequencing 
(Alta Bioscience).  
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2.29 Immunohistochemistry (IHC) and immunoflourescence (IF) 
Sectioning and IHC was kindly carried out by the histology core facility at the CRUK Cambridge 
Institute. After processing paraffin sections were cleared before antigen retrieval with 10mM sodium 
citrate pH6 and blocking for 1 hour with M.O.M. (Vectorlabs, MKB-2213) and 0.5% donkey serum 
(Sigma Aldrich, D9663). Sections were incubated at 4oC for 16 hours with the primary antibodies (Table 
2.9), washed three times with TBS-tween, and incubated with secondary antibody (Table 2.9) and DAPI 
(Sigma Aldrich, D8417-10MG) for 1 hour at room temperature. Autofluorescence was reduced by 10 
minutes incubation with 0.1% Sudan Black (Sigma Aldrich, 199664-25G) before mounting in 
VECTASHIELD (Vector Laboratories, H-1400). IHC sections were counterstained with haematoxylin. 
Slides were imaged on a TCS SP8 microscope or scanned on an Aperio AT2 (both Leica). Images were 
analysed with HALO (Indica Labs) and the Cytonuclear v1.4 algorithm. 
 
Table 2.9: IF / IHC Antibodies 
TARGET PRIMARY ANTIBODY 
(DILUTION) 
SECONDARY ANTIBODY 
(DILUTION) 
NRAS (IF) 
Mouse anti-mouse NRAS, Santa 
Cruz, sc-31 (1:250) 
Donkey anti-mouse 647, Life 
Technologies A-31571 (1:250) 
Mouse Caspase-11 (IF) 
Rat anti-mouse Casp11, R&D, 
MAB86481 (1:50) 
Donkey anti-rat 488, Life 
technologies A-21208 (1:250) 
Mouse CD355 (IF) 
Rat anti-mouse CD355, 
Biolegend, 137602 (1:100) 
Donkey anti-rat 488, Life 
technologies A-21208 (1:250) 
Mouse Ki67 (IF) 
Rabbit anti-mouse Ki67, Genetex, 
16667[SP8] (1:500) 
Donkey anti-rabbit 555, Life 
technologies A-31572 (1:250) 
NRAS (IHC) 
Mouse anti-mouse NRAS, Santa 
Cruz, sc-31 (1:250) 
Envision+ Kit, K500711-2, 
Aligent Techologies 
F4/80 (IHC) 
Rat anti-mouse F4/80 Serotec, 
MCA497 (1:100) 
Envision+ Kit, K500711-2, 
Aligent Techologies 
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2.30 BrDu and SAHF staining 
Cells were incubated with 100µg/ml 5-Bromo-2’-deoxyuridine for 6 hours at 37oC, before fixing with 
4% formaldehyde for 15 mins at room temperature. Cells were permabilised with 0.2% Triton X-
100/PBS and blocked with 0.5% goat serum (Sigma Aldrich, G6767). Cells were incubated with anti-
BrdU (BD, 555627, 1:500) for 45 minutes at room temperature, washed three times with 0.05% 
Tween/PBS, and incubated for 1 hour with goat anti-mouse Alexa-488 (ThermoFisher, A-11034, 1:500) 
and 1µg/ml DAPI. Cells were mounted in VECTASHIELD and slides were imaged with a TCS SP8 
microscope (Leica). 
 
2.31 Senescence-associated beta galactosidase staining 
Cells were fixed with 2% formaldehyde for 3 minutes at room temperature, and washed 4 times with 
PBS. Cells were incubated for 18 hours at 37oC in SAβGAL staining solution. 
Box 2.10: SAβGAL staining solution 
40mM citric acid/sodium phosphate buffer pH6.0 
5mM K4[Fe(CN)6]3H2O 
5mM K3[Fe(CN)6] 
150mM NaCl 
2mM MgCl2 
1mg/ml Xgal 
 
2.32 Cell surface IL-1α staining 
Cells were detached with accutase, fixed in 2% formaldehyde for 5 minutes at room temperature, and 
washed with 0.5%BSA/0.05%NaN3/PBS. Cells were blocked with 1:100 human Fc block (Biolegend, 
422301) for 10 minutes at room temperature, before incubation with 1:20 anti-IL-1α-PE (IC002P, R&D) 
or 1:20 isotype control-PE (FAB200-P, R&D; 1:20) for 30 minutes at room temperature. Cells were 
then washed and analysed by flow cytometry (Accuri C6). 
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2.33 Statistical analysis 
All data are expressed as mean ± standard error of the mean (SEM), unless otherwise stated. To compare 
the means of two populations, an unpaired t-test was used. For experiments with more than two 
populations, a one-way ANOVA was used unless there were two variables (e.g. time and concentration), 
in which case a two-way ANOVA was used. For comparison of each mean with a control mean, a 
Dunnett’s post-hoc test was used. To compare every mean to every other mean, a Tukey’s post-hoc test 
was used. Linear regression analysis was applied to determine correlation. All statistical analyses were 
carried out using the software GraphPad Prism with a threshold for significance set at p≤0.05.
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3. Results: The IL-1α pro-domain inhibits cytokine activity 
3.1 Introduction 
IL-1α is translated as a precursor protein containing a pro-domain of approximately 100 amino acids, 
which can be proteolytically removed by the calcium-dependent cysteine protease calpain (Kobayashi 
et al., 1990). The secretion of IL-1α has been an area of ongoing interest because it lacks a conventional 
signal peptide, does not localise to the Golgi apparatus or ER, and is translated on ribosomes that are 
associated with the cytoskeleton rather than the membrane (Stevenson et al., 1992). The pro-domain 
does, however, contain a stretch of basic amino acids that form a nuclear localisation signal (NLS) 
(Wessendorf et al., 1993). 
Multiple functions have been described for nuclear IL-1α, which are thought to be driven by the 
propiece. These functions include binding to histone acetyl transferases (HATs) to regulate chromatin 
remodelling, and detecting DNA damage (Zamostna et al., 2012, Buryskova et al., 2004, Cohen et al., 
2015). Nuclear IL-1α has also been described to regulate senescence by decreasing endothelial cell 
proliferation and migration (McMahon et al., 1997). Overexpression of the IL-1α propiece in 
transformed HEK cells also induces apoptosis by localising to spliceosome assembly sites, where it 
interacts with RNA-processing enzymes to alter the splicing of apoptotic proteins such as Bcl-X (Pollock 
et al., 2003).  
In contrast to this, the IL-1α propiece has been reported to promote tumour progression by acting as a 
transforming oncoprotein. Overexpression of the pro-domain in glomerular mesangial cells leads to their 
malignant transformation into malignant Karposi sarcoma spindle cells (Stevenson et al., 1997). 
Similarly, overexpression in T cell leukaemia cells promotes proliferation by binding to the SP1 
promoter and upregulating NF-κB signalling, leading to the increased transcription of mitogen and 
growth factor genes (Zhang et al., 2017).  
The role of the pro-domain in regulating intracellular IL-1α actions is reasonably well established. 
However, its function in regulating classical IL-1α cytokine activity has been a topic of considerable 
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debate. The longstanding view in the literature was that pro-IL-1α is “fully active”. However, most 
publications that make this statement either lack an appropriate reference or cite another article that in 
turn does not provide a source (Garlanda et al., 2013, Dinarello, 2009, Dinarello et al., 2012). Although 
an early paper by March and colleagues reports that pro-IL-1α exerts biological activity, there is no 
direct comparison to mature IL-1α (March et al., 1985). There is a single study that investigated the 
biological activity of the IL-1 precursors, which reported that pro-IL-1α is active whereas pro-IL-1β is 
not (Kim et al., 2013). However, in this study the recombinant IL-1α used was purified by high-pressure 
liquid chromatography (HPLC), whereas the recombinant IL-1β was purified by ion exchange 
chromatography. During HPLC, the sample is passed through a column at high pressure in a denaturing 
solvent such as acetone, and as a result the purified proteins often lose their native conformation. 
Therefore, it is possible that the IL-1α generated for these experiments was partially or fully unfolded. 
Furthermore, the data presented in this report consistently shows that although pro-IL-1α has some 
cytokine activity, the mature form is significantly more potent. 
Recent research, by ourselves and others, demonstrates that the biological activity of pro-IL-1α is 
reduced compared to the mature cytokine. Afonina and colleagues showed that IL-1α is cleaved by the 
cytotoxic protease Granzyme B, which significantly increases cytokine activity. They demonstrated this 
both in vitro using recombinant IL-1α in cell assays, but also in vivo by showing that the granzyme B-
cleaved form of IL-1α exhibited significantly higher adjuvant activity in ovalubumin-immunised mice. 
They expanded this finding by showing that the additional enzymes elastase, chymase, and calpain could 
all dramatically enhance IL-1α cytokine activity (Afonina et al., 2011). Work from our group has 
supported this finding by demonstrating that calpain-cleaved IL-1α is significantly more active than pro-
IL-1α due to a 50-fold higher affinity for the IL-1R1 (Zheng et al., 2013).  
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3.1.1 Chapter 3 project rationale 
The fact that pro-IL-1α is markedly less active than mature IL-1α strongly suggests that the pro-domain 
inhibits cytokine activity. The work presented in this chapter explores this in more detail by validating 
our previous observations regarding the relative activities of pro- and mature IL-1α, and interrogating 
how much of the pro-domain is required for this inhibitory function. 
 
 
 
  
  Results: The IL-1α pro-domain inhibits cytokine activity  
58 
 
3.2 Results 
3.2.1 Making recombinant human pro-IL-1α 
To investigate the effect of proteolytic cleavage on IL-1α activity, human recombinant GST-tagged pro-
IL-1α was expressed, purified and quantified (Figure 3.1). Although a GST-tag is larger than a His-tag 
and potentially more sterically obstructive, the method of GST purification produces soluble protein in 
a native structure. We have previously observed that the basal activity of His-pro-IL-1α is higher than 
GST-pro-IL-1α, probably due to the denaturation and renaturation that is required to solubilise the 
protein from inclusion bodies during His purification. Importantly, we have previously shown that the 
GST tag does not affect IL-1α activity or detection (Zheng et al., 2013). 
 
 
 
Figure 3.1: Production of human recombinant IL-1α. (A) pGEX-4T-3 vector map annotated with key features 
including the multiple cloning site (MCS). (B) Trace of the elution of purified recombinant IL-1α from the AKTA 
FPLC highlighting the fractions containing the major peak (red box). (C) Western blot for IL-1α at each stage of 
the protein purification process. (D) Example gel scan for concentration normalisation by coomassie staining.  
A. 
B. C. D. 
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3.2.2 Mature human IL-1α is significantly more active than pro-IL-1α 
Two assays were used to evaluate IL-1α processing and bioactivity. All commercial IL-1α ELISA kits 
only detect the cleaved form of IL-1α, and not the pro-form. Figure 3.2A below exemplifies this, 
showing that when over 55,000pg/ml of p33 pro-IL-1α was applied to the ELISA, less than 40pg/ml 
was detected. To complement the IL-1α ELISA, a bioassay was used to assess IL-1α activity. In this 
assay HeLa cells secrete IL-6 in response to active IL-1α, which can be measured by ELISA (Figure 
3.2B).  
 
 
 
 
To determine which form of IL-1α is most active, two recombinant proteins were produced: p33 pro-
IL-1α and p17 IL-1α (representative of the calpain-cleaved product). HeLa cells were treated with a 
dose response of each form of IL-1α, and IL-6 release was measured as a readout of bioactivity (Figure 
3.3). The p17 mature IL-1α was significantly more active than the p33 pro-IL-1α, particularly at lower 
concentrations. This data shows that the absence of the pro-domain leads to increased IL-1α activity. 
 
Figure 3.2: Techniques for assessing IL-1α cleavage and activity. (A) IL-1α ELISA data showing minimal detection 
of p33 pro-IL-1α. (B) Schematic of the IL-1α bioassay. 
A. B. 
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To demonstrate that the proteolytic activation of IL-1α is not an artefact of using bacterial recombinant 
protein, human vascular smooth muscle cells (VSMCs) were used as a source of mammalian cell-
derived IL-1α. Unlike most cell types, VSMCs do not express significant levels of the decoy receptor 
IL-1R2 that would otherwise ‘protect’ IL-1α from calpain processing during necrosis (Zheng et al., 
2013). Freeze/thaw VSMC lysates were prepared with or without pre-incubation with the calpain 
inhibitor calpeptin. Calpeptin prevented IL-1α processing, as shown by both western blot (Figure 3.4A) 
and the cleaved IL-1α-specific ELISA (Figure 3.4B). The IL-1 bioassay indicated that the lysates 
prepared without calpeptin contained significantly more IL-1α-specific activity (as evidenced by a 
neutralising antibody) than those made with calpeptin (Figure 3.4C). Together these results support the 
recombinant protein data, and confirm that mature IL-1α is significantly more active than pro-IL-1α. 
Figure 3.3: Recombinant mature IL-1α is significantly more active than pro-IL-1α. ELISA data showing IL-6 
secretion by HeLa cells treated with increasing concentrations of mature IL-1α (p17) or pro-IL-1α (p33). Data 
represents mean ± SEM of n=3, p = **≤0.01. 
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Figure 3.4: Calpain-cleaved cell-derived IL-1α is significantly more active than pro-IL-1α. (A-B) Western blot for 
IL-1α (A) and cleaved IL-1α ELISA data (B) showing levels of IL-1α processing in vascular smooth muscle cell 
(VSMC) lysates prepared ± preincubation with calpeptin (CP). (C) ELISA data showing baseline levels of IL-6 
present in VSMC lysates and IL-1α-dependent IL-6 release by HeLa cells treated with VSMC lysates ± a 
neutralising IL-1α antibody (α pAb). Data represents mean ± SEM of n=3, p = **≤0.01, ***≤0.001. 
A. B. 
C. 
  Results: The IL-1α pro-domain inhibits cytokine activity  
62 
 
3.2.3 A model of IL-1α autoinhibition 
Based on the presented functional data, we propose a model of IL-1α autoinhibition (Figure 3.5) that 
resembles that reported for IL-1β (Mosley et al., 1987b). We suggest that the pro-domain folds over the 
cytokine domain and obscures key residues for receptor interaction and cytokine activity. This physical 
obstruction would also explain the lack of pro-IL-1α detection by the ELISA kits, because the pro-piece 
is ‘hiding’ one of the two epitopes that the ELISA antibodies bind. We also propose that the region 
between the pro-domain and cytokine domain protrudes from the IL-1α protein to form a ‘loop’ structure 
that is particularly accessible to proteases. 
 
 
 
 
  
Figure 3.5 Proposed autoinhibition model. A schematic illustrating our working model of the pro-domain folding 
over and masking key residues in the cytokine domain for IL-1α function.  
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3.2.4 IL-1α autoinhibition is mediated by amino acids 56-77 
To define how much of the pro-domain is required to limit IL-1α activity, a series of N-terminal 
truncation mutants were produced. The pro-domain of IL-1α contains blocks of highly conserved amino 
acids with no reported function. Since conservation is often indicative of function, the truncation mutants 
were designed based on these regions of conservation (Figure 3.6).  
 
 
 
 
 
 
 
Figure 3.6 Truncation mutant design. Multiple species alignment of IL-1α protein sequence, with highly 
conserved areas shaded in grey. Red annotations indicate the N-terminal region of IL-1α protein 
removed in each truncation mutant.  
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To assess the effect of each truncation on activity, HeLa cells were treated with a range of matched 
concentrations of each mutant, pro-IL-1α (p33), and mature IL-1α (p18) (Figure 3.7). The dose response 
curves revealed that removing the first 56 amino acids of pro-IL-1α did not affect autoinhibition. Only 
the mutant lacking the first 77 amino acids (Δ77) had identical activity to mature IL-1α. This indicates 
that the N-terminal half of the pro-piece is not required for its autoinhibitory function, and that cytokine 
activity is limited by amino acids 57-77.  
 
 
 
 
 
 
 
 
 
 
Figure 3.7 Amino acids 56-77 are critical for IL-1α autoinhibition. ELISA data showing IL-6 secretion by HeLa cells 
treated with increasing concentrations of mature IL-1α (p18), pro-IL-1α (p33), or truncated pro-IL-1α (Δ37, 
Δ56 and Δ77). Data represents mean ± SEM of n=3. 
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3.2.5 The PXXXP motif maintains basal pro-IL-1α activity 
In our model of IL-1α autoinhibition, we propose the region between the pro-domain and cytokine 
domain forms a ‘loop’ that is targeted by proteases. The multiple species IL-1α alignment shows a 
conserved PXXXP motif within this ‘loop’ (Figure 3.8). Proline is an important determinant of protein 
structure due to the covalent bond between its side chain and the peptide backbone. This is disruptive to 
α-helix and β-strand conformations, and proline residues therefore occur in turns and direct protein 
folding (Deber et al., 2010).  
 
 
 
 
 
 
 
Figure 3.8 The PXXXP Motif. Multiple species alignment of the IL-1α protein sequence, with highly conserved 
areas shaded in grey. Green annotation indicates location of the PXXXP motif.  
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To test if the PXXXP motif forms a hinge in the IL-1α protein and positions the pro-domain over the 
cytokine domain to facilitate autoinhibition, one (P111A) or both (P111A/P115A) prolines were mutated 
an alanine. These mutations were expected to restore full IL-1α activity by unfolding the hinge in the 
loop region. However, both proline mutations completely abrogated basal p33 IL-1α activity (Figure 
3.9). This suggests that these prolines are indeed important for the structure of pro-IL-1α, but are not 
holding the cytokine in an inhibitory conformation as predicted.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 The PXXXP motif regulates basal pro-IL-1α activity. ELISA data showing IL-6 secretion by HeLa cells 
treated with increasing concentrations of mature IL-1α (p18), pro-IL-1α (p33), or proline-mutant pro-IL-1α 
(P111A and P111A/P115A). Data represents mean ± SEM of n=2. 
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3.3 Discussion 
The biological activity of pro-IL-1α has been a matter of great controversy for a number of years. An 
early study suggested that pro-IL-1α is active (March et al., 1985); a statement that has become accepted 
over time without proper validation. More recent publications reporting that pro-IL-1α is fully active 
reference a single study that specifically addressed the relative bioactivities of the precursor and mature 
forms of IL-1α and IL-1β (Kim et al., 2013). However, the authors of this study purified recombinant 
IL-1α, but not IL-1β, by HPLC, which is a technique known to cause protein unfolding. Furthermore, 
despite the high basal activity of pro-IL-1α in this study, mature IL-1α was still significantly more active. 
Both ourselves, and others, have demonstrated that IL-1α activity is dramatically enhanced via cleavage 
by multiple proteases including calpain and granzyme B (Afonina et al., 2011, Zheng et al., 2013).  
Here, we show that calpain-mediated processing dramatically enhances the bioactivity of both bacterial 
recombinant and human VSMC-derived IL-1α, particularly at low concentrations (Figures 3.3 and 3.4). 
IL-1α is constitutively expressed by most cell types, with particularly high levels found in cells with an 
important barrier function such as keratinocytes in the skin (Schmitt et al., 1986). As such, IL-1α is an 
important DAMP that is released during necrosis to signal to the surrounding tissue. When a cell 
undergoes necrosis, there is an influx of calcium ions that activate the canonical IL-1α protease, calpain 
(Brough et al., 2003). Most cells express the decoy receptor IL-1R2 in their cytosol, which binds pro-
IL-1α during necrosis and ‘protects’ it from calpain to contain the inflammatory response. However, 
VSMCs do not express significant levels of IL-1R2, meaning that calpain is able to cleave IL-1α when 
the cell dies. As such, VSMC death is extremely inflammatory and is known to drive the development 
of the chronic inflammatory disease atherosclerosis (Zheng et al., 2013, Clarke et al., 2010).  
The basal activity of pro-IL-1α allows it to function as an alarmin when released during the necrosis of 
large numbers of IL-1R2-expressing cell types. However, the fact that cleavage significantly enhances 
IL-1α activity means that this response can be potentiated when necrosis occurs in response to, or 
alongside, an inflammatory stimulus. For example, bacterial infection leads to the activation of caspases-
1 and -5, which are both able to cleave IL-1R2 and liberate IL-1α (Zheng et al., 2013).  
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From the activity data we propose a model of IL-1α autoinhibition, in which the pro-domain folds over 
the cytokine domain and masks residues that mediate interaction with IL-1R1 (Figure 3.5). The IL-1 
bioassay dose response curves of three IL-1α truncation mutants revealed that a surprisingly small 
portion of the pro-domain (amino acids 56-77) was critical for IL-1α autoinhibition (Figure 3.7). 
Unfortunately, the three-dimensional structure of pro-IL-1α has not yet been solved. However, it would 
be interesting to elucidate whether amino acids 56-77 interact with Arg128, Ile130, Ile180 and Trp225 
that are reported to be the key residues for binding IL-1R1 (Labriola-Tompkins et al., 1993, Ozbabacan 
et al., 2014). Interestingly, the N-terminal half of the pro-domain was dispensable for IL-1α 
autoinhibition. Perhaps the C-terminal half of the propiece is responsible for intramolecular interactions, 
allowing the N-terminal part greater flexibility to modulate intermolecular interactions, for example 
with chromatin or splicing enzymes.  
For proteases to remove the IL-1α propiece, they must be able to access the region between the pro-
domain and cytokine domain. We hypothesise that this linker region forms a loop-like structure that 
allows the pro-domain to fold over the cytokine domain, but also protrudes from the protein to facilitate 
interaction with enzymes. There is a conserved PXXXP motif in the IL-1α loop, which is known to 
direct protein folding and hinge formation. Here, we show through site-directed mutagenesis that the 
prolines do not hold pro-IL1α in an inhibitory conformation as expected, but rather preserve a structure 
with a low level of biological activity (Figure 3.9). It is possible that the prolines hold the pro-domain 
slightly away from the cytokine to allow some receptor interaction, meaning that the immune system 
can be activated upon the necrosis of large numbers of IL-1R2-expressing cells that release pro-IL-1α 
as a DAMP. The effect of these proline mutations on secondary protein structure could be further 
investigated using circular dichroism. 
In conclusion, the work presented in this chapter validates previous observations that mature IL-1α is 
significantly more active than the pro-form, and has provided novel insights into the mechanisms of IL-
1α autoinhibition. This finding underlies the rest of the work presented in this thesis and emphasises the 
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important observation that IL-1α signalling can be potentiated by proteolytic cleavage to amplify the 
inflammatory response. 
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4. Results: Proteases from diverse biological systems activate IL-1α 
4.1 Introduction 
Proteases are enzymes that catalyse the hydrolysis of peptide bonds to break down proteins. They 
account for approximately two percent of the genome, with around 600 individual proteases identified 
to date. Over the course of evolution, proteases have adapted to withstand the varied pH and oxidation 
levels found in increasingly complex organisms. There are two major classes with distinct mechanisms 
of action: serine, cysteine and threonine proteases perform covalent catalysis using an amino acid as the 
nucleophile, whilst metallo and aspartic proteases carry out non-covalent catalysis by deriving their 
nucleophile from an activated water molecule (Turk, 2006).  
Proteases were originally thought to only drive total protein degradation, for example during digestion. 
However, we now know that restricted and specific protease activity regulates a number of cellular 
processes including cell-cycle progression, proliferation, death, DNA replication, and immune cell 
function. Proteases are key components of numerous signalling pathways, and can form proteolytic 
cascades where the signal is propagated by the sequential cleavage and activation of zymogens. Protease 
signalling can be highly complex, for example Cathepsin C converts to a transferase at high pHs, thereby 
switching to catalyse the reverse reaction (Turk et al., 2001b). As such, proteases are now recognised as 
key regulators of both development, homeostasis and disease. 
Due to their powerful signalling function, protease activity is tightly regulated at multiple levels. 
Transcription itself is highly controlled, with many enzymes transcribed as inactive zymogens. At the 
protein level, inhibitors and cofactors are important modulators of protease activity. However, as with 
many potent signalling molecules, dysregulated protease function is implicated in disease. Mutations in 
genes encoding proteases can cause insufficient activity. For instance, the lysosomal storage disorder 
galactosialidosis is caused by a mutation in the gene encoding cathepsin A (Ketterer et al., 2016). 
Conversely, over-activation of protease signalling is also deleterious. For example, inappropriate 
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activation of the most studied protease signalling pathway – the coagulation cascade – by ruptured 
atherosclerotic plaques leads to thrombus formation and blood vessel occlusion (Lusis, 2000).  
Since excessive protease activity is causative in a number of diseases including cancer, atherosclerosis 
and neurodegenerative disorders, they hold significant therapeutic potential. They can be used as 
diagnostic markers, for example the serine protease kallikrien 3 (also known as prostate-specific antigen, 
PSA) is a biomarker for prostate cancer. Furthermore, thanks to their on/off status, proteases are 
attractive drug-targets. For instance, angiotensin-converting enzyme (ACE) inhibitors have been highly 
successful in treating hypertension and heart failure (Turk, 2006).  
Proteases are important regulators of the IL-1 cytokines. Most family members are synthesised as 
precursor proteins that share a similar three-dimensional structure with analogous domain organisation. 
Due to their highly inflammatory nature, most IL-1 precursors have little or no biological activity, and 
proteolysis is an absolute requirement for their function. This extra level of control helps protect against 
aberrant inflammation (Afonina et al., 2015).  
IL-1α is distinct from IL-1β because it is able to bind the IL-1R1 and induce signalling in its pro-form 
(Mosley et al., 1987b). This initial finding in the late 80’s lead to the ongoing assumption that pro-IL-
1α is fully active, despite a simultaneous paper from the same research group confirming that mature 
IL-1α has a significantly higher receptor affinity than pro-IL-1α (Mosley et al., 1987a). As such, the 
significance of IL-1α proteolysis has been underappreciated for many years. The IL-1α field, however, 
is gradually undergoing a paradigm shift in thinking, with increasing recognition that IL-1α cleavage 
increases its potential. Although IL-1α has been an established substrate of the calcium-dependent 
cysteine protease calpain for many years (Kobayashi et al., 1990), the activatory nature of this cleavage 
event has only been acknowledged recently (Afonina et al., 2011). Work by our group demonstrated 
that calpain cleavage increased the affinity of IL-1α for its receptor 50-fold. We also identified IL-1R2 
as an important negative regulator of IL-1α processing by calpain that limits inflammation during 
necrosis in most cell types (Zheng et al., 2013).  
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4.1.1 Chapter 4 project rationale 
Research by Seamus Martin’s group showed that additional proteases are capable of cleaving IL-1α, 
identifying immune cell proteases granzyme B, elastase and chymase as potent activators of the cytokine 
(Afonina et al., 2011). With the exception of digestion, protease secretion or activity generally indicates 
loss of homeostasis and would therefore be a simple, yet elegant, way to activate the immune system in 
response. As such, IL-1α may act as a signalling hub that can integrate multiple proteolytic signals that 
homeostasis has been compromised. The work presented in this chapter aims to explore this hypothesis 
further by confirming previous findings and identifying additional proteases that can activate IL-1α.   
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4.2 Results 
4.2.1 Calpain-I activates IL-1α 
Calpain-I is the canonical protease widely reported to cleave IL-1α during necrotic cell death (Kobayashi 
et al., 1990). We confirmed this finding with our recombinant protein, showing that calpain-I cleaved 
pro-IL-1α in a dose dependent manner (Figure 4.1A), which resulted in a significant increase in IL-1α-
specific activity (Figure 4.1B). Although, despite being the most established IL-1α-processing enzyme, 
the calpain-cleaved form of IL-1α was barely visible by western blot (Figure 4.1C) for reasons that 
remain unclear. 
 
 
 
 
 
4.2.2 Thrombin activates IL-1α 
The most extensively studied protease pathway is the coagulation cascade, which involves the sequential 
cleavage of serine proteases culminating in thrombin activation. Thrombin then cleaves fibrinogen into 
fibrin, which forms a blood clot. Previous work by our group has demonstrated that thrombin can cleave 
IL-1α with a similar efficiency to calpain (Burzynski et al, publication in progress). We were able to 
Figure 4.1: Calpain-I activates IL-1α. (A) ELISA data showing level of cleaved IL-1α following incubation of pro-
IL-1α with increasing concentrations of calpain. (B) IL-1α-dependent IL-6 production by HeLa cells treated with 
reaction products from pro-IL-1α incubated ± calpain, ± neutralising IL-1α antibody (αAb). (C) Western blot for 
IL-1α after incubation of pro-IL-1α ± calpain. Data represent mean ± SEM of n=7 (A) or n=10 (B); p= **≤0.01, 
****≤0.0001. 
A. B. C. 
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recapitulate this finding using the recombinant pro-IL-1α, showing that thrombin cleaves in a dose-
dependent manner (Figure 4.2A) and significantly increases IL-1α activity (Figure 4.2B.). Furthermore, 
an extremely clear 18kDa product was visible by western blot, suggesting that thrombin cleaves at a 
single site (Figure 4.2C). To examine this specificity further, a time-course experiment was carried out 
under the assumption that if the interaction was not absolutely specific, non-specific processing over 
time would gradually decrease IL-1α bioactivity. However, no decrease in IL-1α-specific activity was 
observed after 20 hours of incubation with thrombin (Figure 4.2 D,E), confirming that this interaction 
is highly specific. The plateau in IL-1α activity following longer incubations with thrombin is likely due 
to saturation of the bioassay (Figure 4.2 E). 
 
 
 
 
Figure 4.2: Thrombin activates IL-1α. (A) ELISA data showing level of cleaved IL-1α following incubation of pro-
IL-1α with increasing concentrations of thrombin. (B) IL-1α-dependent IL-6 production by HeLa cells treated 
with reaction products from pro-IL-1α incubated ± thrombin (Thromb) ± neutralising IL-1α antibody (αAb). (C) 
Western blot for IL-1α after incubation of pro-IL-1α ± thrombin. (D-E) ELISA data measuring cleaved IL-1α levels 
in reaction products (D) and IL-1α-dependent IL-6 production by HeLa cells treated with reaction products (E) 
following incubation of pro-IL-1α with thrombin for a range of time points. Data represent mean ± SEM of n=7 
(A) n=6 (B), or n=1 (D,E); p= *≤0.05, ****≤0.0001. 
A. B. C. 
D. E. 
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The time-course data (Figure 4.2D,E) and clear 18kDa western blot band (Figure 4.2C) indicated that 
thrombin cleaves IL-1α at a specific site that is upstream to the calpain site (amino acids 118/119), with 
calpain cleavage generating a 17kDa product. N-terminal sequencing of the 18kDa cleavage product by 
Edman degradation revealed that thrombin indeed cleaves IL-1α between amino acids 112 and 113 
(Figure 4.3). 
 
 
 
We have shown that activated platelets express surface IL-1α, which can be removed using thrombin. 
However, when thrombin is added to platelet-rich-plasma (PRP) to form a clot, no IL-1α is detected 
(Burzynski et al, publication in progress). To investigate if the IL-1α that is cleaved off the platelets 
becomes trapped in the fibrin clot, we attempted to block the interaction between fibrinogen and 
thrombin in the PRP (Figure 4.4). 
Fibrinogen is a large molecule that requires interaction with multiple thrombin sites. During clot 
resolution thrombomodulin binds to exosite 1 of thrombin to prevent fibrinogen from interacting, and 
could therefore be used to block fibrinogen processing. There is some suggestion that thrombomodulin 
also induces allosteric changes in thrombin (Lane et al., 2005). However, the addition of 
thrombomodulin had no effect on the thrombin-IL-1α dose-response curve (Figure 4.4A) suggesting 
A. B. 
Figure 4.3: Thrombin cleaves IL-1α at R112. (A) Coomassie-stained PVDF membrane showing the thrombin-
cleaved IL-1α band sent for N-terminal sequencing by Edman degradation, returned sequence shown 
underneath. (B) Multi species IL-1α protein alignment showing conserved thrombin-cleavage site (arrow). 
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that exosite 1 is not used for IL-1α processing and any allosteric changes do not render thrombin 
completely inactive. Next, we incubated p17 IL-1α with thrombin and increasing concentrations of 
fibrinogen to see if the cytokine became trapped in the developing clot (Figure 4.4B). Fibrinogen had 
no effect on p17 detection, indicating that p17 IL-1α is not trapped or may be small enough to diffuse 
out of the clot. Fibrinogen did, however, competitively inhibit the cleavage of IL-1α by thrombin in a 
dose-dependent manner (Figure 4.4C), possibly because thrombin has a higher affinity for fibrinogen 
than pro-IL-1α. Thrombomodulin, again, had no influence on this inhibition, despite the fact that it is 
known to disrupt the interaction between thrombin and fibrinogen. Interestingly, thrombomodulin 
purchased from two distinct sources failed to relieve the competitive inhibition by fibrinogen (Figure 
4.4D), suggesting that the interaction of thrombomodulin with thrombin may not be strong enough for 
use in an in vitro setting, or that commercially sourced thrombomodulin is non-functional. Together 
these findings suggest that IL-1α is not trapped by the fibrin clot in PRP. One possible explanation for 
the lack of cleaved IL-1α detection in clotted PRP is that fibrinogen is present in such high quantities 
that it saturates the thrombin.  
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Figure 4.4: IL-1α does not get trapped within the fibrin clot. (A-D) ELISA data showing level of cleaved IL-1α 
following incubation of pro-IL-1α with a range of thrombin concentrations ± thrombomodulin (A), incubation 
of p17 IL-1α ± thrombin ± increasing concentrations of fibrinogen (B), incubation of pro-IL-1α with thrombin 
and increasing concentrations of fibrinogen ± thrombomodulin (C), or incubation of pro-IL-1α with thrombin 
and increasing concentrations of thrombomodulin from either Peprotech or R&D (D). Data is n=1. 
A. B. 
C. D. 
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4.2.3 Multiple host defence serine proteases cleave IL-1α 
The discovery that thrombin could activate IL-1α with a similar efficiency to calpain prompted us to 
question what other proteases are able cleave IL-1α. The IL-1 signalling pathway is found throughout 
evolution and is thought to be related to the Spaetzle-Toll pathway in Drosophila melanogaster. Both 
IL-1 and Spaetzle require the proteolytic removal of their pro-domains to interact with their cell-surface 
receptors and activate NF-κB signalling (Hoffmann, 2003). Because of the conserved nature of IL-1, the 
serine proteases were a logical starting point for our studies because they are the most ancient protease 
systems found in both prokaryotes and eukaryotes (Di Cera, 2009).  
Granzyme B is primarily released in the secretory granules of NK and CD8+ T cells, but can also be 
expressed by some non-cytotoxic cells including keratinocytes. The protease enters target cells, which 
may be tumourigenic or infected by a virus, and induces apoptosis by activating caspase-3. It is also 
present in advanced atherosclerotic plaques where it drives VSMC and foam cell death (Choy et al., 
2003). Granzyme B activated recombinant IL-1α dose-dependently to generate a 19kDa product (Figure 
4.5A-C), confirming observations reported previously (Afonina et al., 2011). A limitation of using 
recombinant protein expressed in bacteria is that it is not post-translationally modified. Alterations like 
phosphorylation or glycosylation could affect enzyme-substrate interactions, and so necrotic human 
vascular smooth muscle cells (VSMCs) were used as a source of mammalian IL-1α. As discussed in 
chapter 3, VSMCs do not express significant levels of the decoy receptor IL-1R2 and therefore release 
huge amounts of cleaved IL-1α during necrosis. Because of this, necrotic lysates were prepared 
following pre-incubation with the calpain inhibitor calpeptin. Granzyme B cleavage of VSMC-derived 
IL-1α was less robust (Figure 4.5D,E), however this data represents a single experiment only. The time-
course experiment revealed that Granzyme B-cleavage of recombinant IL-1α is reasonably specific, with 
only a slight decrease in IL-1α activity after 20 hours of incubation (Figure 4.5F,G). 
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Figure 4.5: Granzyme B activates IL-1α. (A) ELISA data showing level of cleaved IL-1α following incubation of 
pro-IL-1α with increasing concentrations of granzyme B. (B) IL-1α-dependent IL-6 production by HeLa cells 
treated with reaction products from pro-IL-1α incubated ± granzyme B (Gzm.B) ± neutralising IL-1α antibody 
(αAb). (C) Western blot for IL-1α after incubation of pro-IL-1α ± granzyme B. (D-E) ELISA data showing level of 
cleaved IL-1α in reaction products (D) and IL-1-dependent IL-6 production by HeLas treated with reaction 
products (E) following incubation of calpeptin-containing VSMC lysates ± granzyme B. (F-G) ELISA data 
measuring cleaved IL-1α levels in reaction products (F) and IL-1α-dependent IL-6 production by HeLa cells 
treated with reaction products (G) following incubation of pro-IL-1α with granzyme B for a range of time points. 
Data represent mean ± SEM of n=3 (A) n=5 (B), n=2 (E) or n=1 (D,F,G); p= **≤0.01, ***≤0.001. 
 
A. B. C. 
D. E. 
F. G. 
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Elastase and proteinase-3 are produced by neutrophils, the most abundant leukocyte that arrives first at 
sites of inflammation. They function both intracellularly by digesting phagocytosed microorganisms, 
and extracellularly interweaved with chromatin fibres in neutrophil extracellular traps (NETs) that 
physically catch and kill invading pathogens. Neutrophil proteases are implicated in numerous diseases, 
such as cystic fibrosis, where they promote matrix destruction and inflammation (Korkmaz et al., 2010). 
Elastase is present in atherosclerotic plaques where it increases vulnerability through ECM degradation 
(Dollery et al., 2003). Conversely, an atheroprotective role has been described for proteinase-3 that is 
reported to improve endothelial barrier function (Knuckleurg and Newman, 2012). Both elastase (Figure 
4.6) and proteinase-3 (Figure 4.7) activated recombinant and VSMC-derived IL-1α. Both proteases 
generated multiple cleavage products visible by western blot (Figures 4.6C and 4.7C), and gradually 
reduced IL-1α bioactivity over longer incubation times (Figure 4.6 F,G and 4.7 F,G), suggesting a lower 
level of specificity. This gradual degradation of IL-1α could represent a mechanism of ‘switching off’ 
the cytokine once the immune system has been alerted to avoid excess inflammation. 
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Figure 4.6: Elastase activates IL-1α. (A) ELISA data showing level of cleaved IL-1α following incubation of pro-IL-
1α with increasing concentrations of elastase. (B) IL-1α-dependent IL-6 production by HeLa cells treated with 
reaction products from pro-IL-1α incubated ± elastase (Elas.) ± neutralising IL-1α antibody (αAb). (C) Western 
blot for IL-1α after incubation of pro-IL-1α ± elastase. (D-E) ELISA data showing level of cleaved IL-1α in reaction 
products (D) and IL-1-dependent IL-6 production by HeLas treated with reaction products (E) following 
incubation of calpeptin-containing VSMC lysates ± elastase. (F-G) ELISA data measuring cleaved IL-1α levels in 
reaction products (F) and IL-1α-dependent IL-6 production by HeLa cells treated with reaction products (G) 
following incubation of pro-IL-1α with elastase for a range of time points. Data represent mean ± SEM of n=5 
(A) n=4 (B), n=2 (E) or n=1 (D,F,G); p= **≤0.01, ***≤0.001. 
 
A. B. C. 
D. E. 
F. G. 
  Results: Proteases from diverse biological systems activate IL-1α 
82 
 
 
 
 
 
 
Figure 4.7: Proteinase-3 activates IL-1α. (A) ELISA data showing level of cleaved IL-1α following incubation of 
pro-IL-1α with increasing concentrations of proteinase-3. (B) IL-1α-dependent IL-6 production by HeLa cells 
treated with reaction products from pro-IL-1α incubated ± proteinase-3 (Prot.3) ± neutralising IL-1α antibody 
(αAb). (C) Western blot for IL-1α after incubation of pro-IL-1α ± proteinase-3. (D-E) ELISA data showing level of 
cleaved IL-1α in reaction products (D) and IL-1-dependent IL-6 production by HeLas treated with reaction 
products (E) following incubation of calpeptin-containing VSMC lysates ± proteinase-3. (F-G) ELISA data 
measuring cleaved IL-1α levels in reaction products (F) and IL-1α-dependent IL-6 production by HeLa cells 
treated with reaction products (G) following incubation of pro-IL-1α with proteinase-3 for a range of time 
points. Data represent mean ± SEM of n=4 (A) n=3 (B), n=2 (E) or n=1 (D,F,G); p= **≤0.01, ****≤0.0001. 
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Chymase is released by mast cells and has multiple functions including attracting leukocytes, inducing 
apoptosis, degrading ECM, and converting angiotensin I to angiotensin II to promote blood vessel 
narrowing. Chymase contributes to atherosclerotic plaque instability, and its inhibition has been shown 
to reduce disease progression in vivo (Bot et al., 2011). Mast cell chymase activated recombinant IL-1α, 
generating two major fragments of 18KDa and 12KDa (Figure 4.8). This is suggestive of two specific 
cleavage events potentially generating active (18kDa) and inactive (12kDa) cytokine.  
 
 
 
 
 
The immune system also has a non-cellular component composed of soluble factors called the 
complement system. The complement system encompasses three serine protease cascades - classical, 
lectin and alternative - that result in the formation of a membrane attack complex, which destroys 
invading pathogens. The MASP proteases of the lectin pathway have been described as thrombin-like 
due to their similar substrate and inhibitor profiles, (Presanis et al., 2004) and were therefore obvious 
candidates for IL-1α activation. Due to a lack of commercial MASP sources the ability of the 
homologous classical pathway protease, C1s, to activate IL-1α was tested instead. C1s induced some 
IL-1α activity, but this effect was not as profound as those observed for other serine proteases and no 
A. B. C. 
Figure 4.8: Chymase activates IL-1α. (A) ELISA data showing level of cleaved IL-1α following incubation of pro-
IL-1α with increasing concentrations of chymase. (B) IL-1α-dependent IL-6 production by HeLa cells treated 
with reaction products from pro-IL-1α incubated ± chymase (Chym.) ± neutralising IL-1α antibody (αAb). (C) 
Western blot for IL-1α after incubation of pro-IL-1α ± chymase.Data represent mean ± SEM of n=3 (A) n=5 (B) 
p= *≤0.05, ***≤0.001. 
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cleavage product was visible by western blot (Figure 4.9). We also tried to activate MASP2 in human 
serum using zymosan, a compound derived from the yeast cell wall that is known to activate the 
alternative complement pathway (Smith et al., 1982) (Figure 4.10). Incubation of p33 pro-IL-1α with 
serum lead to processing, but this was largely due to thrombin as evidenced using the thrombin inhibitor 
PPACK. The addition of zymosan to the reaction did slightly increase cleavage, but this was not 
significant and was reversed using PPACK. As such, it is difficult to conclude from this data whether 
the serine proteases of the complement pathway can really activate IL-1α. 
 
 
 
 
 
A. B. C. 
Figure 4.9: C1s may activate IL-1α. (A) ELISA data showing level of cleaved IL-1α following incubation of pro-IL-
1α with increasing concentrations of C1s. (B) IL-1α-dependent IL-6 production by HeLa cells treated with 
reaction products from pro-IL-1α incubated ± C1s ± neutralising IL-1α antibody (αAb). (C) Western blot for IL-
1α after incubation of pro-IL-1α ± C1s. Data represent mean ± SEM of n=3 (A) n=2 (B). 
 
Figure 4.10: Serum complement activation by zymosan. ELISA data showing level of cleaved IL-1α in reaction 
products from p33 IL-1α ± Zymosan ± Serum ± thrombin inhibitor PPACK ± C1 inhibitor (C1-INH). Data is n=1. 
  Results: Proteases from diverse biological systems activate IL-1α 
85 
 
Epidermal cells of the skin, a critical barrier tissue, express high basal levels of IL-1α. Mice 
overexpressing IL-1α suffer from skin inflammation, with a more severe phenotype observed when IL-
1R1 is also overexpressed in keratinocytes (Groves et al., 1995, Groves et al., 1996). Despite being only 
a few layers of cells thick, the epidermis has an extremely complex structure. It is organised into layers 
of keratinocytes at different developmental stages, with each layer exhibiting a distinct protease and 
inhibitor profile. KLK5 forms part of a kallikrien cascade in the outer layers of the skin that regulates 
desquamation, and is upregulated in inflammatory skin disorders such as psoriasis (Komatsu et al., 
2007). KLK5 cleaved recombinant IL-1α to a 17kDa product (Figure 4.11A,C), but unexpectedly this 
product was inactive (Figure 4.11B). KLK5 was unable to inactivate p17 IL-1α (Figure 4.11D), 
indicating that this lack of activity was not due to a second C-terminal cleavage event. 
 
 
 
Figure 4.11: KLK5 cleaves, but does not activate IL-1α. (A) ELISA data showing level of cleaved IL-1α following 
incubation of pro-IL-1α with increasing concentrations of KLK5. (B) IL-1α-dependent IL-6 production by HeLa 
cells treated with reaction products from pro-IL-1α incubated ±KLK5 ± neutralising IL-1α antibody (αAb). (C) 
Western blot for IL-1α after incubation of pro-IL-1α ± KLK5. (D) ELISA data showing level of cleaved IL-1α 
following the incubation of p17 IL-1α ± KLK5. Data represent mean ± SEM of n=2 or n=3 (B). 
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4.2.4 Multiple matrix metalloproteinases activate IL-1α 
Matrix metalloproteinases (MMPs) are calcium and zinc-dependent proteases that degrade the 
extracellular matrix. MMPs have important roles in tissue remodelling and cellular processes including 
apoptosis and differentiation, and their dysregulation is implicated in a number of diseases including 
cancer metastasis. The gelatinases MMP2 and MMP9 and the collagenase MMP8 are upregulated in 
atherosclerosis (Vacek et al., 2015). MMP2 cleaved recombinant and VSMC-derived IL-1α with high 
specificity (Figure 4.12), indicated by a clear western blot band of approximately 17kDa (Figure 4.12C) 
and sustained IL-1α activity over longer incubation times (Figure 4.12F,G). MMP8 was also able to 
activate IL-1α (Figure 4.13), whereas cleavage by MMP9 was less pronounced (Figure 4.14).  
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Figure 4.12: MMP2 activates IL-1α. (A) ELISA data showing level of cleaved IL-1α following incubation of pro-IL-
1α with increasing concentrations of MMP2. (B) IL-1α-dependent IL-6 production by HeLa cells treated with 
reaction products from pro-IL-1α incubated ± MMP2 ± neutralising IL-1α antibody (αAb). (C) Western blot for 
IL-1α after incubation of pro-IL-1α ± MMP2. (D-E) ELISA data showing level of cleaved IL-1α in reaction products 
(D) and IL-1-dependent IL-6 production by HeLas treated with reaction products (E) following incubation of 
calpeptin-containing VSMC lysates ± MMP2. (F-G) ELISA data measuring cleaved IL-1α levels in reaction 
products (F) and IL-1α-dependent IL-6 production by HeLa cells treated with reaction products (G) following 
incubation of pro-IL-1α with MMP2 for a range of time points. Data represent mean ± SEM of n=5 (A) n=4 (B), 
n=2 (E) or n=1 (D,F,G); p= **≤0.01, ****≤0.0001. 
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Figure 4.13: MMP8 activates IL-1α. (A) ELISA data showing level of cleaved IL-1α following incubation of pro-IL-
1α with increasing concentrations of MMP8. (B) IL-1α-dependent IL-6 production by HeLa cells treated with 
reaction products from pro-IL-1α incubated ± MMP8 ± neutralising IL-1α antibody (αAb). Data represent mean 
± SEM of n=2. 
 
A. B. 
Figure 4.14: MMP9 activates IL-1α. (A) ELISA data showing level of cleaved IL-1α following incubation of pro-IL-
1α with increasing concentrations of MMP9. (B) IL-1α-dependent IL-6 production by HeLa cells treated with 
reaction products from pro-IL-1α incubated ± MMP9 ± neutralising IL-1α antibody (αAb). Data represent mean 
± SEM of n=2. 
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4.2.5 Proteases released by pathogens activate IL-1α 
Whilst it is important to understand the proteolytic activation of IL-1α during sterile inflammation in 
the context of atherosclerosis and other chronic inflammatory diseases, it is also of interest under non-
sterile conditions because many pathogens use proteases during host invasion. The bacterial protease 
Staphyloccocus GluC, also known as the V8 protease, has been reported to disrupt epidermal barrier 
function (Hirasawa et al., 2010). Staphylococcus GluC was capable of modest IL-1α activation, although 
this was not statistically significant or visible by western blot (Figure 4.15). The HIV protease cleaves 
viral polyproteins into mature proteins, a process that is essential for the viral replication cycle (Kohl et 
al., 1988). HIV protease activated recombinant and VSMC-derived IL-1α (Figure 4.16) by producing a 
single 17kDa product (Figure 4.16C). There was only a modest reduction in IL-1α bioactivity after 20 
hours of incubation suggesting that this interaction is reasonably specific (Figure 4.16G). 
 
 
 
 
 
  
A. B. C. 
Figure 4.15: Staphylococcus GluC may activate IL-1α. (A) ELISA data showing level of cleaved IL-1α following 
incubation of pro-IL-1α with increasing concentrations of Staphylococcus GluC. (B) IL-1α-dependent IL-6 
production by HeLa cells treated with reaction products from pro-IL-1α incubated ± Staphylococcus GluC 
(Staph.) ± neutralising IL-1α antibody (αAb). (C) Western blot for IL-1α after incubation of pro-IL-1α ± 
Staphylococcus GluC. Data represent mean ± SEM of n=3 (A) n=5 (B) p= *≤0.05, ***≤0.001. 
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Figure 4.16: HIV protease activates IL-1α. (A) ELISA data showing level of cleaved IL-1α following incubation of 
pro-IL-1α with increasing concentrations of HIV protease. (B) IL-1α-dependent IL-6 production by HeLa cells 
treated with reaction products from pro-IL-1α incubated ± HIV protease (HIV p.) ± neutralising IL-1α antibody 
(αAb). (C) Western blot for IL-1α after incubation of pro-IL-1α ± MMP2. (D-E) ELISA data showing level of 
cleaved IL-1α in reaction products (D) and IL-1-dependent IL-6 production by HeLas treated with reaction 
products (E) following incubation of calpeptin-containing VSMC lysates ± HIV protease. (F-G) ELISA data 
measuring cleaved IL-1α levels in reaction products (F) and IL-1α-dependent IL-6 production by HeLa cells 
treated with reaction products (G) following incubation of pro-IL-1α with HIV protease for a range of time 
points. Data represent mean ± SEM of n=2 (A,B) n=1 (D-G). 
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4.2.6 Proteases involved in protein degradation activate IL-1α 
In the autoinhibition model presented in Chapter 3 of this dissertation, we suggest that the region 
connecting the pro- and cytokine-domains of IL-1α protrudes from the protein to form a loop that is 
particularly accessible to proteases. Based on this theory, it would be reasonable to suggest that non-
specific proteases with roles in protein degradation would temporarily activate IL-1α due to preferential 
cleavage in the loop region. Indeed, incubation with proteinase-K, which is known to have an extremely 
broad substrate specificity, increased IL-1α activity (Figure 4.17). 
 
 
 
 
 
Cathepsin B is a lysosomal cysteine protease involved in the digestion of organelles, removal of invading 
pathogens and cell autolysis. Its expression has been shown to be upregulated in both early and advanced 
atherosclerotic plaques (Chen et al., 2002, Jaffer et al., 2011). Cathepsin B activated both recombinant 
and VMSC-derived IL-1α to generate two products of 21kDa and 17kDa (Figure 4.18A-F). Cathepsin 
B-mediated IL-1α was, in fact, highly specific since there was no loss of activity at longer time points 
(Figure 4.18G,H).  
 
Figure 4.17: Proteinase-K activates IL-1α. (A) ELISA data showing level of cleaved IL-1α following incubation of 
pro-IL-1α with increasing concentrations of proteinase K. (B) IL-1α-dependent IL-6 production by HeLa cells 
treated with reaction products from pro-IL-1α incubated ± proteinase K (Prot.K) ± neutralising IL-1α antibody 
(αAb). Data represent mean ± SEM of n=3; p= *≤0.05. 
A. B. 
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Figure 4.18: Cathepsin B activates IL-1α. (A) ELISA data showing level of cleaved IL-1α following incubation of 
pro-IL-1α with increasing concentrations of cathepsin B. (B) IL-1α-dependent IL-6 production by HeLa cells 
treated with reaction products from pro-IL-1α incubated ± cathepsin B (Cath.B) ± neutralising IL-1α antibody 
(αAb). (C) Western blot for IL-1α after incubation of pro-IL-1α ± cathepsin B. (D-E) ELISA data showing level of 
cleaved IL-1α in reaction products (D) and IL-1-dependent IL-6 production by HeLas treated with reaction 
products (E) following incubation of calpaptin-containing VSMC lysates ± cathepsin B. (F) Western blot for IL-
1α after incubation of calpeptin-containing VSMC lysates ± cathepsin B (G-H) ELISA data measuring cleaved IL-
1α levels in reaction products (G) and IL-1α-dependent IL-6 production by HeLa cells treated with reaction 
products (H) following incubation of pro-IL-1α with cathepsin B for a range of time points. Data represent mean 
± SEM of n=4 (A), n=3 (B) or n=1 (D-H); p=***≤0.001, ****≤0.0001. 
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4.2.7 Caspases-5 and -14 cleave IL-1α 
The caspases are cysteine-dependent proteases that can be categorised into two subgroups according to 
their function; apoptotic or inflammatory. Caspase-14 is expressed in the skin where it regulates the 
final stage of keratinocyte differentiation, known as cornification, which leads to the formation of hair 
or nails. Psoriatic lesions are characterised by impaired cornification, and display reduced caspase-14 
expression (Denecker et al., 2008). Caspase-14 cleaved IL-1α at high concentrations, but this processing 
did not increase activity (Figure 4.19). We also tested the ability of caspases 1-10 to cleave IL-1α, and 
western blot analysis revealed that caspase-5 produced a 19kDa cleavage product (Figure 4.20), which 
will be explored in depth in Chapters 5 and 6 of this dissertation.  
 
 
 
 
 
 
Figure 4.19: Caspase-14 cleaves, but does not activate IL-1α. (A) ELISA data showing level of cleaved IL-1α 
following incubation of pro-IL-1α with increasing concentrations of caspase-14. (B) IL-1α-dependent IL-6 
production by HeLa cells treated with reaction products from pro-IL-1α incubated ± caspase-14 (Cas.14) ± 
neutralising IL-1α antibody (αAb). Data is n=1. 
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4.2.8 Not all proteases can cleave IL-1α 
Fibroblast activating protein alpha (FAPα) is a serine protease that is upregulated in a number of cancers. 
It functions as a collagenase and has been implicated in atherosclerosis where it contributes to fibrous 
cap thinning to promote plaque instability (Brokopp et al., 2011). FAPα was unable to activate 
recombinant IL-1α in our assays (Figure 4.21). The fact that FAPα and the caspases (except 5 and 14) 
could not cleave IL-1α was somewhat promising, as it gave us confidence that the cleavage detected by 
other proteases was not an artefact of incubating recombinant substrate with recombinant enzyme at 
non-physiological concentrations.  
 
 
 
 
 
 
 
Figure 4.20: Caspase-5 cleaves IL-1α. Western blot for IL-1α after incubation of pro-IL-1α ± caspases 1-10. 
(IC=incubation control). 
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Figure 4.21: FAPα does not activate IL-1α. (A) ELISA data showing level of cleaved IL-1α following incubation of 
pro-IL-1α with increasing concentrations of FAPα. (B) IL-1α-dependent IL-6 production by HeLa cells treated 
with reaction products from pro-IL-1α incubated ± FAPα  ± neutralising IL-1α antibody (αAb). Data represent 
mean ± S.E.M. of n=3 (A) or n=4 (B).  
A. B. 
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4.3 Discussion 
The activity of most IL-1 family members is modulated by proteolytic cleavage. For many years, IL-1α 
was believed to be the exception to this rule and was described as fully active in its pro-form. However, 
recent work by ourselves and others has shown that the removal of the IL-1α pro-domain by the 
canonical protease calpain significantly enhances its activity by increasing its affinity for the IL-1R1 
(Afonina et al., 2011, Zheng et al., 2013). Furthermore, there is emerging evidence that additional 
proteases, such as Granzyme B and thrombin, can also activate IL-1α (Afonina et al., 2011) (Burzynski 
et al, publication in progress).  
Here, we show that IL-1α can, in fact, be activated by a range of proteases from diverse biological 
systems that are summarised in Table 4.1. The most robust, and specific, of these proteases were MMP-
2, HIV protease and Cathepsin B (Figures 4.12, 4.16 and 4.18). MMP-2-mediated ECM remodelling is 
heavily involved in metastasis. For instance, it drives the initiation of an invasive phenotype in ovarian 
cancer cells by promoting their attachment to the peritoneum by cleaving fibronectin and vibronectin 
(Kenny et al., 2008). IL-1 has also been implicated in tumour invasiveness (Voronov et al., 2002), and 
is known to enhance the expression of multiple cancer-associated genes through the NF-κB pathway 
(Charbonneau et al., 2014). The processing of IL-1α by MMP2 may therefore be important for triggering 
the immune-mediated killing of malignant cells, or may contribute to disease progression by establishing 
an inflammatory environment. The robust activation of IL-1α by HIV protease was particularly 
unexpected because the natural role of this enzyme is to cleave viral polyproteins, which would suggest 
restricted substrate specificity. This interaction could represent a host defence mechanism for alerting 
the immune system to the HIV infection. However, IL-1α activation may actually be beneficial for the 
virus because it drives NF-κB signalling, a pathway harnessed by HIV to drive its own gene transcription 
(Hiscott et al., 2001). In fact, IL1A overexpression has been shown to increase the production of HIV in 
infected cells by up to seven-fold (McLaren et al., 2015). The seemingly specific activation of IL-1α by 
Cathepsin B was also unanticipated, since the two proteins are spatially segregated in healthy cells. 
Lysosomal membrane permeabilisation occurs during cell death; complete permeabilisation causes 
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necrosis whereas partial permabilisation causes activation of the apoptotic caspases and proteins Bid 
and Bax. The potent activation of cytosolic IL-1α by cathepsin B may represent a mechanism to alert 
the immune system to loss of intracellular homeostasis and recruit immune cells to clear away the dead 
cell. Furthermore, cathepsin B has been reported to translocate to the nucleus and induce rapid DNA 
damage and chromatin condensation. Cathepsin B could therefore also cleave nuclear IL-1α and 
potentially disrupt its apoptotic association with chromatin mediating a switch towards inflammatory 
necrotic death (Boya and Kroemer, 2008). 
We demonstrate that although some proteases such as granzyme B (Figure 4.5) cleaved IL-1α at a single 
site to impart sustained bioactivity, other proteases such as elastase, chymase and proteinase-3 (Figures 
4.5-4.7) were less specific and gradually inactivated IL-1α over time. Granzyme B activity is tightly 
regulated; it is released from cytotoxic lymphocytes inside endocytic vesicles, only exits the vesicles 
following perforin activity and specifically activates caspase 3 in target cells to initiate the cell death 
programme (Lord et al., 2003). This protease would therefore come into contact with IL-1α under 
specific conditions, with regulation of enzyme-substrate interaction at the level of enzyme availability. 
In contrast, chymase, elastase and proteinase 3 have broader substrate specificities and are released into 
the extracellular milieu (Caughey, 2007, Korkmaz et al., 2010). These proteases generated both active 
IL-1α fragments of 18-20kDa and shorter fragments of 10-12kDa that are likely to be inactive. The fact 
that broad-specificity proteases can generate activity supports our working hypothesis that the loop 
region between the pro and the cytokine domains of IL-1α is particularly susceptible to cleavage. The 
subsequent generation of smaller fragments may represent an internal ‘off-switch’ within IL-1α, where 
it is transiently activated by these promiscuous proteases and subsequently degraded to stop aberrant 
inflammation amplification. 
Not all proteases tested were able to activate IL-1α. Some proteases, such as KLK5 (Figure 4.11), were 
able to cleave IL-1α but did not induce activity, which highlights the importance of complementing the 
cleaved IL-1α ELISA with the IL-1 bioassay. Other proteases were completely unable to cleave IL-1α. 
For instance all of the apoptotic caspases (caspases-2, -3, -6, -7, -8, -9, and -10) (Figure 4.20) were 
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unable to process IL-1α. Since pro-IL-1α is constitutively expressed by most cell types, this lack of 
interaction is extremely important to maintain the anti-inflammatory nature of programmed cell death. 
The fact that some proteases were incapable of IL-1α processing and activation also imparts confidence 
that the proteases that do activate IL-1α are not simply an artefact of the in vitro system.  
To enhance our understanding of IL-1α activation further, the cleavage sites of the highly specific 
proteases could be defined by sequencing the N-terminal residues of the cleavage products by Edman 
degradation and/or mutating predicted sites based on known protease specificity. For example, cathepsin 
B has a strong preference for a glycine residue at position P3’ (Biniossek et al., 2011), which is highly 
conserved between species at amino acid 78 in IL-1α. For proteases that exhibited high specificity but 
where western blot analysis revealed only a small proportion of the total IL-1α protein was processed 
(e.g MMP-2 and HIV protease), the cleavage product could be enriched by cloning a C-terminal His-
tag onto the pro-IL-1α protein and purifying the product over a column containing cobalt resin. Finally, 
although the VSMC lysates are a useful source of mammalian, post-translationally modified IL-1α, they 
must be prepared in the presence of calpeptin to prevent calpain activation upon necrosis. Calpeptin is 
known to inhibit other proteases, such as caspase-3 (Peng et al., 2011). An alternative approach could 
be to prepare post-translationally modified recombinant pro-IL-1α by overexpression in HEK or HeLa 
cells or using a baculovirus expression system in insect cells. This would allow further validation of 
enzyme-substrate interactions without the interference of calpain or calpeptin.  
To conclude, the work presented in this chapter has demonstrated that multiple proteases from diverse 
biological systems are able to activate IL-1α, some transiently, others permanently. Unlike IL-1β, pro-
IL-1α is constitutively expressed by most cell types and is therefore always available for activation. As 
such, IL-1α may represent a crucial signalling molecule that integrates diverse proteolytic signals of 
compromised homeostasis. 
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SPECIFICITY 
OF IL-1α 
INTERACTION 
IL-1α 
CLEAVAGE 
SITE  IF 
KNOWN OR 
PREDICTED* 
Calpain Apoptosis and necrosis Unknown   Highly specific 118/119 
Thrombin 
Fibrinogen cleavage 
during coagulation 
Arg   Highly specific 112/113 (Chpt4) 
Granzyme B Apoptosis induction Asp   Highly specific 
103/104 
(Afonina et al., 
2011) 
Neutrophil 
Elastase 
Bacterial membrane 
breakdown 
Val or Ala   
Specific, but 
degrades over 
time 
101/102* 
(Afonina et al., 
2011) 
Neutrophil 
Proteinase-3 
Antimicrobial peptide 
generation 
Unknown   
Specific, but 
degrades over 
time 
Unknown 
Chymase 
Leukocyte attraction, 
ECM degradation, 
apoptosis 
Tyr or Phe 
(Andersson et al., 
2009)  
  Unknown 
116/117* 
(Afonina et al., 
2011) 
C1s 
Classical complement 
pathway activation 
Arg (Kerr et al., 
2005) 
? ? Unknown Unknown 
KLK5 
Keratinocyte 
desquamation 
Arg (Debela et 
al., 2008) 
 X Unknown Unknown 
MMP2 ECM remodelling 
Ser, Gly, Ala, or 
Glu (Turk et al., 
2001a) 
  Highly specific Unknown 
MMP8 ECM remodelling Unknown   Unknown Unknown 
MMP9 ECM remodelling 
Ser  (Turk et al., 
2001a) 
? ? Unknown Unknown 
Staph. GluC 
Bacterial growth & 
survival 
Glu ? ? Unknown Unknown 
HIV protease 
Viral polyprotein 
processing 
Unknown   Highly specific Unknown 
Proteinase K Protein digestion (in lab) Non-specific   Non-specific Unknown 
Cathepsin B 
Lysosomal protein 
degradation 
Arg, Lys (Choe et 
al., 2006) 
  Highly specific Unknown 
Caspase-1 Inflammation activation Asp X X N/A N/A 
Caspase-2 Apoptosis initiation Asp X X N/A N/A 
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Caspase-3 Apoptosis execution Asp X X N/A N/A 
Caspase-4 Inflammation activation Asp X X N/A N/A 
Caspase-5 Inflammation activation Asp   Highly specific 103/104 (Chpt5) 
Caspase-6 Apoptosis execution Asp X X N/A N/A 
Caspase-7 Apoptosis execution Asp X X N/A N/A 
Caspase-8 Apoptosis initiation Asp X X N/A N/A 
Caspase-9 Apoptosis initiation Asp X X N/A N/A 
Caspase-10 Apoptosis initiation Asp X X N/A N/A 
Caspase-14 
Keratinocyte 
cornification 
Asp  X N/A Unknown 
Table 4.1: Summary of proteases tested for IL-1α activation. A table listing each protease tested in this 
chapter, it’s function, its known preferred substrate consensus sequence, whether it cleaves and activates IL-
1α, how specific it’s interaction with IL-1α is, and the IL-1α cleavage site if known or predicted. All target 
sequences from ExPASy Peptide cutter, unless cited specifically. References or thesis locations are provided 
for solved/suggested IL-1α cleavage sites. 
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5. Results: IL-1 is activated by caspase-5/-11 of the non-canonical 
inflammasome 
5.1 Introduction 
The inflammatory caspases are an extensively studied group of proteases due to their important role in 
host defence. The inflammasome serves as a platform for caspase-1 activation, and provides a 
mechanism for a cell to sense danger and respond by alerting the immune system whilst engaging a self-
destruct programme. Over the last six years a significant effort has been placed on understanding an 
alternative pathway of inflammasome activation mediated by the additional inflammatory caspases-4 
and -5 in humans, or -11 in mice, known as the non-canonical inflammasome. 
The Casp11-/- and Casp1-/- mice engineered in the 1990s were both found to be resistant to septic shock 
(Li et al., 1995, Wang et al., 1998), and as a result the two caspases were assumed to phenocopy each 
other. However, in 2011 Vivsha Dixit’s group realised that the original knockout mice were derived 
from embryonic stem (ES) cells of the 129 mouse strain, which harbour an endogenous caspase-11 
mutation. This mutation, a 5 base pair deletion in exon 7, leads to the splicing of exons 6 and 8 that 
results in a frameshift and a premature stop codon. The extremely close proximity of the Casp1 and 
Casp11 genes excluded the possibility for segregation by recombination, which meant that the Casp-1-
/- mice were in fact a double knockout for both caspases-1 and -11. Transgenically reintroducing caspase-
11 using a bacterial artificial chromosome (BAC) showed that caspase-1 deficiency did not protect the 
animals from sepsis - only caspase-11 deficiency did, thus revealing that caspase-11 was the sole driver 
of LPS-induced lethality (Kayagaki et al., 2011). The Casp11 passenger mutation in 129 mice was a 
critical discovery that influenced multiple scientific fields, since injecting targeted 129 ES cells into 
C57BL/6 blastocysts was a common strategy for making early genetic knockouts. Importantly, the 
mutation was not only carried forward when genes adjacent to Casp11 were targeted, but also in 
knockout animals, such as Casp3-/-, where the target gene was located on a different chromosome. 
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Therefore, the re-characterisation of mice engineered using this method is essential because their 
described phenotypes may actually be driven by caspase-11 (Stowe et al., 2015). 
Following the discovery that caspase-11 mediates septic shock, four groups independently demonstrated 
that intracellular LPS from the Gram negative bacterial cell wall directly activates caspases-11, -4 and-
5 (Kayagaki et al., 2013, Hagar et al., 2013, Shi et al., 2014, Baker et al., 2015). The lipid A moiety of 
the LPS molecule must be hexa-acylated for caspase activation to occur; which is a feature exploited by 
some pathogens, such as Helicobacter pylori, that interfere with this interaction by decreasing their  
number of acyl chains to evade immune detection (Raetz et al., 2007).  
In most cell types, non-canonical inflammasome activation is a two-step process: priming followed by 
activation (Figure 5.1). Priming requires PRR engagement by a PAMP, which activates two intracellular 
signalling pathways. NF-κB signalling upregulates the canonical inflammasome components NLRP3, 
ASC, caspase-1 and IL-1, whilst the TRIF-IRF-IFN pathway promotes the expression of non-canonical 
inflammasome factors. Although human caspases-4 and -5 are both referred to as caspase-11 
orthologues based on sequence similarity (Lin et al., 2000), caspases-11 and -5 are highly inducible 
through type I IFN signalling, whereas caspase-4 is constitutively expressed at a high levels in many 
cell types. The IFN pathway is essential for caspase-11 activation during bacterial infection, but 
dispensable for the response to directly transfected LPS. A plausible explanation for this is that the IFN 
pathway also upregulates the guanylate-binding protein (GBP) GTPases that promote the lysis of 
bacteria-containing vacuoles (Yang et al., 2015, Meunier et al., 2014). The GBPs also liberate LPS from 
the outer membrane vesicles of external bacteria that have been endocytosed, facilitating activation of 
the non-canonical inflammasome by extracellular pathogens (Vanaja et al., 2016).  
Our understanding of the non-canonical inflammasome pathway was further advanced in 2015, when 
Vivsha Dixit and Feng Shao’s research groups independently identified Gasdermin D (GSDMD) as the 
effector protein of the non-canonical inflammasome. Caspases-11/-4/-5 cleave GSDMD to liberate a 
30kDa N-terminal fragment (GSDMDN) that both activates the NLRP3 inflammasome and caspase-1, 
and also drives pyroptosis (Kayagaki et al., 2015, Shi et al., 2015). GSDMDN causes cell death by 
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translocating to the plasma membrane and binding to inner membrane phospholipids to form pores 
(Agliettia et al., 2016, Ding et al., 2016, Liu et al., 2016). Over time, the accumulation of these pores 
leads to the loss of plasma membrane integrity, and the cell ruptures. However, recent studies indicate 
that there is a delay between caspase-11 activation and pyroptosis, during which the plasma membrane 
undergoes ‘bubbling’ (Petr Broz, unpublished data). This bubbling is mediated by the ESCRT III protein 
complex that causes the pore-containing regions of plasma membrane to ‘pinch-off’ so that cell integrity 
is preserved, in a similar manner to that reported for necroptosis (Gong et al., 2017). This delay is 
thought to give the cell time to secrete cytokines to communicate its state of damage and recruit immune 
cells before it dies.  
 
 
 
 
 
 
  
Figure 5.1: The non-canonical inflammasome. TLR4 ligation by LPS serves as a priming signal to activate the NF-
κB and TRIF signalling pathways to upregulate the expression of inflammasome components and type I 
interferons (T1 IFN), respectively. Type 1 IFN signalling induces the expression of pro-caspase-11 and guanylate 
binding proteins (GBPs). The GBPs liberate LPS from outer membrane vesicles (OMVs) from extracellular gram 
negative bacteria that have been endocytosed by the cell. Intracellular LPS (icLPS) from the OMVs or 
intracellular bacteria activates caspase-11 (CASP11), which cleaves gasdermin D (GSDMD). The N-terminal 
GSDMD fragment forms membrane pores and activates the NLRP3 inflammasome to drive IL-1β activation. 
The GSDMD pores allow cytokine secretion, but increased pore number over time results in loss of plasma 
membrane integrity and induction of pyroptosis. 
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5.1.1 Emerging roles of the non-canonical inflammasome 
Although the non-canonical inflammasome pathway has predominantly been described as a specialised 
response to bacterial infection, it may also drive sterile inflammation. In dendritic cells, the oxidised 
phospholipid oxPAPC has been reported to activate caspase-11 by eliciting the formation of a caspase-
11 heterocomplex, which potentiates T cell activation (Zanoni et al., 2016). Furthermore palmitate, a 
saturated fatty acid involved in atherosclerosis progression, has been described to activate caspases-4 
and -5 in human monocytes (Pillon et al., 2016). Caspase-5 is also activated by extracellular heme, 
which is associated with a number of conditions including malaria, sickle cell disease and sepsis 
(Boucher-Hayes, 2017). In addition, a common mutation of a polyA repeat within the CASP5 gene that 
leads to a frameshift and premature stop codon has been associated with lung, colon and gastric cancers 
(Offman et al., 2005, Yamaguchi et al., 2006, Bian et al., 2011). The mutation of this polyA motif is 
particularly common in microsatellite instability cancers, suggesting that caspase-5 could play a 
protective role against these types of malignancies in particular. Interestingly, caspase-1 and caspase-4 
mutations are rarely associated with these types of carcinoma, suggesting this protective function is truly 
caspase-5 specific (Soung et al., 2008). The missense CASP5 polymorphism rs5074879 has also been 
associated with increased risk of renal, bladder, and lung cancer, and ageing (Dong et al., 2009, Ulybina 
et al., 2010, Mittal et al., 2011, Zhang et al., 2013).  
The non-canonical inflammasome may also be important in maintaining normal barrier function in non-
myeloid cells. Intestinal epithelial cells (IECs) express particularly high levels of caspase-11, in contrast 
to the low basal level expressed by most cell types. Although this is most likely due to LPS from the 
commensal Gram-negative gut bacteria, it allows these cells to respond rapidly to enteric infection and 
inflammation. The activation of caspase-11 in IECs causes infected cells to undergo pyroptosis and 
removal from the barrier. It also leads to the activation of IL-18, which is an important cytokine for 
sustaining barrier integrity by stimulating proliferation and repair. In line with this function, Casp11-/- 
mice are more susceptible to dextran sodium sulphate-induced colitis, exhibiting higher levels of tissue 
damage and leukocyte infiltration than their wildtype counterparts (Williams et al., 2015). Human IECs 
  Results: IL-1 is activated by caspase-5/-11 of the non-canonical inflammasome 
105 
 
also express high levels of caspase-4, which activates IL-18 that in turn promotes proliferation and 
neutrophil recruitment (Knodler et al., 2014).  
 
5.1.2 Cell-type specific properties of the non-canonical inflammasome 
Different cell types display distinct non-canonical inflammasome properties. Monocytes proliferate 
rapidly following bacterial infection, and have been described to activate their inflammasome in 
response to LPS alone through a ‘one-step’ mechanism. They express high levels of the LPS co-receptor 
CD14, which induces Syk activation and promotes LPS endocytosis and calcium mobilisation. This in 
turn triggers caspase and subsequent inflammasome activation (Vigano et al., 2015). LPS has also been 
proposed to activate an ‘alternative inflammasome’ pathway in human monocytes, but not murine 
monocytes, that signals through caspase-8 to indirectly promote NLPR3 activation and IL-1β secretion 
without pyroptosis (Gaidt et al., 2016). In addition, monocytes secrete mature IL-1β more rapidly than 
macrophages due to their distinct redox status. Monocytes produce low levels of ROS at a resting state 
that increases with LPS, whereas macrophages contain an antioxidant system that buffers the TLR-
induced ROS surge (Carta et al., 2011).  
Neutrophils also exhibit unique inflammasome characteristics. Although most studies have focussed on 
canonical inflammasome activation, neutrophils seem to be particularly resistant to pyroptosis and their 
cytokine secretion typically precedes cell death. Kate Schroder and colleagues reported that Salmonella 
infection leads to NLRC4 inflammasome activation within neutrophils, which secrete huge amounts of 
IL-1β without dying (Chen et al., 2014). This finding was supported by the Pearlman group, who 
demonstrated IL-1β secretion occurs before pyroptosis during ATP-induced NLRP3 inflammasome 
activation (Karmakar et al., 2016). Recent work by the Schroder lab has revealed that neutrophils engage 
two distinct response pathways. When the bacteria are extracellular or vacuolar, an NLRC4-caspase-1-
IL-1β pathway promotes IL-1 release without cell death. However, when bacteria enter the cytosol, 
signifying that the neutrophil has become compromised, the cell activates caspase-11-mediated 
pyroptosis. In addition to initiating cell death caspase-11 drives neutrophil extracellular trap (NET) 
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formation, so that as the neutrophil pyroptoses it releases NETs as a last attempt to kill the invading 
microbes (Schroder, 2017).  
 
5.1.3 Chapter 5 project rationale 
It is commonly reported in the literature that, in addition to IL-1β, mature IL-1α is released following 
non-canonical inflammasome activation (Kayagaki et al., 2011, Gross et al., 2012, Casson et al., 2015, 
Vigano et al., 2015). However, the mechanisms of IL-1α activation are unknown, and it is often assumed 
that IL-1α release is a passive by-product of pyroptosis. However, we hypothesised that the pro-
inflammatory caspases might directly activate IL-1α prior to cell death. Indeed, our western blot for IL-
1α following incubation with caspases 1-10 revealed a distinct 19kDa product in the caspase-5 lane 
(Figure 4.20). The work presented in this chapter aims to characterise the interaction between caspase-
5/-11 and IL-1 further.  
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5.2 Results 
5.2.1 Caspase-5 activates recombinant human IL-1α 
Mature IL-1α is released during non-canonical inflammasome activation, but the proteases that activate 
it are unknown. It is generally assumed that IL-1α is passively activated by calpain during pyroptosis, 
but the 19kDa IL-1α fragment produced after incubation with caspase-5 (Figure 4.20) alluded to a more 
direct interaction. Incubation of pro-IL-1α with each of the pro-inflammatory caspases revealed that 
only caspase-5 was capable of processing IL-1α (Figure 5.2A). Caspase-5 induced IL-1α activation 
(Figure 5.2B), which was dependent on the proteolytic action of caspase-5 since incubation with the 
caspase-5 inhibitor Z-LEVD-fmk significantly reduced both cleavage (Figure 5.3A) and activity (Figure 
5.3B).  
 
 
 
 
Figure 5.2: Caspase-5 cleaves and activates IL-1α. (A) Western blot for IL-1α after the incubation of pro-IL-1α 
with active caspase-1, -4 or-5, or alone (incubation control, IC). (B) IL-1-dependent IL-6 production by HeLa 
cells treated with reaction products from pro-IL-1α incubation ± active caspases, ± a neutralising IL-1α antibody 
(p αAb). Data represent mean +SEM of n=4. p = ****≤0.0001. 
A. B. 
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5.2.2 Caspase-5 cleaves human IL-1α at aspartic acid 103 
Caspases exhibit a strong preference for cleaving after aspartic acid residues (Howard et al., 1991). As 
such, important caspase substrates often exhibit conservation of a consensus sequence between species. 
Analysis of aligned IL-1α protein sequences revealed a conserved IAND tetrapeptide motif in the region 
corresponding to a 19kDa product size (Figure 5.4A). Mutation of the Asp103 to an alanine (D103A) in 
pro-IL-1α completely abolished cleavage (Figure 5.4B) and activation (Figure 5.4C) by caspase-5, 
confirming the location of the cleavage site.  
 
 
 
 
 
Figure 5.3: Z-LEVD-FMK inhibits the activation of IL-1α by caspase-5. (A) Western blot for IL-1α after the 
incubation of pro-IL-1α alone (incubation control, IC) or with active caspase-5 ± Z-LEVD-FMK. (B) IL-1-
dependent IL-6 production by HeLa cells treated with reaction products from pro-IL-1α incubation ± active 
caspase-5, ± Z-LEVD-FMK, ± a neutralising IL-1α antibody (p αAb). Data represent mean +SEM of n=4, p = 
**≤0.01, ****≤0.0001. 
 
A. B. 
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5.2.3 Caspase-5 activates recombinant human IL-1β 
The specific cleavage and activation of IL-1α by caspase-5 then prompted us to question whether 
additional caspases were also capable of IL-1β activation. The incubation of recombinant pro-IL-1β 
with caspases 1-10 revealed that caspases-1 ,-5 and -7 were able to cleave IL-1β (Figure 5.5). Focussing 
on the inflammatory caspases in more detail, both caspases-1 and -5 cleaved IL-1β to produce a 17kDa 
(Figure 5.6A) active (Figure 5.6B) product. Again, Z-LEVD-FMK prevented the cleavage (Figure 5.7A) 
Figure 5.4: Caspase-5 cleaves IL-1α at aspartic acid 103. (A) Multiple species alignment of IL-1α sequence in 
region corresponding to 19kDa cleavage product size. Red arrow indicates candidate aspartic acid 103. (B) 
Western blot for IL-1α after the incubation of WT or D103A mutant pro-IL-1α alone (incubation control, IC) or 
with active caspase-5. (C) IL-1-dependent IL-6 production by HeLa cells treated with reaction products from 
WT or D103A pro-IL-1α incubation ± active caspase-5, ± a neutralising IL-1α antibody (p αAb). Data represent 
mean +SEM of n=4, p = **≤0.01. 
A. B. 
C. 
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and activation (Figure 5.7B) of IL-1β by caspase-5, demonstrating that this interaction was dependent 
on proteolysis.  
 
 
 
 
 
 
 
Figure 5.5: Caspases-1, -5 and -7 cleave human IL-1β. Western blot for IL-1β after the incubation of pro-IL-1β 
with active caspases-1-10, or alone (incubation control, IC).  
Figure 5.6: Caspases-1 and -5 activate IL-1β. (A) Western blot for IL-1β after the incubation of pro-IL-1β with 
active caspase-1, -4 or-5, or alone (incubation control, IC). (B) IL-1-dependent IL-6 production by HeLa cells 
treated with reaction products from pro-IL-1β incubation ± active caspases, ± a neutralising IL-1β antibody (p 
βAb). Data represent mean +SEM of n=4, p = ****≤0.0001. 
A. B. 
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Figure 5.7: Z-LEVD-FMK inhibits the activation of IL-1β by caspase-5. (A) Western blot for IL-1β after the 
incubation of pro-IL-1β alone (incubation control, IC) or with active caspase-5 ± Z-LEVD-FMK. (B) IL-1-
dependent IL-6 production by HeLa cells treated with reaction products from pro-IL-1β incubation ± active 
caspase-5, ± Z-LEVD-FMK, ± a neutralising IL-1β antibody (p βAb). Data represent mean +SEM of n=4, p = 
***≤0.001, ****≤0.0001. 
A. B. 
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5.2.4 Caspase-5 cleaves human IL-1β at aspartic acid 116 
Since caspase-5 generated a similar 17kDa IL-1β product to caspase-1, the highly conserved Asp116 was 
the primary candidate for the cleavage site (Figure 5.8A). Indeed, mutation of this aspartic acid to an 
alanine (D116A) completely prevented the cleavage (Figure 5.8B) and activation (Figure 5.8C) of IL-
1β by caspase-5, demonstrating that caspase-5 cleaves IL-1β at the same site as caspase-1.  
 
 
 
 
 
A. B. 
C. 
Figure 5.8: Caspase-5 cleaves IL-1β at aspartic acid 116. (A) Multiple species alignment of IL-1β sequence in 
region corresponding to 17kDa cleavage product size. Red arrow indicates candidate aspartic acid 116. (B) 
Western blot for IL-1β after the incubation of WT or D116A mutant pro-IL-1β alone (incubation control, IC) or 
with active caspase-5. (C) IL-1-dependent IL-6 production by HeLa cells treated with reaction products from 
WT or D116A pro-IL-1β incubation ± active caspase-5, ± a neutralising IL-1β antibody (p βAb). Data represent 
mean +SEM of n=4, p = ****≤0.0001 
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5.2.5 THP-1 as a cell line model of non-canonical inflammasome activation 
The human cell lines THP-1 and U937 are commonly used to study the non-canonical inflammasome 
(Carta et al., 2011, Shi et al., 2014, Baker et al., 2015, Kayagaki et al., 2015, Vigano et al., 2015). 
Although THP-1 cells are monocytes of blood origin and U937s are lymphoblasts of tissue origin, both 
are considered to be macrophage-like when differentiated using phorbol-12-myristate-13-acetate (PMA) 
(Chanput et al., 2015).  
To characterise non-canonical inflammasome activation in THP-1 cells, a model of cell differentiation 
and activation was established (Figure 5.9A). THP-1 cells were differentiated for 24 hours with PMA, 
primed for 4 hours with the TLR4 agonist LPS, and LPS transfected into the cytosol before incubation 
for 18 hours. Upregulation of CASP5 expression was observed following priming, and a further increase 
was detectable following activation with intracellular LPS (Figure 5.9B). A similar pattern was observed 
for IL-1α and IL-1β secretion (Figure 5.9C,D).  
  Results: IL-1 is activated by caspase-5/-11 of the non-canonical inflammasome 
114 
 
 
 
 
 
 
 
Figure 5.9: Activation of the non-canonical inflammasome in THP-1 cells. (A) Schematic showing the protocol 
for the differentiation of THP-1 cells and the subsequent activation of the non-canonical inflammasome with 
intracellular LPS (icLPS). (B-D) Characterisation of differentiated, primed and non-canonically activated THP-1 
cells. (B) RT-PCR data showing CASP5 gene expression. (C) IL-1α release measured by ELISA. (D) IL-1β release 
measured by ELISA. Data represent mean +SEM of n=3 (B) or 7 (C,D,), p = *≤0.05, ***≤0.001. 
A. 
B. 
D. 
C. 
  Results: IL-1 is activated by caspase-5/-11 of the non-canonical inflammasome 
115 
 
To interrogate the individual roles played by the inflammatory caspases, each gene was knocked down. 
Since THP-1 cells are in suspension and difficult to transiently transfect with siRNA, knockdown was 
performed using shRNA delivered by lentivirus, which is less toxic to cells than adenovirus delivery. 
The second generation lentiviral system (Figure 5.10) used three plasmids; a VSVg plasmid encoding 
the envelope containing a g-protein that binds to most mammalian cells, a BYE plasmid containing the 
lentiviral packaging factors gag, polymerase and reverse transcriptase, and a third plasmid encoding the 
shRNA against the target gene, LTRs to allow integration into the THP-1 genome, the ϕ packaging 
signal and the puromycin resistance gene used for selection. Separating the lentiviral components into 
three vectors reduces the potential of generating a replication competent virus and therefore increases 
biosafety. The three vectors were transfected into HEK-293T cells, which produced pseudovirus 
particles that were used to infect THP-1 cells.  
Multiple shRNAs were used per gene to increase confidence that any effects observed in response to the 
knockdowns were specific (Figure 5.11). Four new caspase-1 shRNAs were tested, with two caspase-4 
and -5 shRNAs that had previously been validated (Goodall group, unpublished). In addition, a non-
targeting shRNA was used to control for effects of lentiviral infection and integration of an exogenous 
DNA sequence. Two infections were carried out per shRNA, denoted A and B.  
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Figure 5.10: Lentiviral shRNA delivery. Schematic illustrating the mechanism of shRNA-mediated gene 
knockdown.  
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To determine which control THP-1 line resembled the uninfected cells more closely, CASP1, CASP4 
and CASP5 expression was measured (Figure 5.12). Although both lines infected with control virus 
showed an upregulation of caspase-1 expression, line CA expressed similar levels of CASP4 and CASP5 
to uninfected cells, whereas CB showed a slight reduction. Because of this, the control line CA was used 
for all further experiments. To evaluate which THP-1 lines exhibited the highest level of knockdown, 
the expression of their target gene was compared to expression in the CA cells (Figure 5.13). This 
analysis revealed that the shRNA02 was considerably less effective at CASP1 knockdown than the other 
caspase-1-targeted shRNAs, whilst all shRNAs used to knockdown CASP4 and CASP5 reduced gene 
expression by 50-80%. The CASP5 gene expression analysis in THP-1 cells infected with shRNA55 
illustrate the importance of carrying out duplicate infections since a stronger knockdown was observed 
in line 55B compared to 55A, even though these cells were infected with identical virus.  
  
Figure 5.11: shRNA strategy. Schematic illustrating the 18 THP-1 lines produced by using multiple shRNAs per 
caspase gene and carrying out duplicate infections for each shRNA. 
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Figure 5.12: The caspase expression profile of control line CA resembles uninfected THP-1 cells. (A-C) qPCR 
analysis showing levels of CASP1 (A), CASP4 (B) and CASP5 (C) gene expression in uninfected and control-virus 
infected THP-1s measured by RT-PCR. Data is mean +SEM of n=2.  
A. B. C. 
Figure 5.13: The knockdown efficiency for each THP-1 line generated. (A-C) qPCR analysis showing level of 
knockdown achieved by shRNAs targeting CASP1 (A), CASP4 (B) and CASP5 (C) compared to cells infected with 
a control shRNA measured by RT-PCR. Data is mean +SEM of n=2.  
A. 
B. C. 
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Although the shRNA knockdown seemed very effective when measuring the expression of the target 
genes, analysis of the expression of the other pro-inflammatory caspases revealed that in most cases 
knockdown was not specific (Figure 5.14). CASP1-targeted shRNAs 03 and 06 also slightly reduced 
CASP5 expression, every shRNA targeting CASP4 also repressed CASP1 expression, and most of the 
CASP5-targeted lines also exhibited lower CASP1 expression. Off-target effects are a recognised 
disadvantage of using shRNA for gene knockdown. However, the loss of CASP1 observed in all lines 
expressing CASP4-targeted shRNAs suggests that caspase-4 may really influence CASP1 expression.  
In addition, although lentiviral delivery is reported to stably integrate the shRNA into the host genome, 
a second gene expression analysis two weeks after infection revealed that the knockdowns were not 
stable (Figure 5.15). In particular, the expression of CASP1 seemed to dramatically increase during the 
two weeks after transfection. A possible explanation for this lack of stability could be that a 
subpopulation of the transduced cells suppressed the shRNA production but kept the antibiotic resistance 
and therefore outcompeted their neighbours.  
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Figure 5.14: The shRNA knockdown was not specific. qPCR data showing the level of CASP1, CASP4 and CASP5  
expression following infection with CASP1, CASP4, and CASP5 targeted shRNAs. Data is mean +SEM of n=2. 
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Figure 5.15: The shRNA knockdown was not stable. A comparison of the gene expression profiles of two CASP1- 
and two CASP5- targetted THP-1 lines at the time of (d0), and two weeks after (d14), transfection. Gene 
expression measured by RT-PCR. Data is mean +SEM of n=2. 
  Results: IL-1 is activated by caspase-5/-11 of the non-canonical inflammasome 
122 
 
Despite the lack of specificity and stability with the shRNA system, the effect of caspase-1 or caspase-
5 knockdown on IL-1α and IL-1β secretion in response to intracellular LPS was investigated using the 
best THP-1 lines (Figure 5.16). IL-1 levels were measured in both the supernatants and the lysates, in 
case interfering with caspase expression affected IL-1 secretion. CASP1 knockdown appeared to 
increase IL-1α levels in both the supernatant and cell lysate, which is in line with our suggestion that 
IL-1α activation and release bypasses the caspase-1 inflammasome. The effect of CASP1 knockdown 
on IL-1β release was variable; shRNA 04A significantly reduced IL-1β release as expected, whereas 
shRNA 06A increased IL-1β release. CASP5 knockdown using the shRNA53B significantly reduced 
both IL-1α and IL-1β secretion, whereas shRNA55B had little effect on IL-1 levels. Although this data 
exhibits some promising trends, the lack of specificity and consistency with the lentiviral system in 
THP-1 cells made it difficult to draw definitive conclusions.  
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Figure 5.16: The effect of caspase-1 or -5 knockdown on the IL-1 response to icLPS ELISA data showing levels of 
IL-1α and IL-1β in the supernatants or lysates of LPS-primed THP-1 cells treated ± intracellular LPS (icLPS). Data 
is mean +SEM of n=5 for supernatant samples or n=2 for lysate samples. 
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Due to the consistency problems with the lentiviral knockdown system in THP-1 cells, we attempted an 
alternative model of overexpression. We overexpressed either WT or the caspase-5 site mutant D105A 
form of pro-IL-1α in THP-1 cells in the hope that the site mutant might act as a dominant negative and 
mute the IL-1α response to intracellular LPS. However, as with the shRNA, the results were highly 
variable and inconclusive (Figure 5.17).  
 
 
 
Since genetically manipulating THP-1 cells was extremely challenging, we attempted to visualise the 
endogenous p19 IL-1α cleavage product following non-canonical inflammasome activation by western 
blot (Figure 5.18). Directly lysing the THP-1 cells into Laemelli buffer revealed an extremely faint 
19kDa band in the cells treated with intracellular LPS, which may be an artefact. We also prepared 
freeze-thaw lysates with and without the calcium chelator BAPTA (to prevent overt calpain activation 
Figure 5.17: The effect of overexpressing WT or D103A IL-1α in THP-1 cells (A-B) ELISA data showing the levels 
of IL-1α (A) and IL-1β (B) in the conditioned media of THP-1 cells nucleofected with an empty vector or a vector 
inducing WT or D103A IL-1α overexpression. Data represent mean +SEM of n=3. 
A. 
B. 
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during necrosis). However, the lysates did not reveal any IL-1α processing. All lysates showed that 
intracellular IL-1α was predominantly in its pro-form, implying that IL-1α is cleaved immediately prior 
to secretion, or that the GSDMD pore is not large enough to mediate pro-IL-1α secretion. Unexpectedly, 
a second slightly lower molecular weight form of pro-IL-1α was induced upon TLR2 ligation with 
PAM3CSK4. It would be interesting to determine if this priming-induced form of IL-1α is differentially 
modified to render it more susceptible to proteolytic cleavage than the higher molecular weight form 
present in resting cells.  
 
 
 
 
  
Figure 5.18: Intracellulular IL-1α is predominantly pro-IL-1α. Western blot for IL-1α in the lysates of THP-1 cells 
differentiated with PMA ± PAM4CSK4 priming ± intracellular LPS activation (icLPS). Lysates were either made 
directly into Laemelli buffer, or by freeze-thawing in liquid nitrogen ± BAPTA. 
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5.2.6 Developing a tool to detect caspase-5 cleaved IL-1α 
After experiencing significant difficulty establishing a model of non-canonical inflammasome activation 
in THP-1 cells, we developed a tool to detect the endogenous caspase-5 cleaved IL-1α released by 
primary cells. We produced a peptide antibody reactive to the region between the caspase-5 and calpain 
cleavage sites (Figure 5.19A) and developed this into a sandwich ELISA that recognised the longer 
caspase-5 cleaved form of IL-1α, but not pro- or calpain cleaved- IL-1α (Figure 5.19B, C), compared to 
the commercial IL-1α ELISA that recognised both forms of cleaved IL-1α (Figure 5.19D) 
 
 
 
 
 
Figure 5.19: Development of an ELISA to detect non-calpain-cleaved IL-1α. (A) Schematic showing the location 
of the custom peptide antibody relative to the calpain and caspase-5 cleavage sites in pro-IL-1α. (B) ELISA data 
showing detection of recombinant pro (p33), calpain cleaved (17) or non-calpain cleaved (>p17) IL-1α. (C-D) 
ELISA data showing specificity of our custom non-calpain cleaved IL-1α ELISA (C) or a total cleaved IL-1α ELISA 
(D) for detecting either calpain or caspase-5 cleaved pro-IL-1α. Data represent mean +SEM of n=3, p = 
***≤0.001, ****≤0.0001. 
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5.2.7 Cleavage and release of IL-1α from primary human macrophages depends on caspase-
5 
To see if caspase-5-cleaved IL-1α is released from cells, we activated the non-canonical inflammasome 
in primary human monocyte derived macrophages (hMDMs) by priming followed by intracellular LPS 
delivery (Figure 5.20A). The conditioned media of cells from three individual donors contained 
detectable levels of caspase-5-cleaved IL-1α (Figure 5.20B). Due to the limited cells and serum 
available, a siRNA SMARTpool was used to knockdown CASP5 in the hMDMs. Although a mixture of 
4 different siRNAS could increase likelihood of off-target effects, these should theoretically be avoided 
because each siRNA is used at a lower (⅟4X) concentration. Importantly, CASP5 knockdown had no 
effect on CASP1 expression, meaning that canonical inflammasome signalling was unaffected (Figure 
5.20C). CASP5 knockdown lead to a significant reduction in total IL-1α (Figure 5.20D), non-calpain 
cleaved IL-1α (Figure 5.20E) and IL-1β (Figure 5.20F) release following intracellular LPS treatment. 
Together, this data suggests that caspase-5 processing of IL-1 is not an artefact of using recombinant 
proteins, but occurs physiologically within cells.  
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D. E. F. 
Figure 5.20: Cleavage and release of IL-1α during non-canonical inflammasome activation in hMDMs depends 
on caspase-5. (A) Schematic showing the differentiation and treatment of human monocyte derived 
macrophages (hMDMs) from peripheral blood mononuclear cells (PBMCs). (B) ELISA data showing detection 
of non-calpain cleaved IL-1α in the conditioned media from hMDMS treated with intracellular LPS from three 
donors. (C) qPCR data showing CASP1 and CASP5 expression in hMDMs after control and CASP5-targeted siRNA 
delivery. (D-F) ELISA data showing level of total cleaved IL-1α (D), non-calpain cleaved IL-1α (E) and IL-1β (F) 
after CASP5 knockdown. Data represent mean +SEM of n=3, p = **≤0.01, ***≤0.001. 
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To investigate a potential role for caspase-5 in canonical inflammasome pathways, hMDMs were also 
primed and treated with ATP. Surprisingly, LPS/ATP activation also induced secretion of non-calpain 
cleaved IL-1α (Figure 5.21). This suggests crosstalk between human inflammasome pathways, similar 
to the reported activation of caspase-11 by caspase-1 in the murine system (Kayagaki et al., 2011).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.21: Caspase-5 cleaved IL-1α is released during canonical inflammasome activation in hMDMs. (A) 
Schematic showing the differentiation and canonical treatment of human monocyte derived macrophages 
(hMDMs) from peripheral blood mononuclear cells (PBMCs). (B) ELISA data showing detection of non-calpain 
cleaved IL-1α in the conditioned media from hMDMS treated with ATP from three donors.  
A. 
B. 
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5.2.8 Caspase-5 cleaves IL-1α in HeLa cells  
To support our primary macrophage data using another cell type we reconstituted the non-canonical 
inflammasome system in HeLa cells, which are very easy to transfect. We overexpressed either WT or 
D103A pro-IL-1α with pro-caspase5 in the cells, and treated them with intracellular LPS. This system 
required the cytosolic LPS to activate the pro-caspase-5, which could in turn cleave IL-1α. Significantly 
less total cleaved and non-calpain cleaved IL-1α was secreted by the D103A IL-1α-expressing cells 
(Figure 5.22A,B) suggesting that the site mutant acts as a dominant negative in this system. Notably, 
calpain could cleave D103A pro-IL-1α equivalently to WT (Figure 5.22C) implying that this mutation 
only affects non-canonical processing. Furthermore, treatment with intracellular LPS produced a 19kDa 
IL-1α fragment in cells overexpressing WT IL-1α, which was absent in the D103A site mutant cells 
(Figure 5.22D). Unfortunately, we could not take a similar approach for investigating IL-1β cleavage 
within a cell system, since caspase-5 cleaves at the same site as caspase-1.  
 
A. B. C. 
D. 
Figure 5.22: LPS-activated caspase-5 cleaves IL-1α in HeLa cells. 
(A-C) ELISA data showing the level of total cleaved IL-1α (A) or 
non-calpain cleaved IL-1α (B) in the conditioned media of HeLa 
cells transfected with pro-caspase-5 and WT or D103A pro-IL1α 
and treated with intracellular LPS, or total cleavage of WT or 
D103A by calpain (C). (D) Western blot for IL-1α in HeLa cells 
transfected with pro-caspase-5 and WT or D103A pro-IL1α ± 
intracellular LPS treatment. Data represent mean +SEM of n=3. 
p = *≤0.05. 
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5.2.9 Investigating the role of caspase-4 in caspase-5 activation 
Although caspases-4 and -5 are often both referred to as the human orthologues of murine caspase-11, 
our data shows that only caspase-5 can activate IL-1. Research by Alessandra Mortellaro’s group has 
shown that in human monocytes CASP4 knockdown reduces the IL-1α, IL-1β and IL-6 responses to 
LPS, whereas CASP5 knockdown only affects the release of IL-1 (Vigano et al., 2015). This suggests 
that caspase-4 could be upstream of caspase-5, and prompted us to question if caspase-4 activates 
caspase-5. Interrogating pro-caspase-5 processing by western blot was challenging due to a lack of 
specific anti-caspase-5 antibodies (Figure 5.23A). Recombinant protein assays showed caspase-4 was 
unable to activate pro-caspase-5 to induce subsequent IL-1α activation (Figure 5.23B,C). This suggests 
that either caspase-4 does not activate recombinant pro-caspase-5, or their interaction requires a post-
translational protein modification that is not present in the bacterial-derived recombinant proteins used 
in these assays.  
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Figure 5.23: Recombinant caspase-4 cannot activate pro-caspase-5. (A) Western blot for caspase-5 after 
incubation of pro-caspase 5 (proC5) ± caspase-4 (C4). (B) Western blot for IL-1α after incubation of pro-IL-1α 
± pro-caspase-5 ± caspase-4, or caspase-4. (C) ELISA data showing IL-1α-dependent IL-6 release from HeLa 
cells treated with the reaction products from the incubation of pro-IL-1α ± pro-caspase-5 ± caspase-4, or 
caspase-4. Data represent mean +SEM of n=3. 
A. B. 
C. 
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5.2.10 CASP5 and Casp11 are upregulated upon cell priming  
Human CASP4 and CASP5 are thought to have arisen from a gene duplication of an ancestral Casp11-
like gene. All three caspases have been found to directly bind and respond to intracellular LPS, which 
implies a functional conservation (Shi et al., 2014, Kayagaki et al., 2013). However, gene expression 
analysis revealed that CASP4 is constitutively expressed, whereas CASP5 and Casp11 are significantly 
upregulated after TLR ligation, suggesting greater functional equivalence between these two proteases 
(Figure 5.24). 
 
 
 
 
  
A. B. 
Figure 5.24: CASP5 and Casp11 share a similar gene expression patterns. (A-B) qPCR data showing changes in 
CASP4 and CASP5 (A) or Casp11 (B) transcript after LPS treatment of primary dendritic cells (A) or macrophages 
(B). Data represent mean +SEM of n=3, p = ***≤0.001.  
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Figure 5.25: Caspase-11, not -1, activates murine IL-1α. (A-D) Western blot for IL-1α (A,C) or ELISA data showing 
IL-1α-dependent IL-6 production by HeLa cells treated with the reaction products (B,D) following incubation 
of pro-IL-1α with caspase-1 (A,B) or caspase-11 (C,D) ± a neutralising IL-1α antibody (p αAb). Data represent 
mean +SEM of n=3, p =***≤0.001. 
5.2.11 Caspase-11 activates recombinant murine IL-1α 
To test if the similarities between caspases-5 and -11 extend to their substrate specificities, recombinant 
murine pro-IL-1α was incubated with the murine inflammatory caspases-1 and -11. Incubation with 
caspsase-1 did not result in IL-1α processing (Figure 5.25A) or activation (Figure 5.25B), in line with 
our findings in the human system and observations reported in the literature (Howard et al., 1991). In 
contrast, murine IL-1α was cleaved (Figure 5.25C) and activated (Figure 5.25D) by caspase-11.  
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Figure 5.26: Caspase-1 and -11 activate murine IL-1β. (A-D) Western blot for IL-1β (A,C) or ELISA data showing 
IL-1β-dependent IL-6 production by HeLa cells treated with the reaction products (B,D) following incubation of 
pro-IL-1β with caspase-1 (A,B) or caspase-11 (C,D) ± a neutralising IL-1β antibody (p βAb). Data represent mean 
+SEM of n=3, p = **≤0.01, ****≤0.0001 
5.2.12 Caspase-11 activates recombinant murine IL-1β 
Next, we examined the activation of IL-1β by the murine inflammatory caspases. As expected, murine 
IL-1β was cleaved (Figure 5.26A) and activated (Figure 5.26B) by murine caspase-1, where the 
negligible effect of the IL-1β neutralising antibody is likely due to saturation of the system. Caspase-11 
was also able to cleave (Figure 5.26C) and activate (Figure 5.26D) IL-1β at an equivalent efficiency in 
vitro to caspase-1.  
 
 
 
 
 
5.2.13 The caspase-11 reaction buffer affects the rate of high molecular weight protein 
migration during electrophoresis 
To elucidate whether caspase-11 cleavage of murine IL-1 was as specific as caspase-5 processing of 
human IL-1, we sought to locate the specific cleavage sites. The molecular weight of a cleavage product 
allows a rough estimation of where the enzyme cleaves. However, when we resolved the caspase-1 and 
caspase-11 cleavage reactions alongside each other on a western blot, it became apparent that a 
component of the caspase-11 reaction mix was increasing the speed of protein migration (Figure 5.27A). 
The caspase-11 buffer contains polyethylene glycol (PEG) which interacts with SDS under reducing 
A. B. C. D. 
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Figure 5.27: The Caspase-11 cleavage buffer makes higher Mw proteins migrate faster. (A) Western blot for IL-
1α following incubation of pro-IL-1α ± caspase-1 or -11. (B) Western blot for IL-1β following incubation of pro-
IL-1β ± caspase-1 or caspase-11 in caspase-1 reaction buffer. (C) Coomassie-stained PVDF membrane showing 
migration of unstained protein marker in PBS or caspase-11 reaction buffer. 
conditions (Zheng et al., 2007). When the SDS binds to the IL-1α protein, PEG increases the charge and 
speed of migration. Carrying out the caspase-11 cleavage reaction in the caspase-1 buffer, which does 
not contain PEG, revealed that the PEG was essential for caspase-11 activity (Figure 5.27B). Running 
a protein marker in the presence of the caspase-11 buffer revealed that PEG skews the apparent 
molecular weight of higher molecular weight proteins, but does not affect lower molecular weight 
(<20kDa) proteins (Figure 5.27C).  
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5.2.14 Caspase-11 can cleave IL-1α at multiple sites, including D106A 
Our initial experiments suggested that caspase-11 cleaved murine IL-1α to give a product of 
approximately 22-25kDa. However, due to the PEG in the buffer, it is difficult to be sure of the exact 
size of this cleavage product. As such, we mutated candidate aspartic acids to alanine based on 
conservation across species and location in the IL1A sequence (Figure 5.28A). Mutation of Asp106, the 
equivalent amino acid to the caspase-5 target site in human IL-1α, did not appear to affect murine IL-
1α processing by caspase-11 (Figure 5.28B), suggesting a refinement of caspase-5 substrate specificity 
over evolution. We also mutated Asp37 and/or Asp49 in the region of the IL-1α protein that would 
correspond to a 22-25kDa product size, which are highly conserved across rodent species. However 
mutation of one, or both, of these sites had no effect on IL-1α processing suggesting that these are not 
the caspase-11 sites (Figure 5.28D-I).  
To interrogate the cleavage of murine IL-1α by caspase-11 more thoroughly and to account for the 
promiscuity of the murine caspase, we conducted the cleavage assay using ten-fold less enzyme over a 
range of time points to identify a preferred cleavage site and/or any transient cleavage products. This 
lower level of cleavage revealed a 19kDa cleavage product (Figure 5.29A), which was lost in the D106A 
mutant (Figure 5.29B), suggesting that caspase-11 prefers to cleave at this aspartate, but will cleave 
elsewhere if the site is unavailable. Indeed, caspase-11-cleaved D106A murine IL-1α exhibited slightly 
lower activity than caspase-11-cleaved WT IL-1α (Figure 5.29C).  
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Figure 5.28: Caspase-11 
may not cleave IL-1α at a 
specific site. 
(A) Multi species 
alignment showing 
location of conserved 
aspartic acids. (B-I) 
Western blot for IL-1α 
(B,D,F,H) and IL-1α-
dependent IL-6 
production by HeLa 
cells treated with 
reaction products 
(C,E,G,I) following 
incubation of WT or 
D106A (B,C) / D37A 
(D,E) / D49A (F,G) / 
D37,49A (H,I) pro-IL-1α 
± caspase-11. Data 
represents mean +SEM 
of n=4 (C) or n=2 (E,G,I). 
 
A. 
B. C. 
D. E. 
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Figure 5.29: Caspase-11 cleaves murine IL-1α at D106A. (A) Western blot for IL-1α following incubation of WT 
pro-IL-1α with caspase-11 for a range of time points. (B-C) Western blot for IL-1α (B) or IL-1α dependent IL-6 
production by HeLa cells treated with reaction products (C) following incubation or WT or D106A pro-IL-1α ± 
caspase-11. Data represents mean +SEM of n=3. 
 
 
 
 
 
5.2.15 Caspase-11 cleaves IL-1β at Asp105 
Unlike for IL-1α, caspase-11 cleaved murine IL-1β to produce a clear 19kDa fragment, for which 
electrophoretic migration was unaffected by PEG due to its relatively low molecular weight. Alignment 
of IL-1β protein sequences revealed a conserved aspartic acid, Asp105, which corresponds to the 19kDa 
product (Figure 5.30A). Mutation of this aspartic acid to an alanine reduced cleavage (Figure 5.30B) 
and activation of IL-1β (Figure 5.30C) by a lower concentration of caspase-11. However, the remaining 
activity of D105A IL-1β implied it was still being cleaved and activated, and repeating the cleavage 
A. B. 
C. 
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with more caspase-11 resulted in total processing of both WT and D105A IL-1β (Figure 5.30D) and no 
significant difference in activation (Figure 5.30E).  
To confirm our hypothesis that caspase-11 has a preferred, but not exclusive, IL-1β target site we 
performed N-terminal sequencing on caspase-11 cleaved WT IL-1β. Although the sequence was weak, 
likely due to N-terminal blocking of the Ser106 residue during sample preparation, the Edman 
degradation confirmed that capase-11 cleaves at Asp105 (Figure 5.31A). Performing the same 
sequencing analysis on caspase-11-cleaved D105A IL-1β revealed a shift to alternative processing at 
Asp111 and Asp117 (Figure 5.31B). Therefore, caspase-11 specifically targets murine pro-IL-1β at 
Asp105, but when this site is blocked it can cleave at alternative aspartic acid residues towards the C-
terminus of the protein (Figure 5.31C).  
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Figure 5.30: Caspase-11 cleaves murine IL-1β at Asp105. (A) Multi species alignment showing location of 
conserved Asp105. (B-E) Western blot for IL-1β (B,D) or IL-6 production by HeLa cells treated with the reaction 
products (C,E) following incubation of pro-IL-1β with a low (B,C) or high (D,E) concentration of caspase-11. 
Data represent mean +SEM of n=3, p =****≤0.0001. 
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Figure 5.31: Caspase-11 cleaves murine IL-1β at Asp111 and Asp117 if Asp105 is unavailable. (A-B) Coomassie 
stained PVDF membrane sowing the caspase-11 cleaved bands from WT (A) or D105A (B) pro-IL-1β that were 
combined and sent for N-terminal sequencing by Edman degradation. Returned sequences are shown 
underneath. (C) Outline of and preference for caspase-11 cleavage sites in pro-IL-1β.  
 
 
 
 
 
 
 
5.2.16 IL-1α release after intracellular LPS only requires caspase-11 
To further examine the requirement for caspase-1 and/or caspase-11 in the secretion and processing of 
IL-1α and IL-1β we used bone marrow-derived macrophages (BMDMs) from WT, Casp11-/-, and Casp1-
/-/Casp11 Transgenic (Tg) mice. IL-1 release in response to intracellular LPS was absolutely dependent 
on caspase-11, as evidenced by the complete loss of cleaved IL-1α (Figure 5.32A) and IL-1β (Figure 
5.32B) secretion in the Casp11-/- BMDMs. Importantly, significant levels of cleaved IL-1α were secreted 
by the Casp1-/-/Casp11Tg BMDMs following intracellular LPS treatment (Figure 5.32C), suggesting that 
A. B. 
C. 
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Figure 5.32: IL-1α cleavage and release in response to intracellular LPS only requires caspase-11. (A-D) ELISA data 
showing the level of cleaved IL-1α (A,C) or IL-1β (B,D) detected in the conditioned media of murine bone 
marrow-derived macrophages from Casp11-/- (A,B) or Casp1-/-/Casp11Tg (C,D) mice that had been primed with 
LPS and then transfected intracellular LPS (icLPS). Data represent mean +SEM of n=3, p = ****≤0.0001. 
IL-1α bypasses the caspase-1 inflammasome and only requires caspase-11 for cleavage and release. The 
modest reduction in IL-1α secretion in Casp1-/-/Casp11Tg BMDMs compared to WT BMDMS is likely 
due to incomplete complementation of the endogenous Casp11 by the transgene, as reported previously 
(Kayagaki et al., 2011). Interestingly, the treated Casp1-/-/Casp11Tg BMDMs failed to release any IL-1β 
(Figure 5.32D), suggesting that although caspase-11 can cleave and activate IL-1β in vitro, cleavage 
and/or release in vivo also requires caspase-1.  
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Figure 5.33: Caspase-11 cleaves primary BMDM-derived pro-IL-1β. (A-B) Western blot for IL-1β following 
incubation of LPS-primed BMDM lysates alone (IC) or with caspase-11 (C11) (A), or a protease inhibitor cocktail 
(PIC) (B).  
To investigate if the discordance between our in vitro and in vivo findings for murine IL-1β was due to 
incorrect folding or a lack of post-translational modification rendering E.coli recombinant murine IL-
1β easier to cleave, we tested the ability of caspase-11 to process mammalian cell-derived IL-1β. Pro-
IL-1β derived from LPS-treated primary BMDMs was cleaved to the p19 form by caspase-11 (Figure 
5.33A) indicating that caspase-11 is capable of cleaving mammalian cell-derived pro-IL-1β. The p22 
form of IL-1β also present in the BMDM lysates without caspase-11 was blocked by using a protease 
inhibitor cocktail, showing that this second band was due to background proteolysis (Figure 5.33B).  
 
 
 
 
 
5.2.17 IL-1α release after Chlamydia trachomatis infection only requires caspase-1 
To investigate the dependency of IL-1 secretion on each caspase during live bacterial infection, primary 
BMDMs from WT, Casp11-/- or Casp1-/-/Casp11Tg mice were infected with the Gram negative bacteria 
Chlamydia trachomatis. Interestingly, IL-1α secretion in response to C.trachomatis infection was 
dependent on caspase-1, not caspase-11. IL-1β release was completely dependent on caspase-1, but was 
also partially affected by the loss of caspase-11 (Figure 5.34). C.trachomatis is not a straightforward 
activator of the non-canonical inflammasome. Many non-canonical activators, such as E.coli, have hexa-
acylated Lipid A moieties, whereas C.trachomatis Lipid A is only penta-acylated. LPS from this 
bacterium therefore cannot induce TLR4 dimerisation and endocytosis (Tan et al., 2015), which may 
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Figure 5.34: IL-1α cleavage and release in response to C. trachomatis is dependent on caspase-1. (A-D) ELISA 
data showing the level of cleaved IL-1α (A,C) or IL-1β (B,D) detected in the conditioned media of murine bone 
marrow-derived macrophages from Casp11-/- (A,B) or Casp1-/-/Casp11Tg (C,D) mice that had been primed with 
LPS and then transfected Chlamydia trachomatis (CT). Data represent mean +SEM of n=3, p = *≤0.05, **≤0.01, 
****≤0.0001. 
explain why C.trachomatis appears to preferentially engage the canonical inflammasome pathway 
despite being an intracellular Gram negative bacterium. Indeed, recent work from Jane Goodall’s group 
has demonstrated that although C.trachomatis activates both the canonical and non-canonical 
inflammasomes, only the canonical pathway mediates IL-1β release and pyroptosis (Webster et al., 
2017).  
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Figure 5.35: IL-1α and IL-1β release in response to intracellular LPS are dependent on GSDMD. (A-D) ELISA data 
showing the level of cleaved IL-1α (A) or IL-1β (B) detected in the conditioned media of murine bone marrow-
derived macrophages from WT and GsdmD-/-  mice that had been primed with LPS and then transfected 
intracellular LPS (icLPS). Data represent mean +SEM of n=3, p = ****≤0.0001, 
 
5.2.18 IL-1α and IL-1β release in response to intracellular LPS is dependent on gasdermin 
D 
Both caspase-1 and caspase-11 are known to liberate the N-terminal fragment of GSDMD that binds to 
inner membrane phospholipids and mediates pore formation. Eventually the accumulation of the 
GSDMD pores drives loss of plasma membrane integrity and pyroptosis, but the cell delays this death 
through membrane ‘bubbling’. This delay is thought to allow the cell time to communicate its situation 
by releasing cytokines through the GSDMD pores, which recruit immune cells. To examine whether 
GSDMD pores are required for IL-1α and IL-1β secretion in response intracellular LPS, primary 
BMDMs from WT or GsdmD-/- mice were primed and transfected with LPS. Both the IL-1α and IL-1β 
responses were lost in the GsdmD-/- cells (Figure 5.35), suggesting that these cytokines exit the cell 
through the GSDMD pores during LPS-mediated non-canonical inflammasome activation. 
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5.3 Discussion 
Successful host defence requires an immune response that effectively resolves an insult without causing 
overt tissue damage. IL-1 is an extremely powerful inflammatory cytokine that is subject to multiple 
levels of regulation. The inflammasome represents an important platform for IL-1 activation, and 
multiple inflammasome sensors have evolved to detect and distinguish a wide range of endogenous and 
exogenous danger signals. Over the last 6 years, the non-canonical inflammasome has emerged as an 
important mechanism for sensing intracellular bacterial infection via LPS-mediated inflammatory 
caspase activation. However, it is not fully understood how IL-1, particularly IL-1α, is activated by the 
non-canonical inflammasome, and very few studies have investigated the human system.  
We find that IL-1α and IL-1β are directly cleaved by human caspase-5, but not caspase-4, and murine 
caspase-11 at highly conserved sites, and this processing leads to enhanced cytokine activity (Figures 
5.2, 5.6, 5.25 and 5.26). In humans, CASP4 and CASP5 arose due to the duplication of an ancestral 
Casp11-like gene. Most literature focusses on caspase-4, which is often described to be the closer 
orthologue of caspase-11 (Shi et al., 2014). Although all three caspases have been shown to bind LPS, 
only CASP5 and Casp11 are upregulated by TLR ligation, whereas CASP4 is constitutively expressed 
(Figure 5.24). Furthermore, we show that both caspase-5 and -11 can directly activate IL-1, which 
suggests a closer functional connection between these two proteases. Our data does, however, suggest 
that caspase-11 is more promiscuous than caspase-5. For both murine IL-1α and IL-1β, if the preferred 
cleavage site is blocked, caspase-11 simply cleaves elsewhere (Figures 5.29 and 5.30), in contrast to the 
complete blockage of human IL-1 activation by caspase-5 following mutation of the target sites (Figures 
5.4 and 5.8). We therefore suggest that caspases-4 and 5 have undergone both substrate specificity 
refinement, and sub-functionalisation, with the functionality of the ancestral caspase-11-like gene now 
distributed between both enzymes. 
We show that caspase-5-cleaved IL-1α is released by primary human macrophages following both 
canonical and non-canonical inflammasome activation (Figures 5.20 and 5.21), which suggests there 
may be crosstalk between the two pathways. Indeed, caspase-11 has been previously shown to activate 
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caspase-1 (Kang et al., 2000). Using our in-house ELISA to detect the release of this longer cleaved 
form of IL-1α from cells demonstrates that IL-1α is not released passively during pyroptosis, but is 
actively processed during non-canonical inflammasome activation before calpain is activated.  
Intriguingly, our murine BMDM data showed that IL-1α secretion following intracellular LPS treatment 
requires caspase-11 only, whereas IL-1β release requires both caspases-1 and -11 (Figure 5.32). This 
finding was somewhat surprising, since our recombinant protein data suggested that caspase-11 cleaved 
murine pro-IL-1β very efficiently. We confirmed that this difference was not an artefact of using 
recombinant protein, because caspase-11 could efficiently process BMDM-derived pro-IL-1β (Figure 
5.33). One possible explanation for this is that active caspase-11 could be compartmentalised away from 
pro-IL-1β inside cells. Indeed, IL-1β is upregulated and translated alongside other components of the 
canonical inflammasome that are known to aggregate at a single point within the cell known as the 
‘speck’, and so it is possible that IL-1β is also targeted to this specific intracellular location. 
Unfortunately, due to a lack of commercially available IL-1β immunofluorescence antibodies, it is 
difficult to interrogate this hypothesis further. Another simple explanation could be that recombinant 
caspase-11 is promiscuous and cuts IL-1β non-specifically in vitro. However, caspase-11 preferentially 
cuts IL-1β at a conserved tetrapeptide sequence 13 residues upstream of the caspase-1 site, which 
strongly suggests cleavage and activation of IL-1β by caspase-11 is a specific action. 
The original Casp1-/- mice showed complete loss of IL-1β release from macrophages during 
endotoxemia. Unexpectedly, reduced levels of IL-1α release were also reported, which has been an 
ongoing puzzle in the caspase field given that IL-1α is not a substrate for caspase-1 (Kuida et al., 1995, 
Li et al., 1995). However, because the Casp1-/- mice were made using stem cells from a mouse of a 
129/Sv background, they also contained an inactivating mutation in their Casp11 gene. Our data 
suggests that the defective IL-1α cleavage and release observed in the original Casp1-/- mice is likely 
because IL-1α cannot be processed by caspase-11 in these animals. Indeed, serum levels of cleaved IL-
1α are undetectable during endotoxemia in Casp11-/- and Casp1-/-/Casp11-/- but are restored in the Casp1-
/-Casp11Tg mice (Kayagaki et al., 2011). 
  Results: IL-1 is activated by caspase-5/-11 of the non-canonical inflammasome 
149 
 
The direct activation of IL-1α by caspase-5 may represent an extremely important immune defence 
pathway. A number of pathogens release proteins that target the canonical inflammasome as part of their 
immune evasion strategy. For example, the viral serpin CrmA, and Myxoma and Vaccinia proteins 
directly inhibit caspase-1, while the Pseudomonas aeruginosa T3SS effector Exoenzyme U and 
Mycobacterium tuberculosis zinc metalloproteinase zmp1 interfere with inflammasomes (Lamkanfi and 
Dixit, 2011, Taxman et al., 2010). The caspase-5 IL-1α activation pathway completely bypasses the 
canonical caspase-1 inflammasome, and could therefore represent a way of reinstating the immune 
response after caspase-1 inflammasome blockade. Furthermore, pro-IL-1α is constitutively expressed 
by most cell types, although held in an inactive state by the decoy receptor IL-1R2, whereas IL-1β must 
be upregulated following priming. We have previously demonstrated that caspases-1 and -5, but not 
caspase-4, are able to cleave IL-1R2 (Zheng et al., 2013). Caspase-5 is therefore an extremely powerful 
protease that can both liberate and activate IL-1α rapidly following intracellular infection. 
In conclusion, the work presented in this chapter has identified caspase-5 as a novel activator of IL-1α 
during non-canonical inflammasome activation by intracellular LPS. Therefore, therapeutically 
targeting caspase-5 may be of great interest in diseases driven by the non-canonical inflammasome, such 
as septic shock.  
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6. Results: Caspase-5/-11 cleavage of IL-1α drives the senescence-
associated secretory phenotype 
6.1 Introduction  
Senescence is a permanent state of stable cell cycle arrest that occurs in response to cellular stress. It 
was first described in the 1960’s, when Hayflick and Moorhead showed that primary human fibroblasts 
undergo permanent proliferative arrest following extended in vitro culture (Hayflick and Moorhead, 
1961). This form of cell cycle arrest is now known as replicative senescence, which naturally occurs due 
to the progressive shortening of telomeres with each cell division and subsequent DNA damage. 
Senescence is an important and protective cellular process with roles in embryonic development, normal 
tissue homeostasis, and wound healing (Storer et al., 2013, Munoz-Espin et al., 2013, Jun and Lau, 
2010). However, senescence is also induced by a number of pathophysiological stimuli, including high 
ROS levels, oncogene hyperactivation (oncogene-induced senescence, OIS), cytotoxic drugs, and 
ageing (Chen et al., 1995, Serrano et al., 1997, Ogryzko et al., 1996, Parry and Narita, 2016). As such, 
senescent cells are implicated in multiple diseases including cancer, arthritis, and atherosclerosis (Pérez-
Mancera et al., 2014, Price et al., 2002, Childs et al., 2016).  
Senescent cells have a number of characteristic features that distinguish them from other non-dividing 
cells, such as those that are terminally differentiated or quiescent. For example, senescent cells develop 
a large and flat morphology in vitro, do not proliferate (e.g. Ki67-negative), upregulate tumour 
suppressors and cell cycle inhibitors (e.g. p16 and p21), and rearrange their genetic material into distinct 
heterochromatic foci to reduce cell cycle gene accessibility (Collado and Serrano, 2006, Narita et al., 
2003). However, perhaps the most widely used marker of senescent cells is senescence-associated beta-
galactosidase (SAβGAL) (Dimri et al., 1995). Importantly, SAβGAL itself is not an enzyme; rather it 
describes the overexpression and accumulation of lysosomal beta-galactosidase that drives the 
production of a blue precipitate when incubated with the substrate X-gal at pH 6.0. Although senescent 
cells exhibit high levels of lysosomal beta-galactosidase activity, there is evidence suggesting that other 
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cell types including macrophages can also upregulate this enzyme (Bursuker et al., 1982). As such, 
although SAβGAL remains an appropriate marker for cellular senescence in vitro, it may not be suitable 
for use in vivo where multiple cell populations are present. 
In addition to these distinct intracellular changes, senescent cells secrete a cocktail of inflammatory 
mediators including cytokines, chemokines, growth factors and proteases, collectively known as the 
senescence-associated secretory phenotype (SASP) (Figure 6.1). The SASP reinforces senescence in 
both an autocrine and paracrine manner, and is reported to be driven by IL-1α (Orjalo et al., 2009, 
Gardner et al., 2015). Whilst the SASP drives immune cell recruitment and therefore the elimination of 
damaged senescent cells, it also induces chronic inflammation that contributes to disease progression. 
For instance, the SASP of senescent vascular smooth muscle cells (VSMCs) in atherosclerotic lesions 
likely drives plaque instability (Gardner et al., 2015). In addition, the SASP within a tumour supports 
metastasis by increasing epithelial cell proliferation, driving epithelial-mesenchymal transition and 
promoting tumour cell invasiveness (Coppé et al., 2010).  
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Figure 6.1: The senescence-associated secretory phenotype. Schematic showing the causes of cellular 
senescence, examples of SASP factors and their effects. 
 
 
  
 
6.1.1 Chapter 5 project rationale 
The IL-1α-dependent SASP is an important sterile inflammatory pathway that is involved in both normal 
tissue homeostasis and inflammatory disease. The protease that activates IL-1α in senescent cells is 
unknown. Previous studies have suggested that the NLRP3 inflammasome modulates the SASP (Acosta 
et al., 2013), even though the proteolytic component caspase-1 is unable to activate IL-1α. We have 
shown that caspase-5, which lies upstream of NLRP3 in the non-canonical inflammasome pathway, is 
a potent inducer of IL-1α activity (Chapter 5). The work presented in this chapter aims to determine if 
caspase-5 regulates the IL-1α-driven SASP.  
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Figure 6.2: The caspase inhibitors Z-YVAD-fmk and Z-LEVD-fmk are not specific. (A-B) ELISA data showing the 
level of IL-1 dependent IL-6 release from HeLas treated with the reaction products following incubation of IL-
1α with caspase-5 (A) or IL-1β with caspase-1 (B) ± a range of Z-YVAD-fmk or Z-LEVD-fmk concentrations. Data 
represent mean ±SEM of n=2. 
 
6.2 Results 
6.2.1 Senescence as a model of sterile inflammation 
Four years ago, Jesús Gil’s group reported that the canonical NLRP3 inflammasome drives the SASP 
(Acosta et al., 2013). They observed that mature IL-1β was released from senescent fibroblasts, and that 
the canonical inflammasome components caspase-1, NLRP3 and ASC were upregulated during 
senescence. Acosta and colleagues reported that treatment of senescent cells with the caspase-1 inhibitor 
Z-YVAD-fmk inhibited the SASP, and concluded that the NLRP3 inflammasome drives IL-1 secretion. 
However, we find that the caspase inhibitors are not specific. The caspase-1 inhibitor Z-YVAD-fmk 
inhibited caspase-5-mediated IL-1α activation with equal potency to the caspase-5 inhibitor Z-LEVD-
fmk (Figure 6.2A). Similarly, Z-LEVD-fmk was a more potent inhibitor of caspase-1-mediated IL-1β 
activation than Z-YVAD-fmk (Figure 6.2B). As such, these inhibitors are not a reliable tool for teasing 
apart the contribution of individual caspases in a cell. Since the NLRP3 inflammasome activation occurs 
downstream of caspase-5 activation, we hypothesised that the non-canonical inflammasome could play 
a role in senescence, and that the effects of Z-YVAD-fmk on the SASP reported by Acosta et al were 
in fact due to the inhibition of caspase-5.  
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6.2.2 H-RAS expression drives oncogene-induced senescence in primary human fibroblasts 
To investigate whether caspase-5 is required for IL-1α-driven SASPs, we (in collaboration with the 
Narita group, CRUK) used a well-characterised system in human IMR90 fibroblasts in which 
tamoxifen-inducible HRAS expression causes senescence (Narita et al., 2011, Hoare et al., 2016). Seven 
days of tamoxifen treatment resulted in an upregulation of SAβGAL (Figure 6.3A), a reduction in 
proliferation (Figure 6.3B), and the formation of senescence-associated heterochromatic foci (SAHF) 
(Figure 6.3C).  
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Figure 6.3: H-RAS overexpression induces senescence in IMR90 fibroblasts. (A-C) Representative images and 
quantification of senescence-associated beta galactosidase (SAβGAL) (A), proliferation by BrDu (B), and 
senescence-associated heterochromatic foci (SAHF) by DAPI (C). Data represents mean +SEM of n=3, p = 
***≤0.001, ****≤0.0001. 
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Figure 6.4: Senescent cells upregulate IL-1α. (A-C) Levels of IL1A expression by qPCR (A), surface IL-1α by flow 
cytometry (B), and cleaved IL-1α in the conditioned media by ELISA (C) in growing (Grow.) and senescent (Sen.) 
IMR90 cells. (D.) Level of cell death in growing and senescent IMR90 cells measured by propidium iodide 
staining. Data represent mean +SEM of n=3, p = **≤0.01, ***≤0.001. 
 
6.2.3 Senescent IMR90 cells upregulate IL-1α expression 
Since the SASP is reported to be driven by IL-1α (Orjalo et al., 2009), we compared the levels of IL-1α 
expression in growing and senescent cells. Senescent fibroblasts upregulated IL1A gene expression 
(Figure 6.4A), increased cell-surface IL-1α expression (Figure 6.4B), and secreted more mature IL-1α 
(Figure 6.4C), compared with growing cells. Importantly, there was no difference in levels of cell death 
between growing and senescent cells, excluding any effects of IL-1α released after necrosis or pyroptosis 
(Figure 6.4D). 
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Figure 6.5: IL-1α secretion by senescent IMR90 cells may be partially GSDMD dependent. (A) qPCR data showing 
relative GSDMD expression in senescent IMR90 cells after transfection of control (Ctrl) or GSDMD-targeted 
siRNAs. (B-C) Cell surface IL-1α by flow cytometry (B), or levels of cleaved IL-1α in the conditioned media by 
ELISA (C), in senescent IMR90 cells after transfection of control or GSDMD- targeted siRNAs. Data represent 
mean +SEM of n=3, p = *≤0.05, **≤0.01, ****≤0.0001. 
 
6.2.4 IL-1α secretion by senescent IMR90 cells is partially GSDMD-independent 
Although the SASP is reported to be driven by cell-surface IL-1α (Orjalo et al., 2009), it remains unclear 
whether membrane IL-1α is a real phenomenon, or if it is actually secreted IL-1α bound to IL-1R1. 
Ongoing research from our group suggests that a significant portion of surface IL-1α may be bound to 
IL-1R1 and IL-1R2 (Chan et al, publication in progress). To test whether IL-1α is secreted through the 
GSDMD pores during senescence, we used two individual siRNAs to knockdown GSDMD expression 
(Figure 6.5A). GSDMD knockdown had no effect on surface IL-1α expression (Figure 6.5B), but did 
elicit a modest reduction in IL-1α secretion (Figure 6.5C).  
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Figure 6.6: Punicalagin has no effect on IL-1α secretion. (A-B) ELISA data showing levels of cleaved IL-1α (A) or 
LDH (B) in the conditioned media of senescent IMR90 cells ± punicalagin treatment. Data represent mean 
+SEM of n=3. 
 
Since the GSDMD-targeted siRNAs achieved approximately 85-95% knockdown, it is possible that the 
remaining 5-15% of GSDMD was sufficient for pore formation and IL-1α secretion. During their 
research on IL-1β release during inflammasome activation, Pablo Pelegrin’s group suggested 
punicalagin as a compound that may block GSDMD pores (Martín-Sánchez et al., 2016). Treatment of 
senescent IMR90s with punicalagin led to a modest increase in total IL-1α secretion, suggesting that IL-
1α is not released through the GSDMD pores (Figure 6.6A). Importantly there was no difference in cell 
death between the treated and untreated samples (Figure 6.6B)  
 
 
 
 
 
6.2.5 IL-6 secretion by senescent IMR90 cells is IL-1α-dependent 
The cytokines IL-6 and IL-8 are considered two of the most strongly upregulated SASP factors in 
senescent cells. The conditioned media of day 7 senescent IMR90s contained extremely high levels of 
IL-6, which was secreted in a completely IL-1α dependent manner as evidenced by an IL-1α neutralising 
antibody and the IL-1RA (Figure 6.7A). Unexpectedly, there was no difference in the levels of secreted 
IL-8 between growing and senescent IMR90s (Figure 6.7B), despite an upregulated transcript (Figure 
6.7C). 
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Figure 6.7: Senescent cells secrete IL-6 in an IL-1α-dependent manner. (A-B) ELISA data showing level of IL-6 (A) 
and IL-8 (B) in the conditioned media of growing (Grow.) and senescent (Sen.) IMR90s treated ± a neutralising 
IL-1α antibody (p αAb) or IL-1RA (RA). (C) Re-analysed RNA-seq data (Hoare et al., 2016) showing level of IL8 
expression by growing (Grow.) and senescent (Sen.) IMR90s. Data is mean +SEM of n=3 (A,B) or 6 (C), p = 
****≤0.0001. 
 
To investigate this further, we assessed the levels of IL-6 and IL-8 in the conditioned media of senescent 
IMR90s over time (Figure 6.8). IL-6 release occurred at the later time points, peaking after 7 days of 
HRAS expression (Figure 6.8A), whereas maximal IL-8 secretion was observed earlier after only 4-5 
days of HRAS expression (Figure 6.8B). It is possible that IL-6 production saturates the protein synthesis 
machinery at day 7, preventing IL-8 protein production despite high levels of gene transcription.  
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Figure 6.8: The temporal pattern of IL-6 and IL-8 release by senescent IMR90 cells (A-B) ELISA data showing level 
of IL-6 (A) and IL-8 (B) in the conditioned media of senescent IMR90s over time treated ± IL-1α neutralising 
antibody (α Ab) or the IL-1RA (RA). Data is mean +SEM of n=3 
 
 
 
 
 
6.2.6 Senescent IMR90 cells do not release cleaved IL-1β 
It has been reported that senescent cells release cleaved active IL-1β (Acosta et al., 2013). Since both 
forms of IL-1 signal through the same receptor, this contradicts our data showing that anti-IL-1α 
neutralising antibody completely abolishes the SASP. However, we were unable to detect significant 
levels of IL-1β in the conditioned media of growing or senescent cells (Figure 6.9A). Analysis of 
intracellular IL-1β levels revealed that senescent IMR90s upregulate pro-IL-1β, but only a small amount 
is processed into an 18-19KDa fragment (Figure 6.9B). In fact, a large portion of the pro-IL-1β was 
processed into a 25kDa form that is likely inactive, which may represent a mechanism to inactivate large 
amounts of pro-IL-1β and prevent aberrant inflammation.  
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Figure 6.9: Senescent cells do not release IL-1β. (A) ELISA data showing level of IL-1β in the conditioned media 
of growing and senescent IMR90s. (B) Western blot for IL-1β and β-actin in growing and senescent IMR90 
lysates. Data is mean +SEM of n=3. 
 
 
 
 
 
 
6.2.7 Senescent IMR90 cells upregulate CASP5 via cGAS signalling 
Gene expression analysis revealed that senescent IMR90 fibroblasts expressed higher levels of CASP5 
than growing cells (Figure 6.10A). This upregulation was also observed when publically available RNA-
seq data (Hoare et al., 2016) was re-analysed (Figure 6.10B). Together, this suggests that the non-
canonical inflammasome might be involved in activating IL-1α in senescent cells.  
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Figure 6.10: Senescent cells upregulate CASP5. (A-B) Levels of CASP5 gene expression growing and senescent 
IMR90 fibroblasts analysed by qPCR (A) and RNA-seq (B). Data represent mean +SEM of n=3 (A) or 6 (B). p = 
**≤0.01, ***≤0.001. 
 
Figure 6.11: Ascorbic acid treatment has no effect on the SASP. (A-B) ELISA data showing the level of IL-1α (A) 
and IL-6 (B) in the conditioned media of senescent IMR90 cells ± ascorbic acid. Data represent mean +SEM of 
n=3. 
 
 
 
   
 
The priming and activating stimuli that drive CASP5 upregulation and pro-caspase-5 activation in 
senescent cells are unknown. RAS overexpression has been reported to increase the levels of 
intracellular ROS (Lee et al., 1999) that could oxidise a number of substrates that may activate caspase-
5, akin to the activation of caspase-11 by the oxidised phospholipid oxPAPC (Zanoni et al., 2016). 
However, treatment with the antioxidant ascorbic acid had no effect on the SASP (Figure 6.11), 
suggesting that ROS are not involved in caspase-5 expression and/or activation.  
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Senescent cells exhibit impaired nuclear membrane integrity due to the loss of lamin B1 (Freund et al., 
2012). This results in the presence of cytosolic chromatin fragments that are reported to mediate the 
SASP via the cyclic GMP-AMP synthase (cGAS) pathway (Gluck et al., 2017). cGAS is an intracellular 
PRR that senses double stranded DNA and drives 2’3’cyclic GMP-AMP (cGAMP) synthesis, which in 
turn activates stimulator of interferon genes (STING). STING upregulates Type I interferon (IFN) 
expression, which is reported to induce the expression of non-canonical inflammasome components 
including Casp11 (Rathinam et al., 2012) and contribute to the development of oncogene-induced 
senescence (Katlinskaya et al., 2016). In addition, cytosolic DNA has been reported to activate caspase-
5 in keratinocytes (Zwicker et al., 2017). siRNA-mediated cGAS knockdown in senescent IMR90s 
(Figure 6.12A) led to a reduction in CASP5 expression (Figure 6.12B), and an impaired SASP (Figure 
6.12C,D). Together, this data suggests that cytosolic dsDNA might mediate CASP5 upregulation 
through the cGAS/STING pathway.  
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Figure 6.12: cGAS knockdown impairs the SASP. (A-B) qPCR data showing level of cGAS (A) or CASP5 (B) 
expression in senescent IMR90s treated with control (Ctrl) or cGAS-targeted siRNA. (C-D) ELISA data showing 
the level of IL-1α (C) and IL-6 (D) in the conditioned media of senescent IMR90 cells treated with control or 
cGAS-targeted siRNA. Data represent mean +SEM of n=3 p = *≤0.05, ****≤0.0001. 
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Figure 6.13: Caspase-5 regulates the IL-1α driven SASP. (A) qPCR data showing relative CASP5 expression in 
senescent IMR90 cells after transfection of control (Ctrl) or CASP5-targeted siRNAs. (B-D) Cell surface IL-1α by 
flow cytometry (B), or levels of cleaved IL-1α (C), non-calpain-cleaved IL-1α (D) and IL-6 (E) in the conditioned 
media by ELISA, in senescent IMR90 cells after transfection of control or CASP5-targeted siRNAs. Data 
represent mean +SEM of n=3, p = *≤0.05, ****≤0.0001. 
 
6.2.8 Caspase-5 controls the IL-1α-driven SASP in IMR90 cells 
The upregulation of CASP5 in senescent cells, coupled with its ability to cleave and activate IL-1α 
(Chapter 5), led us to hypothesise that caspase-5 regulates the SASP. CASP5 knockdown (Figure 6.13A) 
resulted in significantly less cell surface IL-1α expression (Figure 6.13B), reduced secretion of total and 
non-calpain cleaved IL-1α (Figure 6.13C,D) and a subsequent reduction in IL-6 (Figure 6.13E). 
Together, this data shows that caspase-5 modulates the IL-1α driven SASP in senescent IMR90 cells.  
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Figure 6.14: CASP4 knockdown impairs the SASP. (A-B) qPCR data showing level of CASP4 (A) or CASP5 (B) 
expression in senescent IMR90s treated with control (Ctrl) or CASP4-targeted siRNA. (C-D) ELISA data showing 
the level of IL-1α (C) and IL-6 (D) in the conditioned media of senescent IMR90 cells treated with control or 
CASP4-targeted siRNA. Data represent mean +SEM of n=3 p = **≤0.01, ***≤0.001, ****≤0.0001. 
 
Although caspase-4 does not directly activate IL-1α (Figure 5.2), it shares a number overlapping 
functions with caspase-5. For example, both caspases are activated by binding to intracellular LPS and 
share the common substrate GSDMD (Kayagaki et al., 2013, Shi et al., 2014, Kayagaki et al., 2015, Shi 
et al., 2015). siRNA mediated CASP4 knockdown had variable effects on CASP5 expression (Figure 
6.14B), suggesting that caspase-4 activation is not involved in senescent IMR90 cell priming and CASP5 
upregulation. However, CASP4 knockdown led to a reduction in IL-1α and subsequent IL-6 release 
(Figure 6.14C,D), although this effect was much less potent than CASP5 knockdown, thereby supporting 
a more direct role for caspase-5 in IL-1α activation. Therefore, caspase-4 may lie upstream of caspase-
5 in the SASP pathway.  
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6.2.9 Caspase-11 may regulate the DNA damage-induced SASP in primary murine 
fibroblasts 
Demonstrating that caspase-5 modulates the IL-1α-driven SASP in human fibroblasts prompted the 
question of whether caspase-11 drives murine SASPs. Inducing senescence in murine cells in vitro is 
challenging due to the constitutive expression of active telomerase (Calado and Dumitriu, 2013). 
Although many studies use murine embryonic fibroblasts (MEFs) in models of senescence (Dirac and 
Bernards, 2003, Di Micco et al., 2008, Odell et al., 2010), it seems illogical to use embryonic cells to 
mimic what is often considered as an ageing phenotype. Thus, we treated adult ear-derived fibroblasts 
from WT and Casp11-/- mice with bleomycin for three hours to induce DNA damage (Orjalo et al., 
2009), and cultured the cells for 7-14 days. Morphological differences between the two genotypes were 
apparent both 7 (Figure 6.15) and 14 (Figure 6.16) days after bleomycin treatment, with the Casp11-/- 
cells retaining a more spindle-like fibroblast shape whilst the WT fibroblasts developed a larger, 
rounder, and flatter morphology that is typical of senescent cells.  
In addition to the morphological analysis, fibroblasts were stained for SAβGAL. After 14 days of 
bleomycin treatment, there were significantly fewer SAβGAL-positive cells in the Casp11-/- fibroblasts 
compared with WT (Figure 6.17). Treatment with an IL-1α neutralising antibody reduced SAβGAL 
staining in WT cells to the same level as Casp11-/- fibroblasts, which were unaffected by the antibody 
treatment, suggesting that caspase-11-mediated IL-1α activation promotes senescence. 
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Figure 6.15: Casp11-/- fibroblasts are morphologically different to WT fibroblasts 7 days after bleomycin 
treatment. Example images of WT or Casp11-/- adult ear murine fibroblasts fixed and stained for SAβGAL (blue) 
7 days after bleomycin treatment. Representative images of n=3. 
 
 
 
  Results: Caspase-5/-11 cleavage of IL-1α drives the senescence-associated secretory phenotype 
169 
 
Figure 6.16: Casp11-/- fibroblasts are morphologically different to WT fibroblasts 14 days after bleomycin 
treatment. Example images of WT or Casp11-/- adult ear murine fibroblasts fixed and stained for SAβGAL (blue) 
14 days after bleomycin treatment. Representative images of n=3. 
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Figure 6.17: Bleomycin-treated Casp11-/- fibroblasts express significantly less SAβGAL than WT. Percentage of 
SaβGAL- positive fibroblasts cultured for 14 days ± bleomycin treatment ± IL-1α neutralising antibody (p αAb). 
Data represent mean +SEM of n=3, p = **≤0.01, ****≤0.0001. 
 
Figure 6.18: The WT fibroblasts did not produce a SASP. ELISA data showing the level of IL-6 in the conditioned 
media of WT or Casp11-/- fibrobasts ± bleomycin treatment ± IL-1α neutralising antibody (p αAb). Data 
represent mean +SEM of n=3. 
 
 
Although the Casp11-/- fibroblasts appeared to have a senescence defect with regard to SAβGAL 
expression, their IL-6 secretion was extremely variable (Figure 6.18). Unexpectedly, the WT fibroblasts 
released negligible levels of IL-6, and the untreated Casp11-/- fibroblasts secreted more IL-6 than the 
bleomycin-treated cells. As such, it is not possible to conclude from the in vitro fibroblast data whether 
caspase-11 modulates the murine SASP. Since this acute DNA-damage-induced senescence is a 
different model to that used for the rest of our studies, which represent oncogene-induced senescence, 
these experiments were discontinued due to time constraints. However, future work could include using 
a stronger DNA-damaging stimulus such as γ-irradiation or a longer bleomycin treatment. 
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Figure 6.19: Schematic illustrating the hydrodynamic tail vein injection model. NRAS/shRNA plasmid and 
transposase plasmids are mixed and diluted into a volume equivalent to 10% of each mouse’s body weight. 
Over time immune cells, recruited by the SASP, clear the senescent NRAS-positive cells.  
 
 
6.2.10 Caspase-11 controls the murine SASP in vivo 
To interrogate the role of caspase-11 in regulating the murine SASP during oncogene-induced 
senescence, we used the hydrodynamic tail-vein injection model developed by Lars Zender’s group 
(Kang et al., 2011) (Figure 6.19). This model uses two vectors, one encoding NRAS and another 
encoding a transposase, which are diluted in a volume equal to 10% of the mouse’s body weight and 
injected into the lateral tail vein. The high pressure created by the large delivery volume causes the 
vectors to accumulate in the liver, where 5-10% of the hepatocytes take up both constructs and stably 
express NRAS. This leads to oncogene-induced hepatocyte senescence, with the accompanying SASP 
driving recruitment of immune cells that subsequently mediate the killing and clearance of NRAS-
positive senescent cells from the liver. Thus interventions that inhibit the SASP prevent senescent cell 
clearance (Kang et al., 2011, Hoare et al., 2016). 
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To determine whether caspase-11 drives the SASP in senescent hepatocytes, we cloned a shRNA 
targeting Casp11 into the bicistronic NRAS-expressing vector. We chose to carry out shRNA-mediated 
knockdown instead of using Casp11-/- mice to ensure that caspase-11 levels were only affected in the 
senescent hepatocytes. Therefore, any phenotype could confidently be attributed to the SASP-producing 
cells, rather than a defective response due to caspase-11 deficiency in the immune cells, which also 
express caspase-11. To ensure maximal knockdown, five shRNAs designed using a set of rules defined 
by Johannes Zuber’s group (Fellmann et al., 2013) were tested in vitro (Figure 6.20A). The best 
knockdown was achieved using shRNA 731, which reduced Casp11 expression by approximately 60% 
(Figure 6.20B). Importantly the Casp11-targeted shRNAs did not affect Casp1 expression (Figure 
6.20C), ensuring that canonical inflammasome signalling remained intact. Both shRNA731 and 
shRNA1124 were also re-tested following priming with a lower dose of LPS, which resulted in similar 
levels of knockdown to the cells primed with 1µg/ml LPS (Figure 6.21).  
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Figure 6.20: shRNA 731 elicited the strongest Casp11 knockdown. (A) Table showing the target and guide 
sequences of each Casp11 targeted shRNA. (B-C) qPCR data showing Casp11 (B) and Casp1 (C) expression in 
each J2 line following LPS-priming. Data represent mean +SEM of n=2. 
 
 
Figure 6.21: Levels of Casp11 knockdown are unaffected by the priming dose of LPS. qPCR data showing the 
level of Casp11 expression in J2 cells expressing control shRNA or Casp11-targeted (sh731, sh1124) shRNA ± 
priming with a range of LPS concentrations.  
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Figure 6.22: The hydrodynamic tail vein injection model timeline. Schematic showing each time point of the in 
vivo study including n numbers (cohort 1 + cohort 2) and analyses performed.  
 
The in vivo study included two cohorts of mice with tissue collection at three time points (Figure 6.22). 
The level of Casp11 knockdown was assessed by qPCR and immunofluorescence (IF). The qPCR data 
revealed significantly lower Casp11 expression in the livers of mice treated with Casp11-targeted 
shRNA compared with control shRNA three days after injection (Figure 6.23A). Although this reduction 
of approximately 25% appears minimal, it is important to consider that this analysis represents Casp11 
expression in every cell within the liver, not just the targeted hepatocytes. This difference was absent at 
day six (Figure 6.23B), probably due to the infiltration of Casp11-expressing immune cells. IF staining 
for caspase-11 protein expression six days after injection confirmed that caspase-11 expression was 
upregulated in the RAS-positive cells (Figure 6.23C). Furthermore, the RAS-positive hepatocytes from 
the mice treated with the Casp11-targeted shRNA expressed lower, or negligible, levels of caspase-11 
compared with the hepatocytes containing the control shRNA (Figure 6.23 D,E), confirming that 
knockdown was successful in vivo. 
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Figure 6.23: Casp11 was successfully knocked down in vivo. (A-B) qPCR data showing relative Casp11 expression 
in livers from mice injected with control (Ctrl) or Casp11-targeted shRNAs at day 3 (A) and day 6 (B). (C-D) 
Quantification of immunofluorescence (IF) data measuring correlation of caspase-11 and NRAS staining (C) 
and the intensity of caspase-11 staining in NRAS-positive cells (D) in the livers of mice at day 6. (E) Example day 
6 IF images showing caspase-11 and NRAS staining in the livers of mice injected with control or Casp11-
targeted shRNA, white arrows indicate NRAS+Casp11- cells. Data represent mean +SEM of n=5, or n=3 (Ctrl) / 
2 (Casp11 shRNA) (B) p = *≤0.05, ****≤0.0001. 
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The percentage of NRAS-positive hepatocytes was quantified by immunohistochemistry (IHC). There 
was no difference in NRAS cells between the control and Casp11-targeted shRNA livers three days 
after injection (Figure 6.24), thereby establishing an equivalent baseline for vector transduction and 
senescence induction. Six days after injection, significantly more NRAS-positive cells remained in the 
livers of the mice treated with the Casp11-targeted shRNA compared with control (Figure 6.25), and 
linear regression analysis revealed a negative correlation between the number of NRAS-positive cells 
remaining and the level of caspase-11 (Figure 6.26). The Casp11 shRNA-treated livers continued to 
retain more NRAS-positive cells than control at twelve days after injection (Figure 6.27). Together, this 
data shows that Casp11 knockdown leads to impaired immune-mediated clearance of senescent 
hepatocytes, therefore indicating that caspase-11 regulates the murine SASP in vivo.  
 
 
 
 
 
  
  Results: Caspase-5/-11 cleavage of IL-1α drives the senescence-associated secretory phenotype 
177 
 
Figure 6.24: There is no difference in NRAS-positive cell number between control and Casp11-targeted shRNA 
livers at 3 days post injection. (A) Example IHC images showing NRAS staining (brown). (B) Quantification of 
NRAS staining in whole liver sections. Data represent mean ± SEM of n=5. 
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Figure 6.25: Casp11 knockdown reduces senescent cell clearance at 6 days post injection. (A) Example IHC 
images showing NRAS staining (brown). (B) Quantification of NRAS staining in whole liver sections. Data 
represent mean ± SEM of n=9 (control)/=7(CASP11shRNA), p = **≤0.01. 
Figure 6.26: Caspase-11 expression negatively correlates to number of NRAS-positive cells. A graph showing the 
relationship between the percentage of RAS positive cells and the intensity of caspase-11 staining per cell in 
livers at day 6 post-injection. 
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Figure 6.27: Casp11 knockdown reduces senescent cell clearance at 12 days post injection. (A) Example IHC 
images showing NRAS staining (brown). (B) Quantification of NRAS staining in whole liver sections. Data 
represent mean ± SEM of n=10, p = *≤0.05. 
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Figure 6.28: Casp11 knockdown has no effect on proliferation at day 6 post-injection. (A) Example IF images 
showing Ki67 staining (red). (B) Quantification of Ki67 staining. Data represent mean ± SEM of n=5. 
It remains unclear whether the SASP is required, per se, for senescence to occur, or if it simply reinforces 
the phenotype. As such, there are two possible explanations for the delay in senescent hepatocyte 
clearance following Casp11 knockdown: 1) delayed onset or bypass of senescence, or 2) delayed 
immune cell recruitment and senescent cell clearance. To investigate this, levels of proliferation and 
immune cell infiltration were evaluated. At day 6, the control and Casp11-targeted livers contained 
equal numbers of proliferating RAS-positive cells, as evidenced by Ki67 staining (Figure 6.28). This 
suggests that the increased number of RAS-positive cells after Casp11 knockdown was not caused by 
increased proliferation due to the delayed onset or bypass of senescence. 
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Figure 6.29: Casp11 knockdown impairs early macrophage recruitment. (A) Example IHC images showing F4/80 
staining (brown). (B) Quantification of F4/80 staining. Data represent mean ± SEM of n=5. 
Both macrophages and NK cells have been implicated in the immunosurveillance of senescent cells 
(Vicente et al., 2016). IHC staining for F4/80 revealed there were fewer macrophages infiltrating the 
Casp11-targeted shRNA livers compared with the control shRNA livers at day 3 (Figure 6.29), however 
this difference was absent at day 6. In addition, IF staining for CD355 suggested slightly fewer NK cells 
were present in the Casp11-targeted shRNA livers (Figure 6.30). However, due to the lack of a properly 
validated anti-CD355 antibody and the high background fluorescence, it is difficult to draw conclusions 
from this staining. Together these data suggest that the reduced senescent hepatocyte clearance in the 
livers from mice treated with a Casp11-targeted shRNA is likely due to impaired early immune cell 
recruitment because of a reduced SASP.  
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Figure 6.30: Casp11 knockdown has little effect on NK cell infiltration at day 6 post-injection. (A) Example IF 
images of a liver section showing DAPI staining (blue) and CD355 staining (green). White arrows represent cells 
considered CD355 positive (Green), and the matching nuclei (blue) (B) Quantification of CD355 staining. Data 
represent mean ± SEM of n=5. 
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6.3 Discussion 
There is emerging evidence that the inflammatory caspases of the non-canonical inflammasome are 
activated during sterile inflammation (Zanoni et al., 2016, Pillon et al., 2016). An important but rarely 
cited example of sterile inflammation is the IL-1α-driven SASP - a cocktail of inflammatory mediators 
released by senescent cells. The NLRP3 inflammasome has been reported to drive the SASP during 
oncogene-induced senescence (Acosta et al., 2013), however we find that the caspase-1 inhibitor used 
in this study also blocks caspase-5 activity (Figure 6.2), and therefore we hypothesised that the non-
canonical pathway may be involved.  
The work presented in this chapter has dissected a novel pathway controlling the SASP (Figure 6.31). 
We show that CASP5 expression is upregulated in senescent cells (Figure 6.10) via the cGAS pathway 
(Figure 6.12), possibly due to the presence of cytosolic DNA resulting from nuclear blebbing (Gluck et 
al., 2017). In addition, CASP5 knockdown leads to reduced IL-1α secretion and surface expression by 
senescent IMR90 fibroblasts, and a significant impairment of the SASP (Figure 6.12). In line with 
previous reports (Orjalo et al., 2009, Gardner et al., 2015) the SASP was not dependent on IL-1β (Figure 
6.7A), which implies that IL-1α can be cleaved and released by a distinct mechanism to that regulating 
IL-1β. Although pro-IL-1β was upregulated in senescent cells, very little was cleaved and virtually none 
was secreted. A potential explanation for this is that senescent cells exhibit high levels of autophagy, 
which is reported to both clear active inflammasome complexes and modulate IL-1β secretion (Shi et 
al., 2012, Dupont et al., 2011). Therefore, autophagy may simultaneously limit caspase-1 availability 
thereby preventing IL-1β activation, and export pro-IL-1β out of the cell, which is undetectable by our 
ELISA (unpublished data). 
Importantly we confirmed our in vitro findings in vivo, where shRNA-mediated knockdown of Casp11 
in RAS-expressing hepatocytes delayed the clearance of senescent cells (Figures 6.25 and 6.26), which 
is driven by the SASP. Furthermore, we demonstrated that this delay was likely due to impaired early 
immune cell recruitment, as evidenced by decreased macrophage infiltration at the earliest time point 
(Figure 6.29). A limitation to this study was that although the shRNA-mediated Casp11 knockdown was 
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Figure 6.31: The caspase-5 mediated SASP pathway. A schematic showing the proposed pathway by which 
caspase-5 mediates the SASP. Lamin B loss in senescent cells leads to reduced nuclear membrane integrity, 
which allows dsDNA to escape to the cytosol. dsDNA activates cGAS which triggers Type I interferon (IFN) 
production via STING. Type 1 IFNs upregulate CASP5 expression and pro-caspase-5 synthesis. Caspase-5 is 
activated, perhaps via caspase-4, and in turn activates IL-1α to drive the SASP.  
specific to RAS-positive hepatocytes, it did not completely abolish caspase-11 expression. Perhaps a 
more striking phenotype would be observed if Casp11 was knocked out using either a tissue-specific 
promoter, or a bone marrow transplant of WT immune cells into a Casp11-/- mouse to maintain a 
functional non-canonical inflammasome in immune cells. 
 
 
 
Although the hydrodynamic tail vein injection model is a well characterised in vivo system for studying 
the SASP, the hepatocytes express high levels of RAS that are arguably not physiologically relevant. 
Therefore, it would be interesting to examine the role of caspase-11 in models of disease that involve 
senescent cells. For example, within a tumour, the SASP is largely considered beneficial because it 
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drives the clearance of senescent cells, thereby preventing the transmission of damaged DNA to the next 
generation. However, the SASP also establishes an inflammatory microenvironment and is reported to 
promote the proliferation and invasion of surrounding cells (Coppé et al., 2010). Therefore it would be 
interesting to examine whether caspase-11 inhibition reduces tumour invasiveness, or results in the 
accumulation of senescent cells that eventually bypass senescence and worsen disease. 
In addition, it would be important to confirm that caspase-5/-11 regulates the SASP in other types of 
senescence, such as replicative or DNA damage-induced. If so, targeting caspase-5 could represent a 
widely applicable therapeutic strategy that leaves the alternative caspase-1 and -4 immune-response 
pathways intact. For instance, the VSMC SASP significantly increases atherosclerotic plaque 
vulnerability (Wang et al., 2015). Since atherosclerosis is a disease that is normally detected at an 
advanced stage after the patient has already suffered a cardiovascular event, treatment with a specific 
caspase-5 inhibitor could prevent destabilisation of remaining plaques and reduce the likelihood of a 
second major adverse event. In addition, radiotherapy and many chemotherapies work by inducing DNA 
damage and therefore triggering tumour cell senescence. However, these non-selective therapies also 
induce senescence in the underlying stroma, and the IL-6 from senescent fibroblasts acts as a 
reprogramming factor that drives pluripotency and proliferation of cancer stem cells that have survived 
treatment (Iliopoulos et al., 2009, Liu et al., 2011, Mosteiro et al., 2016). Therefore, administering a 
caspase-5 inhibitor with these treatments could prevent cancer stem cell reprogramming and reduce the 
risk of tumour recurrence. 
Finally, although senescence represents an important stress response, there is evidence showing that 
these pathways may be beneficial in early life. As such, cellular senescence and the SASP are often cited 
as an example of antagonistic pleiotropy: a phenotype that is an advantageous anti-tumour mechanism 
in youth, but detrimental later on by promoting age-related pathologies (Wright and Shay, 1995, Rodier 
and Campisi, 2011). Senescent SAβGAL- and p21- positive cells are found at distinct locations and time 
points in the developing mouse embryo including the interdigital regions, tip of the tail, and closing 
neural tube, and p21-deficient mice exhibit defective limb patterning (Munoz-Espin et al., 2013, Storer 
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et al., 2013). Although senescent embryonic cells share a number of overlapping features with oncogene-
induced senescent cells, they do not secrete IL-6 and IL-8 (Storer et al., 2013). It would therefore be 
interesting to determine if caspase-5/-11 also regulates the developmental SASP, for example by 
staining Casp11-/- embryos for SAβGAL and p21 and identifying any morphological abnormalities.  
In conclusion, the work presented in this chapter has identified caspase-5 as the protease that activates 
IL-1α in senescent cells to drive the SASP. Therefore, the caspase-5-mediated IL-1α activation may 
represent an important biological pathway in both homeostasis and disease, and directly targeting 
caspase-5 may limit the deleterious effects of accumulated senescent cells in age-related pathologies. 
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7. Results: The rs17561 SNP reduces LPS-induced IL-1α release 
7.1 Introduction 
A single nucleotide polymorphism (SNP) is the variation of one nucleic acid within a DNA sequence 
that is common within the population. SNPs originate from unique past mutations and therefore often 
indicate a common evolutionary ancestry of individuals carrying the same polymorphism. Studying 
human SNPs is important because the genetic variation that they create may underlie susceptibility to 
disease and responsiveness to therapies (Stoneking, 2001). Although most human SNPs occur in non-
coding DNA, where they might influence transcription or alter RNA half-life, the largest functional 
effects result from polymorphisms that lie within the coding region. Some coding polymorphisms lead 
to amino acid changes, and are referred to as non-synonymous (nsSNPs). nsSNPS are very rare, 
comprising only 1% of all known SNPs, due to the evolutionary selection against amino acid 
substitutions (Shen et al., 2006).  
Rs17561 is the only nsSNP in the IL1A gene, for which 30% of the population is heterozygous (Figure 
7.1). This SNP is a guanine to thymine mutation at +4845 in the IL1A gene, which results in a change 
from an alanine (A) to a serine (S) at amino acid 114 in the protease-targeted region of IL-1α. Rs17561 
is associated with increased C-reactive protein (CRP) levels in coronary angiography patients (Berger 
et al., 2002), as well as the risk of a number of inflammatory diseases (Table 7.1). With regard to 
cardiovascular disease in particular, rs17561 has been associated with increased body mass index in 
obese healthy women (Um et al., 2011), and increased risk of coronary artery disease following 
angiography as part of a composite genotype with two IL-1β SNPS, rs1143634 and rs16944, when 
oxidised phospholipid and lipoprotein(a) levels are also raised (Tsimikas et al., 2014). Furthermore, 
rs17561 is in strong linkage disequilibrium with a second IL-1α SNP in the promoter region of the gene, 
rs1800587, which has been associated with stroke, coronary artery disease and obesity (Zou et al., 2015, 
Haroon et al., 2015, Carter et al., 2008). 
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Whilst the association of rs17561 with disease is indicative of a change in IL-1α function, there has been 
little effort to investigate this further. Kawaguchi and colleagues examined the functional consequence 
of rs17561 in the context of systemic sclerosis (SSc), where they reported an increase in calpain 
processing of pro-IL-1α in minor allele homozygotes. This observation was based on a western blot 
showing IL-1α, isolated from fibroblasts derived from genotyped individuals, that had been incubated 
with increasing calpain concentrations (Kawaguchi et al., 2007). The observation of calpain cleavage in 
these lysates is somewhat surprising as fibroblasts have the decoy receptor IL-1R2 that would prevent 
calpain processing, although the polymorphism could affect this interaction. 
 
 
 
 
 
 
 
Figure 7.1: IL1A SNP map. A schematic illustrating all IL1A SNPs found in >1% of the population. Black SNPS are 
intron variants, blue SNPS are located in the untranslated region, and red SNPS are coding non-synonymous 
mutations. The region surrounding rs17561 is shown in the extended red box. [Map generated using the UCSC 
genome browser.] 
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DISEASE/CONDITION EFFECT OF rs17561 MINOR ALLELE REFERENCE 
Chronic Rhinosinusitis Increased risk of disease (Endam et al., 2010) 
Obesity Increased body mass in healthy women (Um et al., 2011) 
Breast Cancer Increased risk of disease (Sigurdson et al., 2007) 
Ankylosing Spondylitis Increased risk of disease (Sims et al., 2008) 
Juvenile Dermatomyositis Increased risk of disease (Mamyrova et al., 2008) 
Acne Vulgaris Increased risk of acne (Szabo et al., 2010) 
Radiation-Induced Toxicity Increased risk of toxicity following 
treatment for non-small cell lung cancer 
(Hildebrandt et al., 2010) 
Multiple Sclerosis Associated with earlier disease onset (Mirowska-Guzel et al., 2011) 
Ovarian Cancer Decreased risk of clear cell, mucinous and 
endometrioid subtype 
(White et al., 2012) 
(Charbonneau et al., 2014) 
H1N1 Influenza A Virus Increased risk of disease (Liu et al., 2013) 
Nasal polyposis Protected against development of nasal 
polyposis in asthmatics 
(Karjalainen et al., 2003) 
Malaria Predispose to disease but protective for 
severe symptoms 
(Walley et al., 2004) 
Peridontitis Increased risk of disease (Yin et al., 2016) 
Coronary Artery Disease 
and Cardiovascular Disease 
Associated with higher risk of disease as 
part of composite genotype following 
stratification according to oxidised 
phospholipid and lipoprotein(a) levels 
(Tsimikas et al., 2014) 
Systemic Sclerosis Protective against disease (Kawaguchi et al., 2003) 
Table 7.1: Literature summary of the association of rs17561 with disease. A table listing whether the presence 
of the minor rs17561 allele increases or decreases risk of disease. 
 
 
7.1.1 Chapter 7 project rationale 
The rs17561 SNP causes an amino acid change from an alanine, which is hydrophobic, to a serine, which 
is polar uncharged. Because this mutation is located in the ‘loop’ region of pro-IL-1α that is targeted by 
proteases, as shown in chapters 1 and 2 of this thesis, it may affect cytokine activation. The work 
presented in this chapter aims to explore this hypothesis further, and investigate the effect of rs17561 
on IL-1α activation.   
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7.2 Results 
7.2.1 Making recombinant ‘SS’ pro-IL-1α 
The rs17561 SNP causes an amino acid substitution in the protease-targeted region of IL-1α. To 
investigate the effect of the SNP on cytokine activation, human recombinant A114S pro-IL-1α was 
produced to mimic pro-IL-1α from minor allele homozygotes (SS). The mutation was introduced by 
site-directed mutagenesis, and the GST-tagged protein was purified over a glutathione column using the 
AKTA system (Figure 7.2A). The concentration of A114S pro-IL-1α (SS) was normalised to WT pro-
IL-1α (AA) by coomassie staining (Figure 7.2B,C).  
 
 
 
Figure 7.2: The production of recombinant human ‘SS’ pro-IL-1α. (A) Western blot for IL-1α after each stage of 
the purification process. (B) Normalisation of WT (AA) and SNP (SS) pro-IL-1α concentrations by coomassie. (C) 
Example calculation of AA:SS pro-IL-1α concentration ratio from coomassie staining intensity.  
A. B. 
C. 
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7.2.2 The rs17561 SNP affects IL-1α cleavage by some, but not all, proteases 
Proteolytic cleavage assays using matched concentrations of AA and SS pro-IL-1α revealed that the 
rs17561 SNP affects the cleavage of IL-1α by a subset of proteases only. Most proteases cleaved AA 
and SS pro-IL-1α with similar efficiency, as shown by the examples in Figure 7.3. However, chymase, 
MMP2 and proteinase 3, cleaved SS pro-IL-1α with a lower efficiency than AA pro-IL-1α, although 
this difference was not statistically significant (Figure 7.4). One explanation is that the SNP only affects 
cleavage if the protease target site is close to amino acid 114. However, calpain and MMP-2 both cleaved 
pro-IL-1α to produce a 17kDa product (Chapter 4, Figures 4.1 and 4.12), suggesting that they target a 
similar location. Alternatively, chymase, MMP-2 and proteinase 3 could require the alanine for substrate 
docking, and the introduction of a serine may prevent stable interaction.  
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Figure 7.3: The rs17561 SNP does not affect recombinant pro-IL-1α cleavage by calpain, elastase or cathepsin B. 
(A-F) The level of WT (AA) and SNP (SS) pro-IL-1α cleavage by calpain (A,B), elastase (C,D) and cathepsin B (E,F). 
(A,C,E) ELISA data measuring the level of cleaved IL-1α following incubation of AA or SS pro-IL-1α with range 
of protease concentrations. (B,D,F) IL-1-dependent IL-6 production by HeLa cells treated with reaction 
products from AA or SS pro-IL-1α incubation ± proteases, ± a neutralising IL-1α antibody (p αAb). Data 
represent mean +SEM of n=3. 
A. B. 
C. D. 
E. F. 
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Figure 7.4: The rs17561 SNP hinders recombinant pro-IL-1α cleavage by chymase, MMP2 and proteinase 3. (A-
F) The level of WT (AA) and SNP (SS) pro-IL-1α cleavage by chymase (A,B), MMP2 (C,D) and proteinase-3 (E,F). 
(A,C,E) ELISA data measuring the level of cleaved IL-1α following incubation of AA or SS pro-IL-1α with range 
of  protease concentrations. (B,D,F) IL-1-dependent IL-6 production by HeLa cells treated with reaction 
products from AA or SS pro-IL-1α incubation ± proteases, ± a neutralising IL-1α antibody (p αAb). Data 
represent mean +SEM of n=3. 
A. B. 
C. D. 
E. F. 
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7.2.3 The expression of pro-IL-1α in mammalian cells is challenging 
Although bacterial recombinant protein represents a clean and simple system to investigate the 
functional effect of rs17561, it is not post-translationally modified. Since the mutation of an alanine to 
a serine creates a potential phosphorylation site, the effects observed in the recombinant protein cleavage 
assays may not accurately represent how the SNP influences IL-1α activation in mammalian cells. 
Therefore, mammalian cell-derived recombinant IL-1α would be a better system to interrogate the effect 
of the SNP. The overexpression of HIS-tagged AA or SS pro-IL-1α in HEK-293T cells allowed the 
purification of the recombinant protein using a cobalt resin (Figure 7.5). However, despite optimisation 
the protein yield was too low for concentration normalisation by coomassie staining. Furthermore, the 
HEK-293T cells expressed higher levels of SS IL-1α, which was partially cleaved to a 19kDa form 
making it unsuitable for the comparison of cleavage and activity. Another approach could be to 
overexpress both forms of pro-IL-1α in insect cells using a baculovirus system, which would enable the 
production of post-translationally modified protein. Alternatively, to examine the effect of rs17561 
introducing a phosphorylation site, the alanine could be mutated to aspartic acid in the bacterial 
expression system. Aspartate mimics a phosphorylated serine residue, and may therefore cause the 
protein to behave as though it were phosphorylated at amino acid 114. 
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7.2.4 The development of an assay to measure LPS-induced IL-1 release from whole blood 
To investigate the SNP in a more physiological setting, we undertook a human recall-by-genotype study 
in collaboration with the Cambridge Bioresource; a panel of approximately 16,000 genotyped 
volunteers. Prior to participant recruitment, we developed an assay to measure LPS-induced IL-1 release 
from whole blood culture. Blood was extracted into lithium heparin because other anti-coagulants can 
dampen immune responses (Duffy et al., 2014). Optimisation experiments testing a range of LPS doses 
and dilution factors revealed that diluting the blood into media by a factor of 2 or 4, and treating with 
A. 
B. 
Figure 7.5: Purification of AA and SS HIS-pro-IL-1α from HEK293-T cells. (A-B) Western blot for IL-1α at each 
stage of the HIS purification of WT (AA) (A) and SNP (SS) (B) pro-IL-1α expressed in HEK-293T cells. 
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1µg/ml LPS resulted in the largest IL-1 response (Figure 7.6). Importantly, we confirmed that the IL-1 
was not passively released through cell death, as evidenced by similar levels of LDH in the treated and 
untreated samples (Figure 7.7). 
 
 
 Figure 7.6: Optimisation of blood dilution factor and LPS concentration. (A-B) ELISA data showing the level of IL-
1α (A) and IL-1β (B) in the conditioned media/serum of whole blood diluted 1/2, 1/4, 1/10 or 1/20 into media 
and treated with 0, 100 or 1000ng/ml LPS. Data represent mean +SEM of n=4, p = **≤0.01, ***≤0.001, 
****≤0.0001. 
 
A. 
B. 
  Results: The rs17561 SNP reduces LPS-induced IL-1α release 
197 
 
 
 
 
To preserve participant anonymity blood samples are drawn by a nurse at the Cambridge Bioresource 
and are subsequently collected by the researcher, which inevitably results in a delay between 
venepuncture and sample processing. We investigated the impact of this on our assay and observed a 
massive effect of the time between drawing and plating the blood, which resulted in up to 50% less IL-
1α detection (Figure 7.8). Because of this, all samples were collected on-site so that blood could be 
plated within 20 minutes of venepuncture. 
 
 
 
 
Figure 7.7: IL-1 release from LPS-stimulated whole blood is not due to cell death. Quantification of LDH released 
from whole blood ± LPS treatment, with a positive control included for reference. Data represent mean +SEM 
of n=8. 
 
Figure 7.8: Delayed plating of blood leads to a diminished IL-1 response. ELISA data showing the level of IL-1α 
in the conditioned media/serum of whole blood ± LPS plated at a range of time points following venepuncture. 
Data represent mean +SEM of n=2. 
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7.2.5 Preliminary study: rs17561 minor allele homozygotes may secrete less IL-1α 
To determine whether rs17561 has a functional effect on IL-1α activation we initially conducted a small 
preliminary study with 20 participants: 10 major allele homozygotes and 10 minor allele homozygotes. 
To minimise variation, donors were healthy males aged 16-55 who had not taken any 
immunomodulatory drugs (e.g. aspirin, ibuprofen, antihistamine) within the 24 hours before donation. 
LPS-stimulated whole blood from minor allele homozygotes released less IL-1α than major allele 
homozygotes (Figure 7.9A), with minimal effect on IL-1β release (Figure 7.9B). The same pattern of 
results was observed for both blood dilutions (Figure 7.9C,D). Together this data suggests that the 
rs17561 SNP reduces the activation of IL-1α by LPS.  
 
 
 
Figure 7.9: Preliminary study data suggests rs17561 minor allele homozygotes secrete less IL-1α. (A-D) ELISA 
data showing the level of IL-1α (A,C) and IL-1β (B,D) in the conditioned media/serum of whole blood from 
rs17561 major/minor allele homozygotes ± LPS diluted ½ (A,B) or ¼ (B,C) into media. Data represent mean 
+SEM of n=10. 
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An additional blood sample from each participant was drawn into EDTA and sent for full blood count 
analysis to allow proper normalisation. For example, differences in haematocrit levels between 
individuals would influence the volume of the serum and therefore directly affect IL-1 concentration. In 
addition, monocytes are reported to be the main cellular source of IL-1. Therefore, monocyte counts are 
required to confirm that any difference in IL-1 levels is real and not simply due to a difference in 
monocyte number. Furthermore, any difference in whole blood count parameters between major and 
minor allele homozygotes could represent an effect of the SNP on cellular differentiation; indeed, IL-
1α has been shown to modulate TH17 cell differentiation (Mills, 2008). However, there was no difference 
between major and minor allele homozygotes for most blood count parameters (Figure 7.10A-G), 
although minor allele homozygotes had slightly lower basophil levels (Figure 7.10H). Basophils are 
involved in inflammation, particularly allergic reactions where they release histamine to dilate blood 
vessels. Although IL-1α is implicated in allergy (Willart et al., 2012) there are no reports suggesting that 
basophils secrete large amounts of the cytokine. The normalisation of IL-1α and IL-1β levels to each 
blood count parameter, with the exception of basophils, had minimal effect on the p-values (Table 7.2). 
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BLOOD COUNT PARAMETER 
IL-1α p VALUE IL-1β p VALUE 
1/2 1/4 1/2 1/4 
Non-normalised 0.1 0.09 0.3 0.3 
White blood cells 0.16 0.16 0.51 0.64 
Haematocrit 0.11 0.10 0.33 0.48 
Platelets 0.17 0.14 0.39 0.48 
Neutrophils 0.09 0.13 0.29 0.61 
Lymphocytes 0.29 0.26 0.89 0.98 
Monocytes 0.16 0.15 0.50 0.61 
Eosinophils 0.40 0.5 0.80 0.98 
Basophils 0.43 0.5 0.95 0.64 
Table 7.2: Preliminary study P-values following normalisation of ELISA data to each blood count parameter. A 
table listing the p values of significance of the difference between LPS-treated major and minor allele 
homozygote blood following normalisation to different blood count parameters. 
A. B. C. 
D. E. F. 
G. H. 
Figure 7.10: The rs17561 SNP does 
not affect whole blood count 
parameters. (A-H) Whole blood 
count data showing level of white 
blood cells (A), haematocrit (B), 
platelets (C),neutrophils (D), 
lymphocytes (E), monocytes (F), 
eosinophils (G), and basophils (H) in 
major and minor allele 
homozygotes. Data represent 
mean +SEM of n=10. 
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7.2.6 Combined larger cohort: rs17561 minor allele homozygotes secrete significantly less 
IL-1α 
Although the results from the preliminary study suggested that rs17561 minor allele homozygotes 
release less IL-1α, the reduction was not statistically significant. This initial data enabled a power 
calculation to estimate the sample size required for statistical significance (Figure 7.11). The power 
calculation estimated that a sample size of 23 per group was required, which led us to recruit an 
additional 15 participants (giving a total of 25 per group) into the study. Ideally, the second cohort would 
have represented 25 new, rather than 15 additional, volunteers. However, this was not possible due to 
the lack of individuals fitting the strict exclusion criteria, in particular the good health status and 
availability for on-site visits. As such, the results of both cohorts were combined.  
 
 
 
 
 
Figure 7.11: 23 individuals per group are required for statistical power. (A) The power calculation used to 
calculate sample size (From Bernard Rosner’s Fundamentals of Biostatisitcs). (B-C) screenshots from the online 
calculator that applies the given formula (http://www.openepi.com/SampleSize/SSMean.htm) showing the 
input (B) and output (C) data.  
 
A. 
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Since there was no difference between the 1/2 and 1/4 dilutions of blood into media in the preliminary 
study, a single dilution (1/2) of blood was used for the IL-1 release experiments in the second study 
cohort. Combining the data from both groups of volunteers revealed that minor allele rs17561 
homozygotes released significantly less IL-1α in response to LPS compared with major allele 
homozygotes (Figure 7.12A). Importantly, there was no difference in IL-1β release between groups, 
confirming an IL-1α-specific effect of the polymorphism (Figure 7.12B). Initial inspection of the data 
highlighted a single obvious outlier in the minor allele group. Upon further investigation it was found 
that the study participant took aspirin every second day, and he was mistakenly included in the study 
because his blood was drawn on a day that he did not take the medication. However, prolonged use of 
an anti-inflammatory agent would inevitably affect the immune response, and therefore this sample was 
excluded from the analysis below.  
 
 
 
 
As before, whole blood count data was collected and analysed to detect any difference between major 
and minor allele homozygotes (Figure 7.13). For all parameters, there were no significant differences 
between major and minor allele homozygotes. However, minor allele homozygotes tended to exhibit 
lower platelet (Figure 7.13C), eosinophil (Figure 7.13G), and basophil counts (Figure 7.13H). The 
normalisation of IL-1α concentration to platelet, eosinophil, basophil or lymphocyte count led to a non-
Figure 7.12: rs17561 minor allele homozygotes release significantly less IL-1α. (A-B) ELISA data showing the level 
of IL-1α (A) and IL-1β (B) in the conditioned media/serum of whole blood from rs17561 major/minor allele 
homozygotes treated with LPS. Data represent mean +SEM of n=25 (major) or n=24 (minor); p = *≤0.05. 
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significant p-value (Table 7.3). Although monocytes, macrophages and endothelial cells are considered 
to be the primary cellular sources of IL-1α, it is constitutively expressed by most cells. Therefore, it is 
possible that other cell types mediate cytokine release during whole blood activation. Although this 
initial study enabled us to efficiently demonstrate that rs17561 has a functional effect, identifying which 
cells are releasing IL-1α will be essential to fully understand the effect of the SNP.  
 
 
 
Figure 7.13: The rs17561 SNP does 
not affect whole blood count 
parameters.  (A-H) Whole blood 
count data showing level of white 
blood cells (A), haematocrit (B), 
platelets (C),neutrophils (D), 
lymphocytes (E), monocytes (F), 
eosinophils (G), and basophils (H) in 
major and minor allele 
homozygotes. Data represent 
mean +SEM of n=25 (major) or 24 
(minor). 
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BLOOD COUNT PARAMETER IL-1α p VALUE IL-1β p VALUE 
Non-normalised 0.03 0.58 
White blood cells 0.04 0.8 
Haematocrit 0.03 0.49 
Platelets 0.08 0.63 
Neutrophils 0.03 0.86 
Lymphocytes 0.13 0.53 
Monocytes 0.06 0.83 
Eosinophils 0.25 0.85 
Basophils 0.11 0.71 
Table 7.3: P-values following normalisation to each blood count parameter. A table listing the p value significance 
of the difference between LPS-treated major and minor allele homozygote blood following normalisation to 
different blood count parameters. 
 
7.2.7 The rs17561 SNP does not alter IL-1 gene expression 
Although the rs17561 SNP is located in the coding region of IL1A, it is in linkage disequilibrium with a 
second upstream promoter SNP (rs1800587) that could influence gene expression. Although only 50% 
of study participants were genotyped for both SNPs, those who were carried either both major alleles or 
both minor alleles. However, there was no difference in IL1A or IL1B expression between major and 
minor allele homozygotes (Figure 7.14), suggesting that rs17561 and rs1800587 do not affect IL-1 
transcription.  
 
 
 
 
Figure 7.14: rs17561 does not affect IL1 gene expression. (A-B) qPCR data showing the level of IL1A (A) and IL1B 
(B) expression in the adherent monocytes from each study participant ± LPS. Data represent mean +SEM of 
n=25 (major) or n=24 (minor). 
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7.2.8 The rs17561 SNP does not affect the cleavage of IL-1α by caspase-5 
Since rs17561 causes an amino acid change within the protease-targeted region of the IL-1α protein, we 
hypothesised that it could impair cytokine activation. It has been reported that LPS-treated monocytes 
activate non-canonical inflammasomes and release IL-1α and IL-1β via caspase-4 and -5 through a one-
step mechanism (Vigano et al., 2015). Thus, given that caspase-5 can activate IL-1α (Chapters 5 and 6), 
we reasoned that caspase-5 might mediate IL-1α release in LPS-stimulated whole blood, and that 
rs17561 might therefore affect caspase-5 cleavage of IL-1α. Although the amino acid change caused by 
the SNP is 11 amino acids away from the caspase-5 target site, it could influence enzyme docking 
because these two regions may be close in three-dimensional space. Caspase-5 cleaved recombinant SS 
pro-IL-1α to produce a similar 19kDa fragment to AA pro-IL-1α (Figure 7.15A), although there was 
perhaps a lower level of SS IL-1α activation (Figure 7.15B). Furthermore, the inhibitors z-LEVD-fmk 
and z-YVAD-fmk had little effect on IL-1α release from LPS-stimulated whole blood (Figure 7.16), 
suggesting that IL-1α might not be cleaved by a caspase in this system.  
 
 
 
 
 
Figure 7.15: rs17561 does not significantly affect IL-1α cleavage by caspase-5. (A) Western blot for IL-1α after 
the incubation of AA or SS pro-IL-1α alone (incubation control, IC) or with active caspase-5. (B) IL-1-dependent 
IL-6 production by HeLa cells treated with reaction products from AA or SS pro-IL-1α incubation ± active 
caspase-5. Data represent mean +SEM of n=3. 
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7.2.9 The rs17561 SNP does not affect the interaction between pro-IL-1α and IL-1R2 
The IL-1R2 is a decoy receptor that binds to pro-IL-1α to prevent it from interacting with the signalling 
receptor IL-1R1 and protect it from proteases. To determine whether the rs17561 SNP increases the 
affinity of IL-1α for IL-1R2 and in turn reduces cytokine availability for proteolytic activation, we 
examined the effect of increasing IL-1R2 concentrations on basal AA or SS pro-IL-1α activity as a proxy 
measure of binding. The IL-1R2 inhibition curves were identical for AA and SS pro-IL-1α (Figure 7.17), 
suggesting that the SNP does not affect IL-1R2 binding to pro-IL-1α. Since the binding of IL-1R2 to 
pro-IL-1α is enhanced by the accessory protein IL-1RAcP, we repeated the inhibitor study in the 
presence of the accessory protein. Again, the AA and SS curves were identical (Figure 7.18), indicating 
that the SNP does not affect the level of IL-1α inhibition through IL-1R2 and IL-1RAcP. However it 
may be useful to confirm this finding using mammalian IL-1α, since post-translational modifications 
could affect the interaction. 
A. B. 
Figure 7.16: LPS-induced IL-1α release from whole blood is not affected by caspase inhibitors. (A-B) ELISA data 
showing level of IL-1α (A) or IL-1β (B) in the conditioned media/serum from of whole blood treated ± LPS ± z-
LEVD-fmk ± z-YVAD-fmk. Data represent mean +SEM of n=3; p = *≤0.05, **≤0.01. 
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Figure 7.17: rs17561 does not affect the binding of pro-IL-1α to IL-1R2. ELISA data showing IL-1-dependent IL-6 
production by HeLa cells treated with AA or SS pro-IL-1α pre-incubated with a range of IL-1R2 concentrations. 
Data represent mean +SEM of n=2. 
 
Figure 7.18: rs17561 does not affect the binding of pro-IL-1α to IL-1R2 and IL-1RAcP. ELISA data showing IL-1-
dependent IL-6 production by HeLa cells treated with AA or SS pro-IL-1α pre-incubated with a range of IL-
1R2±IL-1RAcP concentrations. Data represent mean +SEM of n=2. 
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7.2.10 A subset of individuals do not release any IL-1α 
Our data suggests that the rs17561 SNP may account for some of the variation in IL-1α secretion 
observed throughout the population. While developing a standardised whole blood stimulation system, 
Matthew Albert and colleagues found that some individuals do not secrete any IL-1α (Duffy et al., 
2014).We find that rs17561 minor allele homozygotes still release some IL-1α, which implies that the 
SNP does not cause this phenotype and raises the question of what limits IL-1α release in these 
individuals. Since all commercial IL-1α ELISA kits that we have tested detect the cleaved form of IL-
1α only (unpublished data), we hypothesised that these ‘non-secretors’ could be releasing pro-IL-1α 
that is undetectable by these methods. To test this, we collaborated with the Albert group, and attempted 
to ‘reveal’ any pro-IL-1α in the samples by incubation with calpain (Figure 7.19). The calpain revealed 
additional IL-1α in the responder samples (204, 221, 318, 340 and 378), suggesting that some IL-1α is 
released in its pro-form. However, calpain did not increase IL-1α detection in the non-responders (203, 
220 and 323). Another potential explanation for the lack of IL-1α detection in ‘non-responders’ is that 
they express higher levels of IL-1R2, which would bind to pro-IL-1α and mask its detection. However, 
IL-1R2 levels were comparable between responders and non-responders (Figure 7.20). Together, this 
data suggests that there were no detection issues in these samples, and that some people really do not 
secrete IL-1α. It would be interesting to genotype the volunteers from the Albert study to identify any 
common SNPs specific to either phenotype.  
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Figure 7.19: Calpain does not ‘reveal’ IL-1α in non-responders. ELISA data showing cleaved IL-1α levels in the 
supernatant/serum of LPS-treated blood incubated ± calpain. Data is n=1. 
 
Figure 7.20: There is no difference in IL-1R2 levels between responders and non-responders. ELISA data showing 
IL-1R2 levels in the supernatant/serum of LPS-treated blood from responders (green) and non-responders 
(red). Data is n=2. 
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7.3 Discussion 
The rs17561 SNP causes an amino acid change from an alanine to a serine in the protease-targeted 
region of IL-1α. Serine is a polar uncharged amino acid, whereas alanine has a hydrophobic side chain. 
In addition, serine residues can undergo post-translational modifications such as phosphorylation and 
O-linked glycosylation. Phosphorylation, for example, introduces a charged hydrophilic moiety that 
could affect amino acid interactions, and regulate protein degradation thereby limiting substrate 
availability. As such, we hypothesised that the SNP could have a functional effect on IL-1α activation. 
Indeed, the polymorphism is associated with multiple inflammatory diseases, such as ovarian cancer 
(Table 7.1). 
Although the recombinant protein cleavage assays did not show a clear effect of the SNP, perhaps due 
to the lack of post-translational modification in bacterial protein, the human recall-by-genotype study 
revealed that LPS-stimulated whole blood from minor allele homozygotes secreted significantly less 
cleaved IL-1α than blood from major allele homozygotes (Figure 7.11), confirming that rs17561 has a 
functional effect. A limitation of the study was the lack of suitable volunteers in the Cambridge 
Bioresource database, since many minor allele homozygotes were taking medication or did not have 
time to donate blood on site. Although the exclusion of minor allele homozygotes due to medication use 
indirectly supports the hypothesis that rs17561 has a functional effect that requires treatment, it resulted 
in the pooling of data from both study cohorts. Future work could include evaluating IL-1α release in 
heterozygous individuals, a more prevalent genotype, to determine if there is a dosage effect of the 
minor allele. 
Importantly, we confirmed that the impaired IL-1α response in minor allele homozygotes was not due 
to a reduction in IL1A transcription (Figure 7.13), which could be influenced by a second IL1A promoter 
SNP that is in linkage disequilibrium with rs17561. Interestingly, the promoter SNP has been studied in 
greater depth than rs17561 and has been linked to increased risk of a number of conditions such as 
stroke, coronary artery disease, and obesity (Zou et al., 2015, Haroon et al., 2015, Carter et al., 2008). 
All SS individuals genotyped for both polymorphisms in the study carried the minor allele for both 
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SNPs, suggesting that the promoter SNP does not affect IL1A expression. Therefore, the aforementioned 
associations of rs18005787 with disease may actually be due to rs17561. 
Alternatively, the rs17461 SNP could affect IL-1α secretion. The mechanism of IL-1α secretion is 
unknown, since pro-IL-1α lacks a conventional signal peptide and does not localise to the Golgi 
apparatus or endoplasmic reticulum (Stevenson et al., 1992). It has been reported that IL-1α is co-
secreted with IL-1β (Fettelschoss et al., 2011). However, IL-1β release from LPS-stimulated whole 
blood was not affected by the SNP (Figure 7.11B), indicating that this secretory pathway remained 
unaltered.  
Since the mutation is located in the loop region of IL-1α that is targeted by proteases, the reduced IL-1α 
release in minor allele homozygotes is most likely due to impaired cytokine activation. To interrogate 
this fully, it will be necessary to identify the protease responsible for IL-1α cleavage in the whole blood 
assay. First, to identify the primary cellular source of IL-1α, the blood could be separated by density-
gradient centrifugation so that the response of each cell type to LPS can be evaluated. Different cell 
types display distinct protease profiles that could narrow down the candidate list. In addition, different 
combinations of protease inhibitors could be added to identify the type or specific identity of the protease 
responsible for IL-1α activation.  
In conclusion, the work presented in this chapter has revealed a functional effect of the rs17561 SNP 
that could have an immediate clinical impact. Genotyping patients who are being considered for anti-
IL-1 therapies for the SNP could help to inform clinicians of the best course of treatment. Since minor 
allele homozygotes release less IL-1α, these patients may benefit more from a therapy targeting both 
IL-1α and IL-1β, such as Anakinra, or IL-1β alone, for example Canakinumab. This personalised 
treatment would save both time and money. In addition, future epidemiological studies that evaluate the 
association of rs17561 with disease could identify novel pathologies that are mediated by IL-1α, and 
provide rationale for the development of new, or the repurposing of existing, IL-1α-targeting therapies. 
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8. General Discussion 
Pro-inflammatory cytokines are critical signalling molecules that enable cells to communicate danger 
and drive inflammation - an indispensable process for managing invading microbes and tissue damage. 
IL-1α is an extremely powerful inflammatory cytokine that exerts a plethora of effects on both innate 
and adaptive immunity. Its extracellular activity regulates inflammatory cytokine production, TH17 cell 
differentiation, B- and T-cell survival and dendritic cell MHC expression, and drives systemic 
hypotension and fever (Sims and Smith, 2010, Gabay et al., 2010). In addition, intra-nuclear IL-1α acts 
as a transcription factor, an oncogene, and a DNA damage sensor (Luheshi et al., 2009, Buryskova et 
al., 2004, Pollock et al., 2003, Stevenson et al., 1997, Zhang et al., 2017, Cohen et al., 2015). Aberrant 
IL-1α signalling has been reported in multiple chronic inflammatory diseases including cancer, 
atherosclerosis, psoriasis and arthritis (Rider et al., 2013, Kamari et al., 2011, Eastgate et al., 1991). As 
such, understanding exactly how IL-1α activity is regulated is essential for dissecting the pathways that 
are dysregulated in disease and developing appropriate anti-IL-1α therapies.  
IL-1α is translated as a pro-protein that was considered to be fully active for many years (March et al., 
1985, Mosley et al., 1986, Kim et al., 2013). However, recent work by ourselves and others has 
demonstrated that the proteolytic removal of the IL-1α pro-piece significantly enhances cytokine activity 
(Afonina et al., 2011, Zheng et al., 2013), thereby prompting a paradigm shift in thinking. The research 
presented in this thesis provides substantial evidence further supporting the hypothesis that IL-1α is 
subject to proteolytic activation (Figure 8.1). We have demonstrated that the pro-domain limits cytokine 
activity (Chapter 3), and that multiple proteases from diverse biological systems are capable of 
proteolytically activating IL-1α (Chapter 4). We have extensively characterised the cleavage of IL-1α 
by human caspases-5 and murine -11, which activate IL-1α during non-canonical inflammasome 
activation under sterile and non-sterile conditions (Chapters 5 and 6). Finally, we have demonstrated 
that a common missense polymorphism that causes an amino acid substitution in the protease-targeted 
domain leads to impaired IL-1α release in minor allele homozygotes (Chapter 7).  
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Figure 8.1: Summary of main thesis findings. Schematic illustrating how the work presented in each chapter of 
this thesis has contributed to our understanding of how IL-1α activity is regulated. 
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Using bacterial recombinant and cell-derived IL-1α we show that the pro-domain, specifically amino 
acids 56-77, inhibits IL-1α activity; and that this inhibition can be relieved via cleavage by multiple 
proteases (Chapters 3 and 4). The diversity of proteases capable of IL-1α activation was unexpected, but 
is perhaps in keeping with the alarmin function of the cytokine. Indeed, it seems logical that any 
proteolytic signal from compromised cellular homeostasis activates immunity. Furthermore, the gradual 
inactivation of IL-1α over time by some proteases, such as elastase and proteinase 3 that are released 
from immune cells in high quantities, may represent a failsafe mechanism that has evolved to prevent 
excess IL-1-driven inflammation. In addition to providing further evidence that IL-1α is subject to 
proteolytic activation, this data challenges the view that pro-IL-1α is passively released during cell 
death. Instead, we suggest that IL-1α might represent an inflammatory signalling hub that integrates 
multiple proteolytic signals from diverse sources. Importantly, unlike IL-1β, pro-IL-1α is constitutively 
expressed in the cytosol of most cells. Thus, without the requirement for cell priming, transcription and 
translation, pro-IL-1α is able to act as a first-responder that can quickly initiate the inflammatory 
cascade.  
The work presented in chapters 5 and 6 of this thesis focusses on the processing of pro-IL-1α by caspase-
5. This interaction was somewhat surprising, since inflammatory caspase signalling is typically 
associated with the activation of IL-1β by caspase-1 via the inflammasome. Although caspases-4 and -
5 have recently gained recognition for their role in non-canonical inflammasome signalling, a rapidly 
progressing field, they are assumed to exert effect by processing gasdermin D (Kayagaki et al., 2015, 
Shi et al., 2015). In Chapter 5 we show that caspase-5 and -11 directly cleave and activate IL-1α in cells 
following intracellular LPS treatment, providing important insights into non-canonical inflammasome 
biology. Firstly, the original Casp1-/- mouse showed reduced levels of IL-1α release during endotoxemia, 
which was unexpected given that IL-1α is not a caspase-1 substrate (Li et al., 1995, Kuida et al., 1995). 
However due to their 129/Sv genetic background, these mice carried an endogenous inactivating 
mutation in Casp11 (Kayagaki et al., 2011). Our data provides a possible explanation for this ongoing 
puzzle, suggesting that the defective cleavage and release of IL-1α in Casp1-/- mice may be due to the 
absence of caspase-11. Furthermore, most non-canonical inflammasome research focusses on caspase-
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4, which is often considered a closer relative of murine caspase-11 than caspase-5 (Shi et al., 2014). 
However, we find that caspase-5 and -11 are both induced upon cell priming (whilst caspase-4 is not) 
and share similar substrate specificities, indicating significant functional equivalence between these two 
proteases. As such, we hypothesise that caspases-4 and -5 have undergone subfunctionalisation over 
time, and that the properties of the ancestral Casp11-like gene are now divided between both human 
proteases.  
We find that caspase-5 can both liberate IL-1α from the decoy receptor IL-1R2 (Zheng et al., 2013) and 
activate IL-1α by direct cleavage. Therefore, caspase-5 can rapidly activate IL-1α independently of the 
caspase-1 inflammasome. Some pathogens target inflammatory caspase signalling to evade immune 
detection. For example, enterohemorrhagic E.coli uses the T3SS effector NIeF to specifically inhibit 
caspase-4 (Song et al., 2017), and the viral serpin CrmA and bacterial protease zmp1 block caspase-1 
activation (Lamkanfi and Dixit, 2011, Taxman et al., 2010). Therefore, caspase-5-mediated IL-1α 
activation may represent an important and distinct inflammatory pathway that is able to establish an 
immune response against these pathogens.  
In addition to demonstrating that caspase-5 cleaves IL-1α in response to intracellular LPS, we have 
shown that that caspase-5 also activates IL-1α in senescent cells to control the SASP (Chapter 6). Since 
the SASP represents sterile inflammation, this work contributes to the growing body of evidence that 
the non-canonical inflammasome is activated by endogenous ligands in the absence of infection (Zanoni 
et al., 2016, Pillon et al., 2016). Although our data indicates that CASP5 expression is upregulated via 
cGAS signalling, we have not yet identified the endogenous ligand that activates caspase-5 in senescent 
cells. Intracellular LPS is reported to activate caspase-5 via direct binding (Shi et al., 2014). Future work 
could attempt mass spectrometry analysis of immuno-precipitated caspase-5 from senescent cells to 
identify any interacting factors.  
Furthermore, we confirm that the SASP is dependent on IL-1α, rather than IL-1β, in line with previous 
reports (Orjalo et al., 2009, Gardner et al., 2015), and show that IL-1α secretion from senescent cells 
occurs in the absence of cell death. Together, these findings contradict the usual notion that IL-1α is 
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released passively upon cell death or co-secreted with IL-1β, and provide crucial evidence that IL-1α 
can be actively released from live cells.  
Senescent cells are reported to accumulate in multiple age-related pathologies such as atherosclerosis, 
cancer and osteoarthritis (Gardner et al., 2015, Martin and Buckwalter, 2003, Collado et al., 2007, Baker 
et al., 2011). In atherosclerotic lesions, the SASP is considered to be deleterious by creating a highly 
inflammatory environment that reduces plaque stability (Wang et al., 2015). However, within a tumour 
the SASP is reported to exert both pro- and anti-tumourigenic functions (Coppé et al., 2010). Therefore, 
it will be important to examine the effect of caspase-5 inhibition in animal models of disease in order to 
understand the contribution of SASPs to specific pathologies and identify disorders that might benefit 
from anti-caspase-5 therapies.  
Chapter 7 of this thesis investigated the effect of a common non-synonymous SNP, rs17561, on IL-1α 
activity. We show that minor allele homozygotes release less mature IL-1α from LPS-stimulated whole 
blood compared with major allele homozygotes. Although we have not confirmed that the SNP does not 
influence IL-1α secretion, the mutation at amino acid 114 is located in the protease-targeted region of 
IL-1α and is therefore likely to affect cytokine activation. To fully understand the functional effect of 
rs17561 it will be important to identify what proteases are affected by the mutation, which could be 
investigated by adding different protease inhibitors to blood during LPS-treatment. In turn, this could 
help identify what proteolytic signalling pathways drive SNP-associated diseases, and enhance our 
understanding of their pathology. 
In addition, IL-1α is a dual function cytokine. Therefore, it would also be of interest to investigate 
whether the SNP influences the intracellular properties of IL-1α. For example, rs17561 is associated 
with increased risk of ovarian cancer (Charbonneau et al., 2014). Is this primarily through lower levels 
of extracellular IL-1α activity and reduced anti-tumour immunity, or due to an effect of the intracellular 
cytokine on transcription? For example, the SNP might influence the binding of intra-nuclear IL-1α to 
DNA and alter the transcription of downstream target genes. Alternatively, the mutation could impair 
the ability of HDAC enzymes to modulate IL-1α acetylation, thereby impeding IL-1α shuttling between 
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the nucleus and the cytosol and interfering with its ability to communicate DNA damage (Cohen et al., 
2015). The intracellular localisation of AA or SS pro-IL-1α could be interrogated by 
immunofluorescence.  
To conclude, the data presented in this thesis has significantly contributed to our understanding of IL-1, 
inflammasome, and senescent cell biology. We have used recombinant proteins, in vitro cell assays, in 
vivo murine models, and a small-scale human study to show that IL-1α activity is enhanced by 
proteolytic cleavage. Furthermore we have revealed a novel link between the non-canonical 
inflammasome and the SASP, thereby identifying caspase-5-mediated IL-1α activation as an important 
inflammasome-independent mechanism of inducing an inflammatory response during sterile and non-
sterile inflammation.  
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